South Dakota State University

Open PRAIRIE: Open Public Research Access Institutional
Repository and Information Exchange
Electronic Theses and Dissertations
2017

Surveillance of Emerging Livestock Viruses
Faten A. Okda

Follow this and additional works at: https://openprairie.sdstate.edu/etd
Part of the Biology Commons, Veterinary Microbiology and Immunobiology Commons, and the
Virology Commons

Recommended Citation
Okda, Faten A., "Surveillance of Emerging Livestock Viruses" (2017). Electronic Theses and Dissertations.
1180.
https://openprairie.sdstate.edu/etd/1180

This Dissertation - Open Access is brought to you for free and open access by Open PRAIRIE: Open Public
Research Access Institutional Repository and Information Exchange. It has been accepted for inclusion in
Electronic Theses and Dissertations by an authorized administrator of Open PRAIRIE: Open Public Research
Access Institutional Repository and Information Exchange. For more information, please contact
michael.biondo@sdstate.edu.

SURVEILLANCE OF EMERGING LIVESTOCK VIRUSES

BY
FATEN A. OKDA

A dissertation submitted in partial fulfillment of the requirements for the
Doctor of Philosophy
Major in Biological Sciences
Specialization in Microbiology & Molecular Biology
South Dakota State University
2017

iii

Dedicated to

My dad, my mom, my lovely husband (Ahmed Atef Sakr),

Julie Nelson, Peace Lutheran child care center, my mother-in-law

My brothers (Khaled and Hamed),

My sisters (Samah and Heba),

My kids (Sandy, Deemah and Moaz),

Special dedication for Youssef (My nephew),

My family, my friends and teachers,

Dr. Eric Nelson and Dr. Steve Lawson

iv

ACKNOWLEDGEMENTS

First I am so grateful and thankful to Allah (God) that he blessed me with the
energy, my lovely husband who stand beside me, my lovely kids and all the type of
support to conduct this work and to face challenge in my life, God’s love to me is my
greatest inspiration and guide.
Special thanks and appreciation with dedication to my major advisor, Dr. Eric
Nelson, who has supported me not only in my research but also for all my life issues. I
was fortunate to join his lab, also for all kind of help and support with this dissertation.
He has been always an inspiration for many, a friend in need and indeed, a dad, and
mentor. He was always the source of advice not only for me but also for my husband.
I express my sincere appreciation to my wonderful co-advisor, Dr. Jane ChristopherHennings, for all the kind of support and help in the dissertation and my career.
I would like to thank my mentor, Dr. Steve Lawson, who offered me his extensive
knowledge of molecular biology, supported me in learning various techniques, and
helped with trouble shooting when I encountered technical problems. He was always
available and willing to help.
I would like to thank my graduate advisory committee members; Dr Feng Li, Dr
Diego Diel for using their labs, with special thanks to Dr Carrie Steinlicht, Dr. Carrie
supported me in the hard time. Furthermore, all my sincerest thanks to Dr. Christopher
Chase, my committee member and my Egyptian dad for all the type of inspiration, care
and support, he was always beside me.

v

I would like to thank my committee members, Dr. Diel for his assistance and advice
on one of my thesis chapters. Also I would like to express my appreciation for providing
reagents and equipment in his lab.
I am very grateful to the Egyptian Government and my institute, National Research
Center for supporting me with full funded scholarship to earn my PhD degree.
I wish to thank Julie Nelson for providing a nice family culture for me, all plus her
tremendous technical support in different experiment in my study. Also I would like to
thank Aaron Singrey, who was a brother in many difficult time, giving a good advice
with helping in some excellent technical support. Furthermore, I thank Kyle Hain,
Chithra Sreenivasan, Laura Ruesch, Karim Abdelsalam, Lok Joshi, Dr. Mahmoud
Darweesh and all the graduate students in the department with special thanks to the
serology and all employees.
My Love and sincere appreciation to peace Lutheran child care center in Brookings
for all their support to me by taking an excellent cares about my Kids. Actually they
helped me in many difficult times, all beside provide the good cares, teaching and love to
my Kids.
All my sincerest thanks and appreciation to my dear husband, Ahmed Sakr, dear
parents, Abdelaal Okda and Atef Sakr, my dear sisters, Samah and Heba, my dear
brother, Khalid and Hamed and my family and friends in Egypt and in Brookings, South
Dakota.
I would like to thank the different sources of funding including the ADRDL, USDANIFA, SDSU Agricultural Experiment Station, Swine Health Information Center,
National Pork Board, Biovet and BIVI for making this work possible.

vi

TABLE OF CONTENTS
ABBREVIATIONS………………………………………………………………… x
LIST OF FIGURES………………………………………………………………... xiii
LIST OF TABLES………………………………………………………………… xvi
ABSTRACT………………………………………………………………………. xvii
Chapter 1. General Introduction…………………………………………………... 1
Introduction……………………………………………………………….... 1
Dissertation Organization………………………………………………….. 4
Chapter 2. Review of Literature…………………………………………….…….. 6
Coronaviruses…………………………………………………………….... 6
Genomic structure of Coronavirus…………………………………. 6
Coronavirus nonstructural proteins………………………………… 8
Coronavirus structural proteins…………………………………….. 10
Replication/transcription complex (RTC) of coronavirus…………. 11
Swine Corona Viruses …………………………………………….. 11
Porcine Epidemic Diarrhea Virus………………………………………….. 14
Evolution and Epidemiology………………………………………. 14
PEDV genome organization and viral gene function ……………... 15
Tropism…………………………………………………………….. 15
Pathogenesis and host responses to infection ……………………... 18
PEDV diagnostics…………………………………………………. 19

vii

Antigenic cross-reactivity among swine enteric coronaviruses……. 26
Prevention and vaccines……………………………………………. 26
Porcine Deltacoronavirus…………………………………………………... 27
Epidemiology………………………………………………………. 27
Genomic structure………………………………………………….. 28
Clinical signs and disease………………………………………….. 28
Diagnosis of PDCoV………………………………………………. 29
Virological methods for PDCoV detection………………………… 30
Serological methods for PDCoV detection…………………….….. 34
Antigenic cross-reactivity among swine enteric coronaviruses……. 36
Influenza D Virus…………………………………………………………... 37
Etiology and evolution……………………………………………... 37
Survival and inactivation…………………………………………... 38
Zoonotic potential………………………………………………….. 39
Transmission……………………………………………………….. 39
Diagnosis…………………………………………………………... 40
Prevention and control…………………………………………….. 42
References for Chapters 1 and 2…………………………………………… 44
Chapter 3. Development of an indirect ELISA, blocking ELISA, fluorescent microsphere
immunoassay and fluorescent focus neutralization assay for serologic evaluation of
exposure to North American strains of Porcine Epidemic Diarrhea Virus………… 59
Abstract…………………………………………………………………….. 59
Background………………………………………………………………… 61

viii

Methods……………………………………………………………………. 67
Results……………………………………………………………………… 78
Discussion………………………………………………………………….. 82
Conclusions………………………………………………………………… 87
Tables and Figures…………………………………………………………. 89
References………………………………………………………..………… 97
Chapter 4. Development of monoclonal antibodies and serological assays including
indirect ELISA and fluorescent microsphere immunoassays for diagnosis of porcine
deltacoronavirus …………………………………………………………………... 101
Abstract…………………………………………………………….……..... 101
Background………………………………………………………………… 103
Methods……………………………………………………………………. 106
Results………………………………………………………..…………….. 114
Discussion………………………………………………………………..… 119
Conclusions…………………………………………………………..…….. 124
Tables and Figures…………………………………………………………. 126
References…………………………………………………………….…… 135
Chapter 5. The S2 glycoprotein subunit of porcine epidemic diarrhea virus contains
immunodominant neutralizing epitopes…………………………………………… 137
Abstract…………………………………………………………….…….... 137
Introduction……………………………………………………………...… 138
Results………………………………………………………..…...……….. 141

ix

Discussion………………………………………………………………..… 146
Materials and Methods……………………………………………..……… 150
Tables and Figures………………………………………………………… 157
References…………………………………………………………….…… 165

Chapter 6. Development of assays for serological diagnosis of the two distinct lineages
of bovine Influenza D co-circulating in the United States………………………… 168
Introduction……………………………………………………….……….. 168
Methods ……………………………………………………………..…….. 170
Results ………………………………………………………………..…… 178
Discussion ……………………………………………………………...…. 181
Tables and Figures ………………………………………………………… 187
References ………………………………………………………………… 199
Chapter 7. Conclusions…………………………………………………………… 202

x

ABBREVIATIONS
ACB: antigen coating buffer

H: hemagglutinin

bELISA: blocking enzyme linked

HE: hemagglutinin esterase

immunosorbent assay

HAT: hypoxanthine-aminopterin-

BSA: bovine serum albumin

thymidine

CAPS: Cyclohexylamino-1-

HEV: haemagglutinating

propanesulfonic acid

encephalomyelitis virus

CoVs: Coronaviruses

HI: hemagglutination inhibition

CPE: cytopathic effect

HRP: horseradish peroxidase

CV: Coefficient of variation

IBV: Avian infectious bronchitis virus

DMSO: Dimethyl sulfoxide

ICV: Influenza C virus

DPI: days post infection

IDV: Influenza D virus

DSe: diagnostic sensitivity

iELISA: Indirect enzyme linked

DSp: diagnostic specificity

immunosorbent assay

E: envelope

IFA: Immunofluorescent assay

ELISA: enzyme linked immunosorbent

IFN: interferon

assay

IPTG: Isopropyl β-D-1-

EM: electron microscopy

thiogalactopyranoside

FBS: fetal bovine serum

IVA: influenza virus A

FFN: fluorescent focus neutralization

IVB: influenza virus B

FITC: fluorescein isothiocyanate

LAMP: loop-mediated isothermal

FMIA: fluorescent microsphere

amplification

immunoassay

M: matrix

xi

mAb: Monoclonal antibody

PED: Porcine epidemic diarrhea

MDCK: Madin-Darby canine kidney

PEDV: Porcine epidemic diarrhea virus

MERS: Middle Eastern Respiratory

pi: post infection

Syndrome

PI: percent inhibition

MEM: Modified Eagles Medium

PRCV: Porcine respiratory coronavirus

MFI: median fluorescent intensity

PRNT: plaque reduction neutralization

MHV: Mouse hepatitis virus

test

MOI: multiplicity of infection

PRRSV: Porcine reproductive and

N: neuraminidase

respiratory syndrome virus

N7-MTase: methyltransferase

ROC: Receiver operator characteristic

NA: North American

rRT-LAMP: real-time RT-LAMP

NP: nucleoprotein

RT: room temperature

nsp: nonstructural protein

RT-PCR: Reverse transcriptase

OD: optical density

polymerase chain reaction

ORF: Open reading frame

S/P: sample to positive

PB1: polymerase protein

S: spike

P/N: Positive to negative

SARS: Severe Acute Respiratory

PK: pig kidney

Syndrome

PBS: Phosphate buffered saline

SDS-PAGE: Sodium dodecyl sulfate-

PBST: PBS plus 0.05% tween 20

polyacrylamide gel electrophoresis

PCR: Polymerase chain reaction

SIV: Swine influenza virus

PCV-2: Porcine circovirus type 2

SMD: sample milk diluent

PDCoV: Porcine deltacoronavirus

ST: swine testicle

xii

TGEV: Transmissible gastroenteritis
virus
TMB: 3,3’,5,5’- tetramethylbenzidine
TPCK: L-1-Tosylamide-2-phenylethyl
chloromethyl ketone
US: United States
UTR: untranslated region
VI: virus isolation
VN: virus neutralization
YT: yeast extract tryptone

xiii

LIST OF FIGURES

Chapter 3.
Figure 3.1.

Purification of antibody capture antigen…………………………... 90

Figure 3.2.

Antigen/antibody specificity……………………………………..… 91

Figure 3.3.

Serum dilution optimization for both ELISA assays and FMIA…... 92

Figure 3.4.

Receiver operator characteristic (ROC) validation and
determination of diagnostic sensitivity and specificity of the
PEDV-NP iELISA, bELISA and FMIA assays……………………. 93

Figure 3.5.

Kinetic time course antibody evaluation……………………..….… 94

Figure 3.6.

FFN antibody and FMIA isotype time course evaluation…………. 95

Figure 3.7.

Assessment of neutralizing antibody titers in different
sample matrices following PEDV exposure……………………….. 96

Chapter 4.
Figure 4.1.

Purification and antigen specificity of PDCoV-NP antibody
capture antigen…………………………………………………….. 128

Figure 4.2.

Antibody capture efficacy comparison between refolded vs
linear PDCoV-NP…………………………………………………. 129

Figure 4.3.

Production and reactivity of serological reference standards and
internal quality control standards for both ELISA & FMIA……… 130

Figure 4.4.

Receiver operator characteristic (ROC) validation and
determination of diagnostic sensitivity (DSe) and specificity

xiv

(DSp) of the PDCoV-NP ELISA and FMIA assays……………….. 131
Figure 4.5.

Serum antibody kinetic time course evaluation…………………… 132

Figure 4.6.

ELISA and FMIA results from a group of 30 piglets sampled
near the time of initial PDCoV field exposure then 28 days later… 133

Figure 4.7.

Development of reagents used for indirect fluorescent antibody
(IFA) testing and immunohistochemical (IHC) staining
of PDCoV infected cells…………………………………………… 134

Chapter 5.
Figure 5.1.

Summary of the properties and characteristics of mouse monoclonal
antibodies against PEDV and specific PEDV spike by IFA………. 157

Figure 5.2A.

Evaluation of the specificity of the PEDV-S mAbs was done by
Western blots using whole virus preparations, recombinant
S- (amino acid [aa] 630-800 or aa 499-600) and N proteins
expressed in E. coli……………………………………………..…. 158

Figure 5.2B. Evaluation of the specificity of the PEDV-S mAbs was done by
ELISA using whole virus preparations, recombinant
S- (amino acid [aa] 630-800 or aa 499-600) and N proteins
expressed in E. coli…………………………………………..…...... 159
Figure 5.3.

Patterns of plaque reduction of serially diluted mouse monoclonal
antibody against PEDV in PRNT assays using in 6-well plates
and FFN using 96 well plate using Vero cells................................... 160

Figure 5.4.

Correlation between endpoint FFN, PRNT and ELISA titer……… 161

Figure 5.5.

Mapping the mAbs against of the dissect epitope regions within the
S1-S2 junction region which capable of inducing neutralizing

xv

antibodies against the porcine epidemic diarrhea virus using
peptide ELISA.................................................................................. 162
Chapter 6.
Figure 6.1.

IFA on IDV infected MDCK cells using positive and negative
bovine serum samples and anti-bovine FITC……………………… 188

Figure 6.2.

SDS-PAGE/Coomassie blue staining of E. coli expressed and
purified NA and HE antigen…………………………………..…… 189

Figure 6.3.

Confirmation of the specificity of the recombinant proteins
compared to whole virus…………………………………………… 190

Figure 6.4.

Western blot identification of selected IDV proteins using the
IDV-convalescent sera …………………….………………………. 191

Figure 6.5A. Mapping the IDV-mAb …………………………………………… 192
Figure 6.5B. Uncleaved IDVD/660 with rabbit antisera………………………… 192
Figure 6.6.

Cross reactivity between the two IDV different clades of D/660
and C/OK using specific polyclonal rabbit anti-IDV sera against
each virus…………………………………………………..……… 193

Figure 6.7.

Receiver operator characteristic (ROC) assessment and
determination of diagnostic sensitivity and specificity of the
IDV-NP (A), and IDV-HE (B) iELISA……….…………………. 194

Figure 6.8.

Cross reactivity of the mutant HE protein at site 212 amino acid… 196

Figure 6.9.

Example of positive and negative FFN results……………………. 197

Figure 6.10.

Scatter correlation………………………………………………… 198

xvi

LIST OF TABLES

Chapter 2.
Table 2.1.

Coronavirus taxonomy……………………………………..……… 13

Chapter 3.
Table 3.1.

Evaluation of statistical agreement among serological
testing platforms……………………………………………..……. 89

Chapter 4.
Table 4.1.

Evaluation of statistical agreement among three serological
testing platforms………………………………………………..…. 126

Table 4.2.

Serological cross reactivity testing among related swine
coronaviruses……………………………………………………… 127

Chapter 5.
Table 5.1.

Characterization of mouse monoclonal antibodies against PEDV
spike protein……………………………………………..……….

Table 5.2.

163

Mapping the mAbs against the epitope regions capable of inducing
neutralizing antibodies against PEDV infected Vero cells……..…. 164

Chapter 6.
Table 6.1.

Summary of the serological survey from different bovine farms
in the US…………………………………………………………. 187

Table 6.2.

Pearson correlation coefficient between all the diagnostic assays… 195

xvii

ABSTRACT
SURVEILLANCE OF EMERGING LIVESTOCK VIRUSES
FATEN A OKDA
2017
Accurate and rapid diagnostic tests are essential for the management and control
of emerging infectious diseases. Therefore, the overall goals of studies presented in this
dissertation were to provide improved diagnostic and surveillance capabilities for several
emerging viral diseases impacting the livestock industry and to provide insight into
appropriate control strategies.
Recent, severe outbreaks of porcine epidemic diarrhea virus (PEDV) in Asia and
North America highlighted the need for well-validated diagnostic tests for identification
of PEDV infected animals and evaluation of their immune status. PEDV was first
detected in the U.S. in May 2013 and another swine coronavirus, porcine
deltacoronavirus (PDCoV) was identified in the U.S. in February 2014. Both pathogens
spread rapidly across the U.S., severely impacting the swine industry. As part of this
project, well-validated serological assays for the detection of antibodies against PEDV
and PDCoV were developed. Monoclonal antibodies (mAbs) against selected PEDV and
PDCoV structural proteins were also developed and applied to serological and antigen
detection assays. Newly developed fluorescence-based virus neutralization assays also
provide valuable tools for assessment of vaccine candidates or protective immunity.
The PEDV spike (S) glycoprotein plays a key role in virus entry into target cells
and mediates the functions of receptor binding and fusion during entry. Therefore,
immunodominant neutralizing epitopes of PEDV were identified using a panel of S-

xviii

specific mAbs. Epitope mapping by peptide ELISA revealed that seven mAbs recognized
linear neutralizing epitopes located in the N-terminus of the S2 glycoprotein subunit.
Two mAbs recognized a neutralizing epitope located in the C-terminus of S2, while only
one neutralizing mAb reacted against a region of the S1 glycoprotein subunit. These
results indicate that the S2 glycoprotein subunit contains major antigenic determinants
and, perhaps, the immunodominant neutralizing epitopes of PEDV.
Influenza D virus is a recently described virus that affects cattle and limited
serological testing capability is currently available. Therefore, new ELISA-based
serological assays based on expressed protein antigens representing conserved regions of
the nucleoprotein and hemagglutinin-esterase proteins were developed. Results of these
assays correlate well with hemagglutination inhibition (HI) and virus neutralization
assays, providing new tools for ongoing sero-surveillance and control efforts.
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Chapter 1
Introduction
Surveillance of new emerging viruses requires a thorough understanding of the
existing and emerging infections and diseases to develop the fastest, most accurate, and
most dependable diagnostic approaches. Establishment of diagnostic reagents and assays
addressing new emerging diseases, especially viruses, plays an important role in
supporting the livestock economy. It can also protect the food production animal,
livestock industry, companies, farms, wild life animals and animal industries by saving
millions of animals that can die from new devastating emerging viruses. The newly
emerging viruses I am investigating are porcine epidemic diarrhea virus (PEDV), porcine
deltacoronavirus (PDCoV), and Influenza D virus (IDV).
Coronaviruses are enveloped, positive sense RNA viruses that consist of several
genera, including Alphacoronavirus, Betacoronavirus, Gammacoronavirus and the
recently described genus, Deltacoronavirus. Some of the most important porcine
coronaviruses include porcine epidemic diarrhea virus, porcine respiratory coronavirus
(PRCV), and transmissible gastroenteritis virus (TGEV); all members of the genus
Alphacoronavirus [1].
Almost four years ago, an economically devastating swine disease was identified
in United States (U.S.) pig farms, causing severe enteric disease associated with
dehydration followed by high mortality in suckling piglets (50-100%). It was caused by
the acute, highly contagious PEDV. A year later, PDCoV was first identified in the U.S.
but presented itself with less severity. Pigs of all ages are susceptible to PEDV and
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PDCoV; but, older pigs usually showed a milder form of the disease with less mortality
[2,3]. PEDV, a member of the genus Alphacoronavirus and family Coronaviridae [4,5,6],
was first recognized in Europe in 1978 as the causative agent of porcine epidemic
diarrhea (PED). A novel PDCoV was identified in swine feces in Ohio farms and linked
with enteric disease similar to PEDV in the U.S. [7]. PDCoV has been identified in
numerous different U.S. states and Canada, associated with acute diarrhea and vomiting
in the absence of other identifiable pathogens.
Although the analysis of field data and the field observations in the U.S. is
confounded by the co-infections with PEDV or other pathogens. PDCoV infections cause
less severe clinical disease than PEDV [8,9]. The severity of disease in both gnotobiotic
and conventional piglets has further defined the pathogenicity and pathogenesis of the
virus. PDCoV causes diarrhea and vomiting in all age groups and mortality in nursing
pigs with lower mortality rates than that shown in cases of PEDV.
The Orthomyxoviridae family contains some of the most important emerging
virus diseases infecting both humans and animals. The family is characterized by
antigenic shift and antigenic drift mutations. Historically, it included three genera:
Influenza A Virus (IVA), Influenza B Virus (IVB), and Influenza C virus (ICV). In 2011,
a novel virus belonging to a putative new genus was isolated from pigs with influenzalike illness in Oklahoma [10] and designated as Influenza D virus (IDV) [11]. Although
the first isolation was from swine, cattle are considered the main reservoir hosts for this
newly discovered virus. IDV strains have been isolated from cattle in several different
states in the U.S. [11,12,13,14], China [15], France [16], Italy [17], Mexico [18] and
Japan [19].
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Influenza C virus and IDV are enveloped RNA viruses in the family
Orthomyxoviridae. They are closely related to each other and contain seven genomic
segments and a hemagglutinin-esterase fusion protein responsible for recognition,
binding, and destruction of host receptors. ICV and IDV are different than IVA or IVB
that contain eight segments. No re-assortment occurs between ICV and IVA strains, but
IDV strains isolated from swine and cattle have been found to frequently reassort with
each other [11]. The lack of rapid clinical diagnostic tests for IDV limits the ability to
respond appropriately to it. Many methods of virus isolation and serological analysis used
in research are not designed for clinical use and probably underestimate the actual
prevalence of IDV due to low viral loads in the respiratory tract which are detected using
the current reverse transcriptase polymerase chain reaction (RT-PCR).
Humans closely working with swine and poultry are at high risk of zoonotic
infection with an influenza virus. During the 1918 pandemic, there was the first
connection between influenza in swine and humans, when both swine and human
populations became ill simultaneously [20]. In 1976, transmission of an influenza virus
from pigs to humans was first documented, subsequently zoonotic infections have
occurred throughout the world [21].
Our overall project objectives were to: develop, validate and apply serological
assays for PEDV, PDCoV in swine and IDV in cattle. Also, we conducted detailed
characterization and epitope mapping of the PEDV spike protein using monoclonal
antibodies and evaluated the neutralizing ability of the spike specific monoclonal
antibodies against PEDV infection in Vero cells. This work is justified because these are
all very important diseases with significant economic impact and current serological tests

4

are marginal or not available at all. Serological tests are critical for the management and
control of these diseases. One of the assays, the fluorescent microsphere immunoassay
(FMIA), will allow multiplexing, so eventually we can test for previous exposure to
many different diseases at the same time.

Dissertation Organization
This dissertation is composed of two published papers in BMC Veterinary
Research and one ready for submission, plus a chapter on influenza D diagnostics. A
comprehensive literature review is included for all viruses in Chapter 2.
Chapter 3 is a published paper entitled: “Development of an indirect ELISA,
blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus
neutralization assay for serologic evaluation of exposure to North American strains of
Porcine Epidemic Diarrhea Virus”. The objective of this study was to develop and
validate multiple improved serological assays for PEDV, including an indirect ELISA
(iELISA), a highly specific monoclonal antibody-based blocking ELISA (bELISA), an
FMIA that can be multiplexed to monitor exposure to multiple antigens and pathogens
simultaneously, and a fluorescent focus neutralization assay (FFN) to measure functional
virus neutralizing antibodies.
Chapter 4 is a published paper entitled: “Development of monoclonal antibodies
and serological assays including indirect ELISA and fluorescent microsphere
immunoassays for diagnosis of porcine deltacoronavirus”. The overall objective of this
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project was to develop and validate selected diagnostic reagents and assays for PDCoV
antigen and antibody detection.
Chapter 5 is entitled “The S2 glycoprotein subunit of porcine epidemic diarrhea
virus contains immunodominant neutralizing epitopes”. Our goal in this project was to
develop and characterize a panel of monoclonal antibodies to different antigenic and
neutralizing epitopes on the spike (S) protein of PEDV.
Chapter 6 involves studies to develop serological assays for IDV and a
seroprevelance survey of IDV in cattle using ELISAs based on different putative epitopes
of IDV in cattle. The overall objective of this project was to develop and validate
diagnostic assays selecting for IDV antigen and antibody to IDV antigens in diagnostic
samples. Most of the recently published virological surveys are based on the initially
described RT-PCR method, designed on the PB1 gene. It is important to extend the
investigation to different animal species and geographic areas, which requires a
continuous update of molecular diagnostic tests. Also, the availability of alternative
serological assays is essential to confirm data and to ensure the detection of the widest
number of strains.
Chapter 7 consists of a general discussion summarizing the research results and
discusses the implications for future research.
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Chapter 2
Review of Literature
Coronaviruses
Coronaviruses (CoVs) have high zoonotic potential and are a major cause of a
variety of diseases in animals and humans, for example Severe Acute Respiratory
Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS). The CoVs
belong to the order Nidovirales, and the family Coronaviridae contains two subfamilies,
Coronavirinae and Torovirinae [22]. The first member of the coronavirus family was
discovered in the 1930s. After the SARS outbreak shook the world in 2002–2003,
substantial focus was placed on the epidemic potential of CoVs, leading to the
identification of many new family members. The sudden appearance of MERS in 2012 in
the Middle East demonstrated the capability of coronaviruses to jump across species. The
diseases associated with coronaviruses were mainly of veterinary interest and several
cause life-threatening diseases among animals. Coronaviruses spread among a wide
variety of mammals and birds, causing acute or persistent enteric and respiratory diseases
and, in some rarer cases, neurologic disease or hepatitis. In the U.S., TGEV and now
PEDV lead to fatal, watery diarrhea and dehydration in piglets. Avian infectious
bronchitis virus (IBV), a highly contagious respiratory infection in chickens, causes a
severe economic loss by reducing meat and egg production [23].
Genomic Structure of Coronavirus
Coronaviruses are enveloped, spherical or pleomorphic single-stranded positive
sense RNA viruses. CoVs have a genome size of approximately 25.4–31.7 kb which
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replicates in the host cell cytoplasm [22]. Upon the fusion between the virion envelope
and the host cell membrane, they deliver their nucleocapsid into the host cell. The spike
glycoprotein is a primary determinant of cell tropism, pathogenesis, and mediates virus
entry. CoVs spike proteins are classified as a Class I fusion protein responsible for
binding to the receptor on the host cell. After binding to the receptor, fusion occurs
through a process driven by major conformational changes of the S protein. The
conformational change of the S protein is initiated by receptor binding, low pH exposure
and proteolytic activation [24].
The genome contains six to ten open reading frames (ORFs) which are packaged
into a helical nucleocapsid surrounded by host derived lipid bilayer. The first ORF
represents two-thirds of the genome and encodes the replicase proteins. The last third of
the genome contains the structural protein genes in a fixed order: (HE)-S-E-M-N. More
accessory proteins could be present between these genes [25].
The virion envelope includes three viral proteins, the S protein, the membrane
protein (M) and the envelope protein (E). In addition, some coronaviruses contain a
hemagglutinin esterase. The M and E proteins have a critical role in virus assembly. The
S protein is the key of viral entry and determines host range [26]. Enveloped viruses
require fusion with a host cell membrane in order to introduce their genome into the host
cell. Combining cell-biological, infection, and fusion assays, it can be clearly
demonstrated that the CoV family enters cells via clathrin-mediated endocytosis.
Moreover, although some CoVs depend on a low pH for fusion, some rely on trafficking
to lysosomes for proteolytic cleavage of the S protein and membrane fusion to occur [27].
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Following the fusion and initial binding of the receptor, CoVs fuse their envelope
with the host cell membrane and then deliver their nucleocapsid to the target cell. The S
protein leads the process of entry by mediating receptor binding and membrane fusion.
The fusion process requires a major conformational change of the S protein.
Coronaviruses are characterized by the wide variation of their receptors and their
mechanism of triggers to activate fusion [8].
Coronavirus nonstructural proteins
The proteolytic cleavage of pp1a and pp1ab by the viral protease--chymotrypsinlike protease generates the coronavirus nonstructural proteins (nsp) and protease-papainlike proteases play a critical role in viral replication and transcription [28]. Nonstructural
protein 1(nsp1) is the first N-terminal protein released from the ORF1a polyprotein pp1a
which is found only in the alpha and beta coronavirus genus. The sequence and structure
of nsp1 is different among genera and shares low homogeneity. TGEV nsp1 is a protein
of 9 kDa and 28 kDa for SARS-CoV. Nsp1 can functionally suppress the innate immune
response and the expression of host mRNA [29].
Nsp2 is also cleaved from pp1a by the protease activity of nsp3 (PLpro domain).
Nsp2 is dispensable for viral replication as the mouse hepatitis virus (MHV) and SARS
CoV with nsp2 deletions could survive in cell culture. The nsp2 deletion results in
attenuated viral growth and RNA synthesis defects [30]. Nsp3 carries one or two papainlike proteases that belong to the cysteine protease family [31]. The nsp3 is a subunit of
alpha coronaviruses and subgroup 2a beta coronaviruses which contain two active
papain-like protease domains, PL1pro and PL2pro. The PLpro protein is responsible for
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the cleavages between nsp1-nsp2, nsp2-nsp3, and nsp3-nsp4 regions of the coronavirus
[32]. Nsp 4 is critical in double membrane vesicles (DMV) biogenesis. Nsp 5 is a 3C-like
protease (Mpro, 3CLpro), or the main protease of coronavirus that is responsible for
processing eleven cleavage sites from nsp4 to nsp16. Nsp5 is essential for virus
replication [31]. Mutations in the cleavage sites at nsp6-nsp7, nsp7-nsp8, nsp8-nsp9, and
nsp10-nsp11 showed a lethal effect on viral propagation [33]. Nsp6, together with nsp3
and nsp4, are considered the membrane anchor proteins which compromise the
transmembrane domains and participate in formation of reticulovesicular network and
double membrane vesicles (DMV) [34].
Nsp7 and nsp8 form a hollow cylinder-like complex on the surface of an inner
channel for binding to the double stranded RNA. They initiate the de novo RNA
synthesis. Nsp7 structure is featured with 3 α-helix bundles found at the N-terminal,
HB1, HB2 and HB3, and one α- helix is present at the C-terminal. Two different
conformations, nsp8I and nsp8II have a “golf-club like structure”, of which the N
terminal is the shaft containing an α- helix, while the C terminal is the head containing 3
α- helices and 7 β-strands. Eight copies of nsp7 cross link with four copies of nsp8I and 4
copies of nsp8 II respectively leading to the formation of the hexadecamer [35]. Nsp9 has
RNA and DNA binding activity while the interaction between nsp10 and nsp14 or nsp16
has a valuable role in the fidelity and methylation of the virus. The nsp10 is the main
activator of nsp14 and nsp16. The nsp14 has two domains: S-adenosyl methionine dependent (guanine-N7) methyltransferase at the C-terminal and 3’ to 5’ exonuclease at
N-terminal. The nsp16 acts as the AdoMet-dependent (nucleoside-2’O)-methyltransferase
[36].
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Nsp11 is essential for the viral replication. Nsp12 is the viral RNA dependent
RNA polymerase with canonical motifs which are located at the C-terminal. Nsp12
functions as the trigger of the RNA extension with help from a primer, which results from
the de novo synthesis of nsp8 in coronaviruses. Nsp13 is a helicase of the virus, which
directs both RNA and DNA in a 5’-to-3’ direction. Nsp13 has RNA 5’-triphosphatase
activity related to the viral capping process. Nsp15 is a viral endoribonuclease, of which
the C-terminal region [37,38,39].
Coronavirus structural proteins
The structural proteins; S, E, M, and N are translated from multiple sub-genomic
mRNAs and contribute to the architecture of the virus particle. The S protein is
characterized by a typical structure of a crown-like corona in a form of trimers, and is
displayed on the virus membrane. The S protein is classified as a class I viral fusion or
type I transmembrane protein. It is cleaved into S1 and S2 subunits by the protease,
including trypsin and cathepsin required during the infection [40]. This cleavage is
essential to trigger the cell-to-cell fusion and virus entry into cells. The S1 subunit carries
the receptor binding domain, which is responsible for receptor binding, host range, and
virus cell and tissue tropism [41]. The S2 subunit contains a fusion peptide, heptad repeat
regions 1 and 2, which acts as critical component for virus-host fusion and syncytial
formation. Furthermore, S proteins from most coronaviruses, including SARS-CoV,
MHV and PEDV, are able to be cleaved by trypsin at two specific sites. One cleavage
site, S1/S2, which is located at the boundary of the S1 and S2 site and the S2’ site,
located close to the fusion peptide. The S2’ is considered to be crucial for fusion activity
of the S protein [42].
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The N protein is the most abundant protein in virus infected cells. The N protein
harbors the viral genome RNA molecule in a ribonucleoprotein complex. The N protein
consists of an N-terminal domain, a C-terminal domain, and intrinsically disordered
regions, in which multiple sites within the three regions are able to bind and activate with
RNA [43]. Moreover, the N protein has been determined to associate with the replication
transcription complex; for example, the N protein of MHV binds to the viral nsp3
through the N-terminal domain and the linker region. Also, N protein of SARS-CoV
inhibits the synthesis of interferon (IFN)-β [44]. Recently, PEDV N protein was
demonstrated to antagonize IFN-β production through sequestering interaction between
interferon regulatory factor 3 and TANK binding kinase 1, which is a critical step in type
I IFN signaling [45]. The M protein is the most abundant in the viral envelope and both
M and E proteins have been demonstrated to be essential for virus assembly.
Replication/transcription complex of coronavirus
The replication transcription complex of most CoVs contains all non-structural
proteins (nsp1-15 or nsp16). The replication transcription complex is associated with the
double membrane vesicles derived from endoplasmic reticulum. The non-structural
proteins of SARS-CoV, nsp3, 4 and 6 are able to induce the double membrane vesicles
formation and initiate the replication transcription complex anchor to the membrane.
Double membrane vesicles are an ideal place for RNA replication and provide the
protection from host defense mechanisms that could be triggered by dsRNA
intermediates during the replication [46].
Swine Coronaviruses
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Porcine coronaviruses are considered a highly significant cause of enteric and
respiratory disease of swine. Five CoVs have been identified in pigs: TGEV, porcine
respiratory coronavirus (PRCV), PEDV, hemagglutinating encephalomyelitis virus
(HEV), and PDCoV. Within the past four years, PEDV and PDCoV were detected in the
U.S. domesticated pig population. In 1946, an alphacoronavirus, porcine TGEV, was
identified as a devastating enteric disease of pigs in the U.S. In 1984, another U.S.
porcine -CoV, PRCV, was officially identified as a deletion mutant of TGEV. PRCV is
characterized by having a different viral tropism from intestinal to respiratory epithelia.
PRCV replicates almost entirely in the respiratory tract and is similar to other porcine
viral pneumonias. Later, in 1971, PEDV was identified in the United Kingdom. PEDV is
similar to TGEV in which they both replicate in small-intestinal enterocytes. PEDV
causes life threatening acute enteric disease in suckling piglets due to profuse watery
diarrhea, emesis, and dehydration with high morbidity and mortality. Since 2010,
different variant strains of PEDV other than the classic European strain (CV777) have
appeared in China, South Korea, Japan, and different Asian countries, leading to 100%
mortality in suckling piglets. PEDV was identified as a new cause of neonatal diarrhea in
Iowa in May 2013, consequently the infection rapidly spread to more than 30 states,
Canada, and Mexico causing devastating economic losses in the swine industry
[47,48,49]. During an investigation for new CoVs in a variety of mammalian and avian
species, the species deltacoronavirus was discovered [8]. In February 2014, the Ohio
Department of Agriculture officially documented the identification of PDCoV in the US.
PDCoV causes severe, watery diarrhea, and vomiting appears within 48–72 h post
infection [50]. Examples of coronavirus genus and species are shown in Table 2.1.
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Table 2.1. Coronavirus taxonomy
Genus

Species

Receptor

Alphacoronavirus

*Alphacoronavirus 1 comprising: Feline coronavirus
serotype 2, Canine coronavirus serotype 2,
Transmissible gastroenteritis virus (TGEV)

Aminopeptidase
N

*Human coronavirus 229E

Aminopeptidase
N

*Human coronavirus NL63
*Porcine epidemic diarrhea virus PEDV
*Rhinolophus bat coronavirus HKU2
*Scotophilus bat coronavirus S12/05
*Miniopetrus bat coronavirus 1
*Miniopetrus bat coronavirus HKU 8
Betacoronavirus

Aminopeptidase
N
Aminopeptidase
N
ACE2
Aminopeptidase
N

*Betacoronavirus 1 comprising: Bovine coronavirus
(BCoV), Human coronavirus OC43 (HcoV-OC43),
Equine coronavirus (ECoV), Human enteric
coronavirus (HECoV), Porcine haemagglutinating
encephalomyelitis virus(PHEV), Canine respiratory
coronavirus (CCoV)

Neu 5,9 AC2

*Murine coronavirus comprising: mouse hepatitis
virus (MHV)\, Rat coronavirus, Puffinosis virus

Neu 5,9 AC2

*Human coronavirus HKU 9 *Rousettus bat
coronavirus HKU 4

CEACAMI

*Tylonyeteris bat coronavirus HKU 5
SARs coronavirus comprising: Human SARs
coronavirus and Rhinolophus bat virus
GammaCoronavirus

Avian coronavirus comprising: IBV and various
coronavirus infecting turkey, goose, duck, pigeon
and pheasant
Beluga whale coronavirus SW1

DeltaCoronavirus

Bulbul coronavirus HKU11, Thrush coronavirus
HKU12, Munia coronavirus HKU 13

ACE2
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Porcine Epidemic Diarrhea Virus (PEDV)
Evolution and Epidemiology
Porcine epidemic diarrhea virus is the cause of an economically devastating swine
disease. The disease causes high mortality and morbidity in pigs, especially in young
piglets. The causative agent belongs to the genus Alphacoronavirus in the family
Coronaviridae, [51]. PEDV was initially identified in Europe in 1978 [25]. The virus was
detected in Japan in 1982, spreading to several neighboring countries, including China,
Korea, Thailand, Vietnam and Taiwan, in which the virus remains endemic to date
[5,52,53].
Since 2010, highly virulent PEDV spread in China then appeared in the U.S. in
2013, causing health concerns and significant economic loss, followed by spreading to
Canada and Mexico [47,54,55]. PEDV is an enteropathogenic virus which targets the
epithelia of the small intestine, leading to villous atrophy causing severe diarrhea,
vomiting, and dehydration followed by high mortality rates (50-100%) in suckling piglets
and weight loss secondary to diarrhea in older animals [2,3]. The virus replicates
primarily in enterocytes of the small intestines leading to villous atrophy and
malabsorptive diarrhea followed by electrolyte imbalance, metabolic acidosis and death.
Characteristic clinical signs of PED include watery diarrhea, vomiting, anorexia,
dehydration and death of piglets while in older pigs the disease is usually milder resulting
in low mortality rates. Trypsin is required for the activation of virions to aid in the
membrane fusion through it is role in cleaving the spike glycoprotein [56].

15

PEDV genome organization and viral gene function
The PEDV genome is a large (~28 Kb) enveloped, positive-sense, single stranded
RNA virus which contains seven open reading frames (ORF1a, ORF1b, and ORF2-6).
The genome is arranged into orderly 5′-UTRs (5′-untranslated regions), the polymerase
gene, spike (S), open reading frame 3 gene (ORF3), envelope (E), membrane (M),
nucleocapsid (N), and 3′-UTR. Subgenomic mRNAs of PEDV are transcribed from its
genomic RNA, then translated producing viral proteins [27,57,58]. ORFs 1a and 1b
encode large polyproteins (pp1a and pp1b). These large proteins are cleaved by viral
encoded proteases into 16 non-structural proteins (nsp1-16) involved in basic
mechanisms of viral RNA transcription and replication [6].
Four structural proteins are encoded in ORFs2-6, including the spike (S,180–220
kDa) glycoprotein, membrane (M, 27– 32 kDa) protein, envelope (E,7 kDa) protein, and
the nucleocapsid (N, 55–58 kDa) protein, and one more accessory protein ORF3 [49,59].
The M and N proteins are conservative proteins that are often used for the development
of serological and other diagnostic assays for PEDV [42,60].
Tropism
The homogenous or heterogenous proteases activate the fusion process between
the viral envelope and the cell membrane and facilitate the viral RNA genome release
into the cytoplasma. Firstly, the replicase polyproteins 1a and 1ab are synthesized and
then the viral proteases cleave it into 16 nsps, including nsp3 and nsp5. Secondly, the
nsps participate in genome replication and synthesis of full-length negative-strand RNA
at a low concentration, which acts as the template for full-length genomic RNA. Nested
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genome is specific characteristic of coronaviruses and other Nidoviruses, with
subgenomic mRNAs that an identical 3’ end terminal and 5’ leader sequence. Finally,
mRNAs are translated to viral structural proteins and extra accessory proteins. After
synthesis and posttranslational modification in the endoplasmic reticulum and Golgi
compartment, mature structural proteins are then assembled with genomic RNA into
virions. The virion is released outside the cell by exocytosis for the next generation
infection [61].
PEDV evades the innate immune response as it does not evoke a vigorous IFN
response. PEDV infection interferes with the activation of interferon regulatory factor 3
that leads to blocking of the synthetic dsRNA-induced IFN-β. PEDV replicase encoded
papain-like protease 2 is an IFN antagonist which depends on the catalytic activity for its
function. PEDV Papain-like protease 2 inhibits RIG-I- and STING-activated IFN
expression (the key components of the signaling pathway for IFN expression) through a
co-immunoprecipitation and deubiquitination process which interferes with the RIG-Iand STING-mediated signaling pathway. PEDV infection represses the production of
IFN-β [62].
PEDV receptor binding and cell entry are essential steps in the cycle of viral
infection and critical determinants of viral host range and tropism which makes these
processes important targets for antiviral discovery. The envelope-anchored spike protein
initiates the virus entry into the cells. The spike ectodomain contains a receptor-binding
subunit, S1, and a membrane fusion subunit, S2. The S1 subunit consists of two domains,
an N-terminal domain and a C-terminal domain, which work as receptor-binding
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domains. The ability of coronavirus receptor-binding domains to recognize the receptor
determines the host range and tropism of coronaviruses [63].
PEDV uses porcine aminopeptidase N as its receptor. Addressing whether it uses
sugar co-receptors is critical for developing effective vaccines and antiviral drugs to
control PEDV. The S1-N-terminal domain and C-terminal domain (NTD-CTD) fragment
might serve as a subunit vaccine candidate. Monoclonal antibodies against S1-NTD-CTD
may serve as immunotherapeutic agents to block PEDV attachment to both the
aminopeptidase N receptor and the sugar co-receptor. In addition, sugar or sugar
analogues may serve as antiviral drugs to block PEDV attachment to its sugar coreceptor. The development of these antiviral strategies is important because of the
damaging impact that PEDV exerts on the U.S. pork industry [64].
The trimetric spike proteins characterize the virion envelope and initiate the
receptor binding and membrane fusion. Due to the molecular features, this S protein has
been known as a class I fusion protein that has a locked conformation generation to
inhibit the premature triggering of the fusion mechanism then prepared for the proteolytic
process called priming. This results in a cleavage of S protein producing two functional
protein domains, a soluble head domain that is responsible for receptor binding and a
membrane bound subunit for the fusion process. A characteristic feature of the cleaved,
fusion-ready subunit is an N-terminal fusion peptide. Proteolytic priming can occur in the
extracellular environment, virus-producing cell or after contact of the virus with the
target cell membrane. Priming of the PEDV S protein is generated by intestinal digestive
enzymes [42].
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Pathogenesis and host responses to infection
PEDV infects all pigs of different ages, but suckling pigs are the most severely
affected. After fecal-oral transmission, PEDV replicates in intestinal enterocytes that
express large amounts of the porcine aminopeptidase N receptor that is considered to be a
receptor for PEDV. The PEDV S protein facilitates the binding process to the receptor
which then cleaves into subunits S1 and S2, leading to a conformational change in the
receptor and internalization of the virus by the cell [59].
Replication of PEDV in enterocytes leads to cell lysis, causing villous atrophy
and subsequent destruction of the brush border. PEDV cell receptors play a critical role in
digestion and nutrient absorption, so destruction caused by PEDV infection leads to
malabsorption and severe, acute watery diarrhea within one week leading to higher viral
shedding in infected pigs. Replicating virus is then shed in the feces where it is spread to
other animals. Despite its ability to cause disease in swine of all ages, PEDV has notably
higher mortality rates in suckling piglets. Physiological factors associated with the age of
the pigs may play important roles, specifically the slower rate of enterocyte regeneration
in young pigs. Although mortality is rare in older animals, there is still considerate
morbidity associated with PEDV infection [65,66].
The PEDV incubation period varies according to the age of the pigs, for instance,
it can be one day in 1-day old nursing piglets or 3-6 days in 3-week old weaned piglets.
The characteristic clinical signs of PED are diarrhea and vomiting which can persist for
5-10 days. Fecal shedding of PEDV often starts 1-3 days’ post infection (pi) and can be
detected in feces for up to 24-30 days’ pi [47,65,67,68].
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The early detection of PEDV specific antibodies in serum varies between days 6
and 14 pi [60]. Clearly, the antibody responses detected were against PEDV N and S
proteins, which are considered the two major structural proteins of the virus. Neutralizing
PEDV antibodies are first detected between days 7 and 14 pi, peaking on day 21 pi and
persisting for at least 6 months’ pi [69].
PEDV Diagnostics
After the first appearance of PEDV in the U.S in 2013. Several molecular
biological and immunological techniques have been developed to diagnose PEDV.
Highly specific virological and serological methods have been developed including realtime and conventional PCR, enzyme-linked immunosorbent assays (ELISA),
immunofluorescence assays (IFA), immunohistochemistry, 3’ isothermal amplification
assays, and electron microscopy (EM) [70].
In April 2013, the Iowa State University Veterinary Diagnostic Laboratory was
not able to differentiate between PEDV and TGEV in the initial case because of clinical
symptoms that are consistent with TGEV. Consequently, tissue samples from small
intestines were collected and stained with hematoxylin and eosin for microscopic
examination. The examination showed severe atrophy of villi in all segments of the small
intestines and villus-epithelial syncytial cells. Negative-staining EM revealed presence of
coronavirus-like particles in the feces and intestinal contents but PCR testing for TGEV
was negative. A pan-CoV RT PCR was done and suggested a positive amplification of
the S gene and the N gene of PEDV, which by sequence comparison showed high
identity to known PEDV strains but negative of TGEV and PRCV [47].
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Virus isolation: Vero cells are the most widely used cell line for isolation and
propagation of PEDV. Replication in cell culture induces typical cytopathic effect (CPE)
that is characterized by cell fusion, syncytia formation and eventually cell detachment
[4,63,71]. One of the important requirements for PEDV replication in cell culture is the
presence of exogenous trypsin in the cell culture medium. The proteolytic activity of
trypsin triggers the cleavage of the S glycoprotein into the S1 and S2 subunits, leading to
virus-to-cell and cell-to-cell fusion and increased virus infectivity and release from
infected cells [42].
Direct and Indirect Immunofluorescence assay: The direct FA has been used
to confirm virus isolation and to detect PEDV antigens (antibody-antigen reaction) in cell
culture [63,71]. The direct FA is to detect intracellular viral antigens using fluorophoreconjugated PEDV-specific antibodies which can be visualized under a fluorescent
microscope. The direct FA showed value to detect virus antigens in infected intestinal
enterocytes in formalin fixed tissues [4,72,73]. Using the direct FA assay, the viral
antigens can be detected in intestinal samples for up to 72 h after the onset of clinical
signs [72,73,74].
The IFA is a serological assay and utilizes PEDV infected Vero cell cultures as
antigen to detect PEDV specific antibodies found in serum samples of pigs suspected to
be infected. If the sample is positive, the PEDV specific antibodies bind to the antigens
and then these antibodies can be detected with fluorophore-labeled anti-porcine
secondary antibodies and visualized with a fluorescence microscope [66]. The IFA assay
is specific, less time consuming than other assays detecting antibody and easier to
perform [5]. Moreover, IFA can be used for qualitative or quantitative evaluation of
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PEDV-specific antibodies in serum. The titers of antibodies can be determined by
incubation of serial two-fold dilutions of serum with PEDV infected Vero cells. The
antibody titer is the reciprocal of the highest dilution of serum in which specific
fluorescent signal is detected. Antibody can be detected from 7 to 14 days’ post-exposure
by IFA and detected for at least 43 days’ pi after which the antibody titer starts to decline
[75].
Polymerase chain reaction-based assays for detection of PEDV nucleic acid:
PCR is a method in which an in vitro amplification of specific nucleic acid sequences can
be done. The PCR rapidly and specifically produces more than a million copies of a
target nucleic acid sequence through a simple three-step cycling process. The specificity
of the assay depends mainly on the primers (oligonucleotides with ~18-24 nt in length).
These primers are complementary and capable of hybridizing with opposite strands of the
target region to be amplified [76].
It is important to be able to differentiate PEDV from other related swine
coronaviruses including TGEV and PDCoV when we design primers for PCR [63]. The
structural proteins of the PEDV; N, M or S, have been used as diagnostic targets but
consideration of their genetic variability is important [77,78]. For instance, the spike gene
is the most variable and several strains all over the world are characterized by deletions in
their spike gene so this may not represent a good diagnostic target [79].
PCR shows good sensitivity for the detection of the PEDV genome in feces,
swabs, intestinal or rectal samples from infected pigs [65,71]. Also, oral fluid has been
used in an RT-PCR based test [80]. In comparison to IFA and other diagnostic assays,
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PCR is a more sensitive, specific and rapid method to detect viral nucleic acid, although
it may be positive when no infectious virus is present in the clinical sample.
Conventional RT-PCR: Briefly, the conventional RT-PCR amplifies a target
nucleic region of the PEDV genome using virus specific primers in RT-PCR reactions,
followed by electrophoresis and visualization of amplicons in agarose gels [81,82,83].
Recently, multiplex RT-PCR assays have been developed for detection and
differentiation of several porcine enteric viruses, including PEDV, TGEV and porcine
rotaviruses [84,85,86,87].
Real-time reverse transcriptase PCR (rRT-PCR): The detection of amplicons
in rRT-PCR depends on two different methods; the first utilizes a nonspecific fluorescent
probe that interacts with PEDV double stranded DNA, and the second depends on
sequence-specific oligonucleotide probes that are labelled by a fluorescent reporter that
hybridizes with the target sequence. The amount of fluorescent emission by the probe
during the extension of the target sequence can be detected in real time by a
thermocycler. The sequence-specific probe based rRT-PCR proves to be the best and
most specific diagnostic molecular technique [88].
A multiplex rRT-PCR assay has been developed for detection of PEDV, TGEV,
Group A rotaviruses, and porcine circovirus. This test serves as a rapid identification and
differentiation between different strains of PEDV [89], and also with other enteric viral
pathogens of swine, including the closely related coronaviruses, TGEV and PDCoV
[89,90]. At the South Dakota State University Animal Disease Research and Diagnostic
Laboratory, a multiplex rRT-PCR assay for simultaneous detection of PEDV, PDCoV

23

and TGEV has been used routinely since July 2014. Since then, more than 50,000
samples from more than 25 US states have been tested (Clement, T., personal
communication).
There are two rRT-PCR assays developed recently targeting the N and the S gene
of PEDV. The detection limit of these rRT-PCRs were 10-6 and 10-5 for the N and S
assays, corresponding to a virus suspension containing ~10-2.2 and ~10-0.2 TCID50/mL of
PEDV, respectively. The S assay performed better than the N-based assay [78].
Virus neutralization assays: Virus neutralization (VN) is the reduction of the
viral infectivity mediated by antibodies, specifically neutralizing antibodies. The basics
of the test are the binding of the antibodies to the virions, so if the sample is positive, the
antibodies will either block the entry of the virus, prevent binding to the receptors, or
restrict the uncoating cycle [91]. Originally, the test depended on the ability to read
reduction of CPE when neutralizing antibody was present [92]. A difficulty arises when
trying to determine CPE on cells infected with PEDV due to importance of adding trypsin
to the PEDV culture media in order for the virus to grow. It is difficult to differentiate
between the cell rounding and detachment that occurs because of virus infection or the
effect trypsin has on cell monolayers. Recently, a modification of the VN test was
developed called a fluorescent focus neutralization (FFN) for rapid PEDV neutralizing
antibody detection [60,66]. The PEDV infectivity is assessed by using an anti-PEDV
fluorophore-conjugated antibody and the neutralizing antibody titers are determined as
the reciprocal of the highest serum dilution resulting in 90% or greater reduction in
fluorescent foci relative to negative control samples [60]. The neutralizing antibodies
have been detected by 7-14 days’ pi in experimentally infected animals and can be
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detected for at least 6 months post natural PEDV infection. The FFN assay has been
optimized and validated for the detection and quantitation of PEDV neutralizing Abs in
serum, colostrum and milk samples [69,75].
Antibody ELISAs: Since 2013, after the first appearance of PEDV in U.S. swine
farms, different PEDV diagnostic ELISAs have been developed. The PEDV indirect
ELISA has been developed based on different antigens; for instance, whole virus
preparation [66] or recombinant structural proteins expressed in bacteria, such as the N
protein [60] and S protein [93,94,95,96]. The indirect ELISA immobilizes antigen on a
solid phase and then is incubated with the test sample to allow the antibody-antigen
complex formation. An enzyme-linked secondary antibody coupled with a colorimetric
substrate detection system is used to develop the test [97].
PEDV blocking ELISAs or competitive ELISAs have been developed based on
using PEDV-specific monoclonal or polyclonal antibodies [60,98]. In these assays, the
labeled antibodies are added to the antigen coated microplates together with the test
sample allowing competition between the antibodies present in the serum and labeled
monoclonal antibodies for the antigen immobilized in the wells [97]. The reaction is also
developed as for the indirect ELISA. The blocking ELISA is characterized by a greater
specificity than the indirect ELISA [98].
Fluorescent microsphere immunoassay: The FMIA basically depends on a
fluidic fluorescent microsphere laser scanning system. The FMIA has several advantages
compared to the ELISA, including higher sample throughput, sensitivity, and the ability
to multiplex or detect antibodies specific to multiple pathogens simultaneously [99]. The
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FMIA can be done by coupling a specific viral antigen to fluorescent microspheres, then
antigen-specific antibodies are detected using a biotin/streptavidin/fluorophore detection
system. The results are expressed as median fluorescent intensity (MFI) in which a duallaser instrument (i.e. Bio-Plex 200, Bio-Rad) can detect the florescent emission of the
antigen-antibody reactions. PEDV N-specific antibodies were developed and specifically
able to detect the antibody level as early as 6 days’ pi with peak antibody levels detected
on day 21 pi [60].
Immunohistochemistry: Immunohistochemistry is a highly specific and
sensitive test used for the detection of PEDV antigens in intestinal tissues [47,68]. The
test involves immunological (antibody-antigen) and chemical (enzyme-substrate)
reactions [100]. PEDV-specific antibodies, which can be polyclonal or monoclonal, are
able to detect the viral antigen early, prior to the appearance of clinical signs. The assay
allows the visualization of target cells and the antigen in the intestinal tissue during the
course of infection starting one-day pi to 14 days’ pi. [68,101]. One more advantage of
immunohistochemistry is that archived fixed samples can be tested.
Isothermal amplification assays: Loop-mediated isothermal amplification
(LAMP) is a nucleic acid amplification method characterized by simple, specific and
cost-effective techniques. It has been recently applied for infectious disease diagnosis,
including disease due to PEDV [102,103,104]. In the assay, 4-6 primers are used to
recognize six to eight regions of target DNA associated with the Bst DNA polymerase.
This acts as a strand-displacement activity. The amplification step is performed under a
single temperature (isothermal), leading to the synthesis of large amounts of nucleic acid
[102,103]. The amplification reactions can be simply performed using inexpensive
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equipment (i.e. water bath), without using thermocyclers [102,105]. Addition of a
fluorescent dye in the reaction mix can be done and allows the assessment of the results
by simple visual inspection [106].
Ren and Li [103] designed the RT-LAMP to amplify the N gene of PEDV with a
detection limit lower than that of the RT-PCR. Recently a real-time RT-LAMP for the
detection of PEDV has been developed, in which five sets of primers targeting the M
gene of PEDV have been used followed by a detection of the amplified target sequence
using a loop amp real-time turbid meter. The sensitivity and specificity of RT-LAMPbased assays associated with the low cost and efficiency make this method an alternative
for PEDV diagnosis [104].
Antigenic cross-reactivity among swine enteric coronaviruses
Swine hyperimmune antisera against TGEV (Miller strain) cross-reacted with
PEDV in the cell culture IFA, however swine antisera against PEDV did not cross-react
with TGEV by the same test. This one-way antigenic cross-reactivity could be due to a
single epitope on the N-terminal region of PEDV/TGEV [107]. Another study showed
that the PEDV whole virus-based ELISA and S1 protein-based ELISAs did not crossreact to swine antisera against PDCoV, PRCV, or TGEV Purdue strain [108].
Prevention and Vaccines
Development of vaccines for enteric pathogens like PEDV are still considered a
major challenge, especially because of the requirement for lactogenic immunity. The
crudest strategies to prevent PEDV infection was the exposure of pregnant sows to live,
infectious virus in which older animals are not susceptible to PEDV associated mortality
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and will recover from the disease [70]. Subsequently, sows exposed to PEDV are able to
transfer PEDV specific antibodies passively to their offspring in the colostrum. The
maternal antibodies effectively protect the piglets from disease. Specific IgG and IgA are
secreted in colostrum, with 60% being IgG. In addition, subsequent immunity to PEDV
can be achieved by exposing animals to feces or minced intestines of infected animals
[109]. Infecting healthy animals results in inconsistent immunity and has several negative
implications, as well as the inherent dangers of its spread to other animals and farms.
The proper sanitary and hygienic precautions to prevent spread of the highly infectious
virus are considered the best strategies for preventing PEDV.
Since PEDV emergence, initially in Europe, then Asia, the most current PEDV
vaccines have been developed for different strains circulating in Asia [110]. In 1977,
PEDV CV777 strain was used as a vaccine in either inactivated or attenuated forms in
Europe. Attenuated vaccines were developed by multiple passages in cell culture, leading
to significant mutation in the viral genome. The Korean KPEDV-1 strain and the
Japanese P-5V strain were successfully attenuated by passaging the virus many times in
Vero cells. Both vaccines are moderately effective producers of lactogenic immunity, and
are capable of passive immunization of suckling piglets [111].
Porcine Deltacoronavirus
Epidemiology
Initially, porcine deltacoronavirus was first recognized in 2009 during a molecular
surveillance study in pig samples collected in Hong Kong [8]. In February 2014, PDCoV
emerged in U.S. swine and the virus rapidly spread in the U.S. [7,112,113]. Shortly after
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the emergence of PDCoV in US, the virus was detected in the South Korean pig farms
[114] followed by emergence in mainland China and Thailand [115,116].
Genomic Structure
Like other coronaviruses, PDCoV is an enveloped, positive-sense, singlestranded, RNA virus characterized by a genome of about 25 kb in length. The genomic
organization is in the order of: 5 UTR, ORF1a/1b, S, E, M, nsp6, N, nsp7, and 3 UTR
region. PDCoV protein functions are unknown. However, like other CoVs, the replicase
polyproteins 1a (pp1a) and pp1ab are cleaved by virus-encoded proteases producing 1516 nsps involved in viral transcription and replication [22]. The spike glycoprotein of
CoVs is the key protein for receptor binding, cell membrane fusion and entry; moreover,
the S protein harbors the neutralizing epitopes.
In the whole genome sequences, the S and the N gene sequences of PDCoV have
been used for phylogenetic analysis [115,117]. The S, M and N protein genes of PDCoV
also have been used for the development of virological and serological diagnostic assays
[50,118,119].
Clinical signs and disease
Similar to the other swine enteric pathogens like PEDV and TGEV, PDCoV
clinical manifestations are diarrhea, vomiting, dehydration and mortality in neonatal
piglets, but generally milder than PEDV infection [116,120]. The histopathological
lesions presented are primarily atrophic enteritis [121]. Conventional and gnotobiotic
piglets inoculated with PDCoV showed mild to severe diarrhea, gross and microscopic
intestinal lesions in experimental infection studies [122].
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Clinical studies were performed by inoculating 10 to 19 day-old gnotobiotic pigs
with cell culture-adapted PDCoV isolates and/or PDCoV positive intestinal contents. The
inoculated pigs showed diarrhea and vomiting from 24 -72 hr post inoculation and the
diarrhea persisted for 72–120 hr pi. The viral RNA was detected in feces from 24 hr pi
and lasted to 72–120 hr pi [50,65]. A second study in which 5-day-old conventional pigs
were inoculated experimentally by 3*104 TCID of cell culture adapted PDCoV isolates
showed diarrhea starting 5 days’ post inoculation and maintained to day 7 pi. The viral
RNA shedding in feces lasted from 2-7 days’ pi [118]. In another study, inoculation of
four 10-day-old conventional pigs were done orally using 5ml of virus containing 106
PFU of PDCoV. The diarrhea occurred on 1 day pi and persisted for 7–10 days. All of the
inoculated pigs recovered from disease by 10 day pi. The fecal viral RNA shedding was
detected on 1–2 days’ pi, increased to the peak on 7 day pi, then gradually declined after
10 day pi [50].
Diagnosis of PDCoV
PDCoV diagnostic samples: Individual fecal swabs, pen-based oral fluids, and
pen-based feces can be collected and used for PDCoV PCR and/or virus isolation (VI)
assays. Due to the transient viremia caused by PDCoV infection and the low level of
virus in the serum, serum is not the best choice for PCR or VI [118]. The small intestinal
tissues, especially the jejunum and ileum, are considered good samples for PCR and VI
during the acute infection from 1-10 days’ pi. The tissue samples should be collected
fresh and placed in 10% buffered formalin for histology and immunohistochemistry
examinations [50,65].
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Virological methods for PDCoV detection
The virological methods for PDCoV include detection of virus particles using
EM, detection of viral nucleic acid using different RT-PCRs and in situ hybridization,
detection of viral antigen by immunofluorescence staining and immunohistochemistry,
and detection of viable virus through the virus isolation and swine bioassay techniques.
Virus Isolation: The National Veterinary Services Laboratories under USDA has
isolated PDCoV USA/IL/2014 strain and Michigan/8977/2014 strain in a swine testicular
cell line [50,118]. Hu et al. [123] reported successful isolation and propagation of
PDCoV OHFD22 strain in the LLC-pig kidney 1 (PK1) cell line and the swine testicle
(ST) cell line. PDCoV cytopathic effects (CPE) in LLC-PK1 and ST cells can be seen as
enlarged, rounded, granular cells followed by cell detachment. In addition, PDCoV
OHFD22 replicated in LLC-PK1 cells in the absence of trypsin with 10,000-fold less
virus titer than with trypsin. Moreover, the addition of small intestinal contents from
gnotobiotic pigs together with trypsin or pancreatin to the culture medium resulted in low
PDCoV titer of 7 log10 PFU/ml compared to the trypsin only. Interestingly, trypsin did
not support PDCoV OH-FD22 propagation in ST cells; but, PDCoV propagated
efficiently in ST cells when 10% pig swine intestinal content or 1% pancreatin was added
[123].
A high concentration of virus and the use of the fresh samples are the critical
factors for success of VI in cell culture. PDCoV VI is not a reliable assay to determine
whether infectious virus is present in a clinical specimen due to the low success rate of
PDCoV VI in cell culture.
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Electron microscopy: Electron microscopy is considered a first step in the
diagnosis of many viruses. Although EM cannot identify viruses to the related species
and is a less sensitive test that needs at least 105–6 virions per milliliter and a highly
skilled microscopist, it allows direct examination and visualization of the virus particles.
There are two EM techniques commonly used in diagnostic laboratories: negative-stain
EM that detects virus particles in a fluid matrix, and ultrathin-section EM for detection of
virus particles in fixed tissues or cells. The PDCoV characteristic morphology and size of
virus particles seen under EM identify it as coronavirus-like particles.
Polymerase chain reaction-based assays: RT-PCR is the in vitro amplification
of specific nucleic acid sequences to produce a billion copies of target sequences by 35–
40 cycles of three-step process denaturation, annealing, and extension within a few hours.
A number of specimen types such as feces, intestinal tissue, rectal swabs, contents, oral
fluid, environmental samples, and feed can be tested for presence of PDCoV RNA by
RT-PCR. Magnetic bead-based reagents and automated extraction on different magnetic
particle processors like Qiagen BioSprint, Thermo KingFisher, and Life Technologies
MagMAX Express have been used for high throughput nucleic acid extraction with
optimization required based on specimen types.
Pan-coronavirus RT-PCR: A pan-coronavirus one step RT-PCR targeting a
conserved region of about 251 bp of the CoV polymerase gene has been developed to
confirm the identity as coronaviruses [124]. Using electron microscopy together with
pan-coronavirus RT-PCR followed by genetic sequencing were critical keys in
identifying PEDV and PDCoV during the early stage infection in the United States. Pan-
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coronavirus RT-PCR is not PEDV- or PDCoV-specific and that makes the test not
suitable for routine PDCoV diagnostic testing [47,120].
Standard PDCoV-specific RT-PCR: Conventional or gel-based one-step RTPCR or nested RT-PCR assays have been developed for the specific detection of PDCoV
[7,116]. They target a conserved region of PDCoV M or N genes for PCR amplification,
electrophoresis on agarose gels and then visualization of amplicons under UV light. The
nested RT-PCR is at higher risk of contamination due to the two steps of reaction set up,
which explains why the test has not been widely used.
Real-time RT-PCR for PDCoV detection: The real-time RT-PCR remains the
method of choice for PDCoV detection and is commonly used by veterinary diagnostic
laboratories. A variety of probe-based real-time RT-PCR assays have been developed for
the specific detection of PDCoV [118,125,126]. These assays target the conserved
regions of PDCoV M or N genes with the limit of detection of 2 viral RNA copies and
LOD of 0.056 TCID50 per reaction. Zhang et al. [126] developed a duplex real-time
PEDV/PDCoV RT-PCR targeting M genes for simultaneous detection and differentiation
between the two viruses. The limit of detection of this duplex rRT-PCR is 7 RNA copies
per reaction for PEDV and 14 RNA copies per reaction for PDCoV.
Reverse transcription-insulated isothermal PCR: Recently, a point-of-need
PCR detection platform accompanied by the insulated isothermal PCR technology and a
field-deployable device (POCKITTM Nucleic Acid Analyzer) has been developed and
validated for diagnostic testing and automatic detection in which the interpretation of
PCR results can be done within one hour [126,127]. This assay has a limit of detection of
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9 RNA copies per reaction for PDCoV and is considered a potentially useful tool for onsite detection.
Immunofluorescence staining: Immunofluorescence staining is a method for
viral antigen detection using virus-specific monoclonal or polyclonal antibodies. These
antibodies are either fluorophore-conjugated which is used directly, or unconjugated in
which a fluorophore-conjugated secondary antibody is needed. The immunofluorescence
staining is a viable test conducted on PDCoV-infected cell culture for confirmation of
virus isolation [123], or performed on cryosections of tissues for determining the location
of viral antigen in tissues [65]. The visualization of the viral antigens requires using a
fluorescent microscope.
Immunohistochemistry: Immunohistochemistry is a method to detect viral
antigen in formalin fixed paraffin-embedded tissues labeled by virus-specific monoclonal
or polyclonal antibodies followed by development of the reaction using an enzyme-linked
secondary antibody and chemical substrate; the results can be visualized under a light
microscope [50,118]. M peptide-specific rabbit antiserum or polyclonal antiserum against
PDCoV generated in pigs has been used for PDCoV immunofluorescence staining and
immunohistochemistry [50,65,123]. PDCoV N protein-specific monoclonal antibody has
been recently developed by South Dakota State University and is available commercially
through Medgene Labs.
In situ hybridization: In situ hybridization is a technique in which the viral
nucleic acid present in fixed tissues can be detected using a labeled complementary DNA,
RNA or modified nucleic acid strand (e.g. probe). In contrast to PCR, in situ
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hybridization detects viral nucleic acids that are not going through an amplification
process [65].
Serological methods for PDCoV detection
Indirect fluorescent antibody assay: The IFA assay primarily requires PDCoVinfected ST or LLCPK1 cell plates which are then fixed at the appropriate time points.
Double-fold serial dilutions of the tested serum samples are added to the plates to bind to
the virus antigen followed by adding a fluorophore-conjugated anti-swine secondary
antibody, then visualization under a fluorescence microscope. IFA can be used in a
qualitative manner or in a quantitative manner for detection of PDCoV antibody.
Antibody isotyping can be determined using different types of secondary antibody;
however, commonly it has been used to determine IgG antibody. The IFA is not
automated and is subjective with respect to result reading and reporting. To date, the
dynamics of PDCoV IFA antibody has not been well defined and correlations of PDCoV
IFA antibody to other serological assays are not determined [50].
Virus neutralization assays: In the VN assay, heat-inactivated serum samples
are serially twofold diluted and incubated with a fixed amount of PDCoV (between 100–
200 TCID50) at 37 ◦C for 1–2 h., then the virus-serum mixture is added to a confluent
monolayer of ST or LLC-PK1 cells and incubated at 37 ◦C. The endpoint determination
of neutralizing antibody can be based on either conventional methods using viral CPE
development or based on fluorescence staining called an FFN assay. The conventional
CPE-based VN test needs enough time to allow a viral CPE which has fully developed in
the virus control wells which may take 3-4 days. However, the serum cytotoxicity can be
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mistaken as viral CPE. For the FFN assay, the confluent cell monolayer plates inoculated
with virus-serial diluted serum mixture are incubated for 24–48 h and then stained with a
FITC-conjugated monoclonal antibody against PDCoV N protein (Medgene Labs).
Results are read as the reciprocal of the highest serum dilution resulting in >90%
reduction of fluorescent staining compared to the negative serum control [60,66]. The
assays are labor intensive and need manual reading and interpretation of the results. It
also detects neutralizing antibody activities with no determination the antibody isotypes.
To date, there have been no publications describing dynamics of PDCoV VN antibody
production and duration.
Enzyme linked immunosorbent assays: Subsequent to the first occurrence of
PDCoV in the United States, different indirect ELISAs have been developed for the
detection of PDCoV antibodies. These type of ELISAs include a eukaryotic expressed
PDCoV S1 protein-based ELISA which was validated using 210 field serum samples.
The test showed a diagnostic sensitivity of 90.6% and a diagnostic specificity of 94.8%
depending on the clinical exposure history and PDCoV PCR testing on fecal samples to
reflect the true PDCoV serological status [119].
Another PDCoV N protein-based ELISA expressed in a prokaryotic system was
validated using 62 serum samples and revealed high a sensitivity of 100% and a
specificity of 90.4% when compared to the Western blot results on the same 62 serum
samples [128].
Moreover, the PDCoV whole virus-based ELISA was validated using a few
immune sera originated from gnotobiotic pigs that were immunized intramuscularly twice
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with inactivated PDCoV. The diagnostic sensitivity and specificity were not provided in
the paper [122]. The optical density (OD) of ELISA is measured using an ELISA plate
reader and the sample to-positive (S/P) ratios are then calculated. The ELISA is
considered a high throughput assay and is more suitable for testing a large number of
samples. In addition, the ELISA has the ability to measure antibody isotypes (e.g. IgG,
IgA, and IgM) in various specimen types [94].
Fluorescent microsphere immunoassay: The FMIA is a microsphere bead
(magnetic or non-magnetic)-based fluidic assay that showed a high sensitivity and
specificity result for serologic testing of animal infectious diseases [99,129,130]. Up to
100 color-coded fluorescent microspheres bead sets are used in which each bead set can
be conjugated to individual antigens for the detection of antibodies in biological samples.
The variation of the beads allows simultaneous detection of antibodies to multiple
pathogens found in a single sample. A FMIA based on PDCoV N protein has recently
been developed for the detection of PDCoV antibody in serum samples [129].
Antigenic cross-reactivity among swine enteric coronaviruses
The antigenic relationships between PDCoV, PEDV and TGEV are considered a
concern and motivate developing specific immunoassays for each virus. It has been
shown that although the similar conserved N protein among PEDV and PDCoV, the
swine PDCoV antisera was not able to neutralize PEDV and the pig PEDV antisera did
not cross-neutralize PDCoV either [122]. Moreover, the PDCoV serological tests
including IFA, S1 protein-based ELISA, and N protein-based ELISA assays specifically
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detected the antibodies against PDCoV with no cross-reaction to antisera against PEDV
or TGEV [122,128].
Influenza D Virus
Etiology and evolution
Influenza D virus is an enveloped virus recently placed in the family
Orthomyxoviridae. The main difference between ICV and IDV is the hemagglutininesterase (HE) fusion protein. The difference between IDV and the other influenza viruses
is the spike glycoproteins found on the surface of both IAV and IBV contain
hemagglutinin (H) and neuraminidase (N) separately. The HE protein is the main factor
and plays the major role in receptor recognition, viral fusion, and binding of the host
receptor in IDV [131]. Moreover, ICV and IDV contain seven genomic segments, while
IAV and IBV each contain eight [10].
Influenza viruses are characterized by formation of new antigenic progenies able
to evade the host immune systems. Antigenic drift occurs through mutation and antigenic
shift occurs through reassortment within recombination of viral genetic material in
different strains among a genus. The influenza genome’s division into segments aids
reassortment between strains especially in case of the concurrent infection with more than
one virus strain [132].
IBV and ICV diverged from IAV, in which ICV as a genus is suggested to have
evolved before the split between IAV and IBV. A recent study of IBV and ICV
reassortants with IAV show that they are unable to produce viable progeny due to the
genomic RNA sequence variation [133].
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The matrix (M1) protein and nucleoprotein (NP) share only a 20–30% homology
and are the antigens used to distinguish between the influenza viruses. The novel IDV
shares only 50% amino acid homology with human ICV, similar to the level of
divergence between IVA and IVB [10]. Analysis of the most conserved influenza viral
protein, the polymerase protein (PB1), revealed that this new virus is more closely related
to ICV than to IAV or IBV. The PB1 segments of ICV and IDV share a 72% identity,
while the segment containing HE has diverged to 53% [12].
In vitro reassortment and serological studies indicate that the virus is antigenically
distinct from human ICV and unable to produce viable reassortants. However, an isolate
of IDV from swine and another from bovine were found to frequently reassort with each
other [134].
Survival and inactivation
Influenza viruses are susceptible to pH extremes, heat, dryness, and are unstable
in the environment (Kapoor et al., 2014). The ideal temperature for IDV replication is
33˚C and the variation in the HE protein is responsible for virus-cell fusion at various
temperatures [11].
Influenza viruses can be inactivated by sunlight, disinfectants, and detergents.
Also glutaraldehyde, formaldehyde, beta propiolactone, and binary ethylenimine in the
presence of organic matter can inactivate the viruses. Without organic matter, destruction
of the virus can be achieved with phenolics, 5.25% sodium hypochlorite, quaternary
ammonium compounds, 4% sodium carbonate dilute acids, 2% sodium hydroxide and
hydroxylamine [135].
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Zoonotic potential
According to the serological studies carried out in Japan and China, the ICV
infect pigs with the probability of interspecies transmission of ICV between pigs and
humans. Human ICV isolates were able to replicate in experimentally infected pigs but
the role of pigs as a potential animal reservoir host for human ICV has not been proven.
[136]. Little is currently known about the epidemiology of IDV, but it is monitored as a
potential zoonotic pathogen. It has been transmitted by contact and can cause clinical
disease in ferrets, the preferred animal model for human influenza studies [137].
In Florida’s cattle industry, cow-calf operations pose a greater risk of IDV
transmission to humans than operations housing adolescent and adult cattle. Whereas it is
still unknown whether IDV causes disease in humans, IDV is a zoonotic risk and is
considered an emerging pathogen among cattle-exposed workers because of the high
seroprevalence (94–97%) among the bovine population [138].
Transmission
In both humans and animals, the major route of influenza transmission is through
nasopharyngeal exposure by direct contact. Also, it can be transmitted through direct and
indirect contact with contaminated surfaces and aerosol transmission. In pigs, influenza
viruses replicate in the upper and lower respiratory tracts. The infection is maintained by
recurrent infections among populations [21].
Intensive farming practices and close contact can facilitate the spread of the IDV.
There is no evidence of IDV being spread through consumption of meat from infected
animals. IDV can spread among the herd in few days and may be spread to adjacent
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farms through wild boars or other wild animals. The infection can be maintained for 25
days’ pi [20].
Diagnosis
Serological surveys revealed that cattle are considered the species with the highest
seroprevalence and the highest antibody titers for IDV [11]. It has been experimentally
shown that IDV can also infect guinea pigs and ferrets, replicating in their respiratory
tract [139]. The antibodies specific for IDV have been detected in sera of small ruminants
in North America [140]. In spite of the apparent generally low seroprevalence in humans
[10], a recent study has demonstrated that 94–97% of cattle-exposed workers in some
states have specific antibodies against IDV, confirming the concerns of a possible
zoonotic risk [13,138].
PB1 is one of the most, if not the most, conserved region of IDV genome, based
on phylogenetic analysis of 14 PB1 sequences of IDV from GenBank (GenBank
accession numbers: JQ922306, KM392469, KM392476, KM392483, KM392490,
KM392497, KM392504, KF425653, KF425660, KF425667, KM015492, KM015499,
KM015506, LN559121) [12,16]. A recent real-time PCR, specific for IDV was
developed in which target sequences of primers and probe are the PB1. The investigators
used in silico by BLAST, and in vitro with a wide panel of common swine and bovine
respiratory pathogens to confirm the specificity of the method. The sensitivity of the RT
PCR was determined using synthetic RNA molecules with a limit of detection that was
about 20 copies/µL [141].
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Samples: Influenza viruses replicate in the epithelial cells of the upper and lower
respiratory tract, so the infectious virus can be isolated from nasal mucosa, trachea,
ethmoid, tonsils, lungs, bronchoalveolar lavage, oropharyngeal swabs and regional lymph
nodes [21]. Lung tissue and nasal swabs have successfully been used for real time RTPCR in detection of IDV [10].
Primarily, clinical diagnosis of influenza has been achieved by virus isolation but
potentially low viral loads may require more sensitive methods [132]. Virus isolation has
been successfully achieved by inoculation of 8-10 day old embryonated chicken eggs
[142,143,144]. The propagation of the virus can be done using Madin-Darby canine
kidney (MDCK) and the supplementation of MDCK cells with high concentrations of
trypsin increases their susceptibility to IDV infection [145,146]. Human hepatocarcinoma
cell (HuH7), [147] and human malignant melanoma (HMV-II) cells have been used for
creating and obtaining in vitro reassortant viruses [148] in addition to African green
monkey kidney (Vero) cells and human embryonic kidney (293T) cells [131]. Moreover,
IDV can be readily isolated and cultured in ST cells [10].
Hemagglutination inhibition: Hemagglutination inhibition (HI) assays are the
major assay used to identify unknown influenza viruses by their antigenic cross-reactivity
and sort isolates into antigenic groups [10]. Antigenic variation among ICV isolates can
be evaluated with anti-HE monoclonal antibodies [149,150,151]. ICV causes
agglutination in chicken and turkey erythrocytes, but not in guinea pig erythrocytes [148].
Conventional reverse transcription polymerase chain reaction: RT-PCR can
be used for detection of viral RNA in infected supernatants [134]. The test has also been
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used in detection of IVA, IVB [152] and ICV [153] as well as the recent IDV [12,16].
Multiplex PCRs have been one of the assays used for detection of human ICV,
rhinovirus, and coronavirus [147]. Another multiplex PCR has been developed for
simultaneous detection of IVA, IVB, ICV, adenovirus, and both A and B respiratory
syncytial viruses [154].
Electron microscopy: Electron microscopy can identify orthomyxoviruses in cell
cultures while enzymatic assays can detect a particular genus of influenza. With these
methods, RT-PCR is typically used for definitive diagnosis [10].
Antibody detection serological assays: Antibody based assays are valuable
diagnostic tools for the differentiation of newly identified influenza viruses [11]. Some
enzyme-linked immunosorbent assays (ELISA) detecting the antibodies against ICV
virion proteins have been described [155]. There is a good correlation between the HI test
and SVN test [156]. Although the sensitivity of ELISA is similar or slightly higher than
HI, a positive result in both assays is sufficient confirmation of infection and the results
can also be confirmed by Western blotting [157].
Prevention and Control
Cattle farm workers, veterinarians, and meat processing workers with increased
exposure to bovine, swine and poultry and represent a high risk for potential zoonotic
influenza infection and viral reassortment (Lade et al., 2011). So utilizing personal
protective equipment when in close contact (at least within six feet) with infected animals
can help to decrease the risk of infection [158]. Biosecurity and appropriate disinfection
protocols between animal groups or farms can limit spread of this virus.
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Vaccines: Seasonal human vaccines are available in the United States for both IVA
and IVB. There are inactivated trivalent and quadrivalent vaccines, recombinant trivalent
vaccines, and live-attenuated quadrivalent vaccines; administered through intramuscular
injection, intradermal injection, or nasal spray. There are no bovine or licensed modified
live swine vaccines are currently available [132]. Up to this date, antibody crossreactivity has not observed between ICV and IDV isolates [12].
The immune response to influenza in animals includes cell mediated immunity
and the production of antibodies [21]. The response can vary according to the inoculated
strains of the virus [159]. Immunity against the specific strain causing the infection may
last several years based on previous human studies, suggesting that the infection does not
induce sufficient protective immunity in all individuals [160].
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Abstract
Background: Recent, severe outbreaks of porcine epidemic diarrhea virus (PEDV) in
Asia and North America highlight the need for well-validated diagnostic tests for the
identification of PEDV infected animals and evaluation of their immune status to this
virus. PEDV was first detected in the U.S. in May 2013 and spread rapidly across the
country. Some serological assays for PEDV have been previously described, but few
were readily available in the U.S. Several U.S. laboratories quickly developed indirect
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fluorescent antibody (IFA) assays for the detection of antibodies to PEDV in swine
serum, indicating prior exposure. However, the IFA has several disadvantages, including
low throughput and relatively subjective interpretation. Different serologic test formats
have advantages and disadvantages, depending on the questions being asked, so a full
repertoire of tests is useful. Therefore, the objective of this study was to develop and
validate multiple improved serological assays for PEDV, including an indirect ELISA
(iELISA); a highly specific monoclonal antibody-based blocking ELISA (bELISA);
fluorescent microsphere immunoassays (FMIA) that can be multiplexed to monitor
exposure to multiple antigens and pathogens simultaneously; and a fluorescent focus
neutralization assay (FFN) to measure functional virus neutralizing antibodies.
Results: A recombinant North American nucleoprotein (NP) based iELISA was
developed and validated along with a bELISA using newly developed PEDV-NP specific
biotinylated monoclonal antibodies (mAbs) and an FMIA using magnetic beads coupled
with expressed NA PEDV-NP. Receiver operating characteristic (ROC) analysis was
performed using swine serum samples (iELISA n=1486, bELISA n=1186, FMIA
n=1420). The ROC analysis for the FMIA showed estimated sensitivity and specificity of
98.2% and 99.2%, respectively. The iELISA and bELISA showed a sensitivity and
specificity of 97.9% and 97.6%; and 98.2% and 98.9%, respectively. Inter-rater (kappa)
agreement was calculated to be 0.941 between iELISA and IFA, 0.945 between bELISA
and IFA and 0.932 between FMIA and IFA. Similar comparative kappa values were
observed between the iELISA, bELISA and FMIA, which demonstrated a significant
level of testing agreement among the three assays. No cross-reactivity with the closely
related coronaviruses, transmissible gastroenteritis virus (TGEV) or porcine respiratory
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coronavirus (PRCV) was noted with these assays. All three assays detected
seroconversion of naïve animals within 6-9 days’ post exposure. The FFN assay allows
relative quantitation of functional neutralizing antibodies in serum, milk or colostrum
samples.
Conclusion: Well-validated iELISA, bELISA and FMIA assays for the detection of
PEDV antibodies were developed and showed good correlation with IFA and each other.
Each assay format has advantages that dictate how they will be used in the field. Newly
developed mAbs to the PEDV-NP were used in the bELISA and for expediting FFN
testing in the detection and quantitation of neutralizing antibodies. In addition, these
PEDV mAbs are useful for immunohistochemistry, fluorescent antibody staining and
other antigen-based tests. Measurement of neutralizing antibody responses using the FFN
assay may provide a valuable tool for assessment of vaccine candidates or protective
immunity.

Keywords: porcine epidemic diarrhea virus (PEDV), serology, ELISA, fluorescent
microsphere immunoassay (FMIA), Fluorescent Focus Neutralization (FFN)

Background
Porcine epidemic diarrhea virus (PEDV) was first described in Europe in the
1970s with more recent and severe outbreaks in Asia [1,2]. The virus was identified in
the United States in May 2013, causing severe diarrhea and vomiting in pigs across age
groups, with high mortality of up to 90%-95% in suckling pigs [3]. PEDV is an
enveloped, single stranded RNA virus belonging to the Coronaviridae family. The
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coronaviruses taxonomically form a subfamily (Coronavirinae) within the order
Nidovirales. Recently, the International Committee on Taxonomy of Viruses (ICTV)
recognized four genera within the Coronavirinae subfamily: Alphacoronavirus,
Betacoronavirus, Gammacoronavirus, and Deltacoronavirus [4]. PEDV belongs to the
genus Alphacoronavirus along with other swine viruses including transmissible
gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV).
The genome is composed of a large ~28 Kb molecule consisting of a 5’
untranslated region (UTR), a 3’ UTR, and at least seven open reading frames (ORFs)
encoding three nonstructural proteins: ORF1ab (pp1a and pp1ab) and ORF3, an
accessory protein. The four major structural proteins of the mature virion include the
spike (S) glycoprotein (Mr 150-220 kDa), the nucleoprotein (NP) (Mr 45-57 kDa) that is
associated with the positive stranded RNA providing integral support for its helical
structure, the glycosylated membrane protein (M) (Mr 20-30 kDa), and the glycosylated
envelope protein (E) (Mr 7kDa) [5,6,7].
Coronaviruses are taxonomically assigned to different genera based on their
rooted phylogeny and calculated evolutionary distance for seven highly conserved
genomic domains within ORF 1ab [8]. The genetic diversity of coronaviruses may be due
to their high frequency of recombination [9]. The heterogeneity among coronavirus
subfamilies is well documented [7], and the factors that contribute to PEDV’s ability to
gain or lose parts of its transcriptome are believed to have contributed to quasispecies
with novel traits that are able to adapt to new hosts, ecological niches and zoonotic
events. The exact origin of PEDV in North America is not entirely clear, but there is
evidence of genetic similarities to Chinese PEDV strains [10].
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Recently, a novel NA PEDV recombinant strain was identified (S INDEL)
containing both insertions and deletions within the N-terminal domain of the ORF 3 and
S1 genes. Specifically, sequence alignment indicated spike gene nucleotide deletions at
positions 164-169 that correspond to amino acid deletions at positions 55 and 56 in
addition to substitutions at positions 23 (I), 31 (H), 57 (K), and 59 (E) as compared to the
CV777strain [10,11].
The relatedness of several PEDV strains circulating in China was evaluated by Li
et al. [5] using phylogenic analysis of the NP gene and no insertions or deletions were
noted. Sequence comparison with other European and Korean PEDV strains obtained
from GenBank indicated that the NP genes were highly conserved (94.7%- 97.7%) even
though these strains originated from different geographic regions [5]. In addition to being
highly conserved among PEDV variants, the NP is the most abundant viral protein
expressed in PEDV infected cells [12,13]. In contrast, the spike protein is presented on
the viral surface and subject to various host immune pressures, which predisposes it to a
greater range of genetic heterogeneity including insertions and deletions. Because the NP
protein is highly abundant in virus infected cells, it provides an attractive target for the
development of antigen-based serological assays. Taken together, this evidence provided
rationale for using it as our antigen of choice for the iELISA, bELISA and FMIA.
In response to the recent outbreaks of highly virulent PEDV in North America
(NA), PCR assays were quickly developed to detect the presence of PEDV RNA in
intestine or fecal material. These assays provide an important tool in control of the virus;
however, well-validated, high-throughput assays to detect antibodies following infection
would provide additional valuable diagnostic tools for the swine industry. The ability to
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detect and evaluate antibody responses using serologic tests is important in efforts to
answer basic production related questions. These questions may include whether a
production site is naïve or has historically experienced a PEDV exposure, even though a
producer has not seen obvious clinical signs; the level of immune response sows may
have in relation to vaccination, initial wild-type virus infection or intentional feedback
exposure; and whether sow immunity is inadequate when clinical infection occurs in
individual litters after initial PEDV exposure in a herd.
One of the most pressing issues of PEDV disease is maintaining herd site
biosecurity through exclusion measures to prevent viral entrance into swine units.
However, PEDV infection may not always be obvious in finishing pigs so the widespread
transport of these animals may represent additional risks. Thus, sensitive serological tests
provide a valuable tool in the detection of recent infection to avoid the introduction of
these animals into naïve herds.
Since PEDV was widespread in Europe in the 1970s and 1990s and more recently
in Asia, various serologic tests have been developed and subjected to varying degrees of
validation [14,15,16,17,18,19,20]. However, few assays have been developed using
antigens associated with contemporary strains currently circulating across NA. The need
to develop more sensitive serological assays has become paramount in order to address
questions regarding PEDV infections and epidemiological transmission patterns, as well
as to analyze disease progression.
Currently, serum virus neutralization (SVN) tests are the most widely employed
serological assays used to detect PEDV antibodies. It is a test that is highly specific and
useful for screening of antibody titer post vaccination [1,16]. However, the test is
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expensive and labor intensive, requiring manual reading and interpretation of virus
induced cytopathic effect (CPE) endpoints. Moreover, serum cytotoxicity can be
mistaken for viral CPE, giving rise to false interpretations at lower serum dilutions.
Several laboratories have generated in-house indirect ELISAs using either virus
derived antigen or recombinant structural proteins. Early indirect ELISAs were
developed using Vero cell derived, whole virus preparations [15,21] or Vero cell
expressed viral proteins [16]. These methods may be problematic because serum from
animals vaccinated with cell culture derived PEDV may cross-react with cellular
components of ELISA antigen, causing low specificity and high background. Other
groups have used recombinantly expressed, purified, structural S and NP proteins for
iELISA serodiagnosis, but because low numbers of experimentally derived samples were
used to evaluate the performance of the assay, full validation of the diagnostic
sensitivities and specificities could not be assessed [19,20].
Both the iELISA and bELISA formats have proven useful for the serodiagnosis of
experimental and natural infections. Blocking or competitive ELISAs have been shown to
be especially useful where a higher level of specificity is required. The increased
specificity has been shown to be dependent on both the isotype and on the target
specificity of the monoclonal or polyclonal antibodies [6,17,22]. Various laboratories
have developed sensitive blocking ELISAs, and Carvajal et al. [17] demonstrated their
bELISA was able to detect an antibody response 3 to 5 days earlier than IFA, which
suggested higher sensitivity of the bELISA. In addition, the bELISA is valuable as a
confirmatory test where unexpected positive results appear in presumably negative herds.
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The fluorescent microsphere immunoassay is based on fluidic, particle array
technology (Luminex Corp., Austin, TX) and has become increasingly standardized and
accepted in applications involving the serologic diagnosis of autoimmune and animal
infectious diseases [23,24]. There are distinct advantages of the FMIA over the ELISA,
which include higher sensitivity, higher sample throughput analysis, and the ability to
multiplex and monitor exposure to multiple pathogens simultaneously in a single sample.
In addition, multiple bead sets in the FMIA could be added to a standardized assay
against newer virus subtypes that continue to emerge in the field or to assess
antigenic/phylogenetic differences between genera of coronaviruses.
In this study, we report the adaptation of a recombinant, highly purified, NA
PEDV-NP antigen to the development of iELISA, bELISA and FMIA platforms for the
detection of PEDV antibodies in serum. These assays provide high throughput serological
tests designed to address PEDV disease diagnostics. They were fully validated using a
large number of serum samples of known status, and validation of the tests was detailed
using methods for the validation of serological assays for the diagnosis of infectious
diseases previously described by Jacobson for the Office International des Epizooties
[25]. In addition, a fluorescent focus neutralization (FFN) assay was developed for the
rapid evaluation of neutralizing antibody responses.
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Methods

Animal samples for assay validation and time-course serological evaluation
For time course studies, serum samples from experimentally infected animals
were obtained courtesy of Dr. Richard Hesse (Kansas State University Veterinary
Diagnostic Laboratory, National Pork Board Grant #13-228). Thirty-three PEDV naïve 3week-old feeder pigs were obtained from a private, high-health status swine production
farm. Of the 33 pigs, 23 were inoculated with PEDV at 4 weeks of age via intranasal and
oral routes with a pool of gut derived intestinal contents that had been used as “feedback”
inocula for controlled exposure of a sow herd. Serum was collected prior to challenge and
at days 0, 6, 9, 14, 21, 28, 35 and 43 days’ post-infection (DPI). Multiple aliquots of all
samples collected were shared with requesting laboratories to expand diagnostic testing
and vaccine development capabilities.
To accurately assess the diagnostic sensitivity and specificity of the assays,
samples of known serostatus for PEDV were used. This included sera from multiple
animal populations including experimentally infected animals and serum samples from
animals with known historical exposure to PEDV that were submitted to the South
Dakota Animal Disease Research and Diagnostic Laboratory (ADRDL). PEDV negative
sample sets included samples from PEDV negative control pigs used in experimental
studies and selected high biosecurity herds with no history of PEDV. In addition,
archived serum samples collected prior to the emergence of PEDV in the U.S., including
samples testing positive for the related swine coronaviruses TGEV and PRCV (n=>50),
were used. The exact number of positive and negative sera used for sensitivity and
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specificity calculations per assay with statistical testing agreement calculations based on
serum numbers is listed in Table 3.1. The majority of these sera were identical among
assays, but limited serum volume did not allow for use of all sera samples among all
assays.

Antigen production, expression of recombinant PEDV-NP protein
The development and validation of the iELISA and bELISA made use of a
recombinantly expressed full length NA PEDV-NP. The NP open reading frame (ORF)
of PEDV was amplified from RNA extracted directly from intestinal contents by RTPCR from a case submitted to the South Dakota ADRDL. It was subsequently
directionally cloned into the E. coli, pET 28a(+), plasmid expression vector (Novagen,
Madison, WI), then transformed into BL21-Codon Plus (DE3)-RP competent cells
(Stratagene, La Jolla, CA) for protein expression. Primers used for the amplification of
the full length (1323bp) nucleoprotein were: PEDV-NP-fwd (5’CGCGGATCCATGGCTTCTGTCAGTTTTCAG-3’); PEDV-NP-rev (5’CACACTCGAGATTTCCTGTGTCGAAGATCTC-3’). Next, 20µl of transformed cells
were plated onto Luria-Bertani agar plates containing 50µg of kanamycin/ml and
incubated overnight. The following morning, colonies from the agar plates were added to
1L of pre-warmed 2X yeast extract tryptone (YT) culture medium containing 50µg
kanamycin/ml and allowed to grow to an OD600 of 0.5 at 37 ºC. PEDV-NP expression
was induced using isopropyl -D-1-thiogalactopyranoside (IPTG) at a final
concentration of 1.0 mM to induce transcription of the Lac operon, and the E. coli was
allowed to incubate for an additional 8 hours at 37 ºC with shaking at 200 RPM. The agar
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was strained out and bacteria pelleted by centrifugation at 12,000 g for 10 minutes at 4°C.
The pellet was resuspended in 40 ml of lysis buffer solution (B-PER, Pierce, Rockford,
IL), incubated for 15 minutes at 20-22 ºC, then centrifuged at 12,000 g to separate the
soluble from insoluble proteins. The PEDV-NP recombinant protein was expressed as
insoluble periplasmic inclusion bodies. The resulting 441 amino acid recombinant protein
was denatured using 8M urea, subsequently purified three times using nickel-NTA
affinity column chromatography and refolded back to its native conformational state.
Individual affinity column elutions were collected, pooled and confirmed by SDS-PAGE,
then aliquoted/frozen at -80 ºC. The correct nucleotide sequence was confirmed by
sequence and restriction endonuclease analysis. The average protein yield produced by
the pET28a-PEDV-NP plasmid construct was calculated to be 11 mg PEDV-NP per liter
of 2XYT under the aforementioned conditions. The recombinant protein was detected
and a predicted molecular weight of 51 kDa confirmed via Western Blotting using
convalescent sera, a 6X histidine-specific mAb (Novagen, Madison, WI) and a PEDV-NP
specific mAb (Figure 3.1 and 3.2).

mAb production and biotinylation
Two separate mAbs were developed in our laboratory (SD6-29 and SD17-103)
that recognize both the native conformation of the PEDV-NP and the full length, linear,
recombinant protein used in all antibody capture assays. Hybridomas were produced as
previously described [26]. Immunoglobulin isotyping of the resulting mAbs was
performed using a commercial lateral flow assay (Serotec, Raleigh, NC). Subsequently,
mouse ascites fluid was produced in pristane-primed mice, and the antibodies were
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purified and biotinylated for use as the detection moiety for the bELISA [23]. The
conjugated antibody solution was quantified via the Lowry protein method, and carrier
BSA was added to a final concentration of 10 mg/ml, then aliquoted and stored at −20 ºC.

IFA
Vero-76 cells (ATCC CRL-1587) were cultured with MEM + 10% FBS for 48-72
hours until fully confluent in 96-well plates, then washed twice with MEM.
Subsequently, alternating rows of 96-well plates were inoculated with the cell culture
adapted PEDV NVSL-CO strain of PEDV (PEDV USA/Colorado/2013, GenBank
accession number KF272920) at a multiplicity of infection (MOI) of 0.05 with MEM
supplemented with 1.5 µg/ml trypsin (TPCK treated, bovine derived (Sigma, St. Louis,
MO)). After incubation at 37 ºC for 20-24 hours, monolayers were fixed with 80%
acetone for 20 minutes. Serum samples were initially serially diluted from 1:40 to 1:320
with PBS in duplicate wells, and 100 µls of the diluted serum were added to each well.
The plates were incubated at 37 ºC for 1 hour and then rinsed 3X with PBS. Next,
fluorescein isothiocyanate (FITC)-conjugated goat anti-swine IgG (KPL, West Chester,
PA) was prepared at a dilution of 1:15 with PBS and 50 µl added to each well. After 1
hour of incubation at 37°C, plates were rinsed 3X with PBS and examined using
fluorescent microscopy. For each individual test, each PEDV infected well was compared
to its respective uninfected partner well, and a positive sample was indicated if a PEDV
specific fluorescent signal was observed at a serum dilution of 1:40 or greater. All
samples were tested in duplicate, and the antibody titer was expressed as the mean of all
replicates.
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iELISA
The serological PEDV-NP indirect ELISA was performed by coating alternate
wells of Immulon 1B, 96-well, microtiter plates (Thermo Labsystems, Franklin, MA)
with 250 ng/well of purified, recombinantly expressed PEDV-NP antigen. The optimal
dilution of the recombinant protein and secondary detection antibody was determined by
a checkerboard titration that gave the highest signal to noise ratio. In addition, a single lot
of pooled convalescent serum from PEDV infected pigs was used to generate quality
control standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD =
0.5 to 1.0; and negative OD < 0.2). PEDV-NP recombinant protein was diluted to 2.5
µg/ml in 15 mM sodium carbonate-35 mM sodium bicarbonate- antigen coating buffer
(ACB) pH 9.6. Odd-numbered columns were coated with 100 µl of ACB plus antigen,
while the even-numbered columns were coated with ACB without antigen, serving as
background control. The plates were incubated for one hour at 37 ºC, then washed 3X
with PBS plus 0.05% tween20 (PBST). Each well was then blocked with 200 µl of sample
milk diluent (PBST plus 5% nonfat dry milk, (SMD)) and allowed to incubate overnight
at 4 ºC. The following day, the plates were washed 3X with 300 µl of PBST. Test and
control sera were diluted 1/50 in SMD, mixed, and 100 µl of the solution was added to
each well. The plates were incubated for 1 hour at 20-22 ºC. Next, 100 µl of biotinylated,
goat anti-swine detection antibody (Bethyl Laboratories, TX) was added at a
concentration of 200 ng/ml of PBST and allowed to incubate at 20-22 ºC for 1 hour. The
plate was washed 3X with 300 µl of PBST, then 100 µl of streptavidin-HRP conjugate
(Pierce, Rockford, IL) was added and incubated for another hour at 20-22 ºC, then
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washed and developed with 3,3’,5,5’- tetramethylbenzidine, peroxidase substrate (TMB)
(Surmodics, Eden Prairie, MN). Color development progressed until the positive control
attained a standard OD and was stopped using 2N H2SO4. Colorimetric development was
quantified spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek
Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories,
Westbrook, ME). The raw data was normalized and transformed into an Excel
spreadsheet. Sample to Positive (S/P) ratios were calculated using the following formula:
S/P = optical density (OD) of sample - OD of buffer/OD of positive control - OD of
buffer.

bELISA
The serological bELISA was performed using Immulon 1B, 96-well microtiter
plates (Thermo Labsystems, Franklin, MA). Alternate wells of each plate were coated
with 500 ng per well of expressed PEDV-NP antigen. The optimal dilution of the
recombinant protein and mAb antibody was determined by a checkerboard titration that
gave the highest signal to noise ratio with an OD reading of approximately 2.0, in the
absence of swine serum/competitor antibody. First, PEDV-NP recombinant protein was
diluted to 2.5 µg/ml of ACB. Odd-numbered columns were coated with 100 µl of ACB
plus antigen, while the even-numbered columns were coated with ACB without antigen
serving as background control. The plates were incubated for 1 hour at 37 ºC, washed 3
times with PBST, then placed at 4 ºC overnight. The following day, each well was
blocked with 300 µl of SMD and incubated one hour at 37 ºC. Plates were washed 3
times with PBST, and 100 µl of test and control sera were diluted 1/3 with PBST + 0.1%
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nonfat dry milk and added to each of the duplicate wells. Plates were incubated 1 hour at
37 ºC. During sample incubation, PEDV-NP specific biotinylated, mAbs (SD6-29 and
SD17-103) were adjusted to equal titers and mixed together in a 1:1 ratio. Next, 100 µl of
a 1:40,000 dilution of the antibody detection mixture was added to the microtiter plate
containing the competitive swine antibody, then swirled and incubated for an additional
30 minutes at 37 ºC. The plates were washed 3 times, and 100 µl of high sensitivity,
streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL) was added to all
wells of the microtiter plate for 1 hour at 37 ºC.
Plates were washed 4 times with PBST, and 100 µl of TMB was added to all wells and
gently swirled. After approximately15 minutes, color development progressed until the
negative control attained a standard OD of approximately 2.0 and was subsequently
stopped using 2N H2SO4. Colorimetric development was quantified
spectrophotometrically at 450 nm with an ELx800 microplate reader (BioTek Instruments
Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook,
ME). The raw data was normalized and transformed into a Excel spreadsheet, and the
percent inhibition (PI) ratio was calculated using the following formula: PI= 1-{(OD of
sample - OD of buffer)/(OD of negative control – OD of buffer)} X 100.

Preparation of PEDV-NP coupled microspheres for the FMIA
A two-step carbodiimide coupling procedure was used to couple NA PEDV-NP
protein to Luminex™ microspheres. Briefly, the coupling of fluorescent microsphere was
performed by washing 3.125 x106 microspheres twice with 250 µl activation buffer
(0.1MNaH2PO4, pH6.2) and sonicating them for 60 seconds after each wash.

74

Microspheres were activated for 20 minutes at 20-22 ºC in 500 µl activation buffer
containing 2.5 mg N-hydroxysulfosuccinimide (sulfo-NHS) and 2.5 mg N-(3dimethylaminopropyl)-N-ethylcarbodiimide (EDC) (Pierce Chemical, Rockford, IL).
Activated microspheres were washed twice with PBS and sonicated. Coupling was
initiated by the addition of 12.5 µg of recombinant NA PEDV-NP protein, brought to a
final volume of 500 µl with PBS and incubated in the dark for 3 hours at 20-22 ºC with
rotation. Coupled microspheres were washed once with 1 ml of PBS plus 0.05% NaN3
and 1.0% bovine serum albumin (PBS-NB). Next, the microspheres were blocked with 1
ml of PBS-NB for 30 minutes to reduce nonspecific binding. Microspheres were then
washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0
x106 antigen-coupled microspheres/ml.

FMIA
A 96-well hydrophilic membrane filter plate was blocked for 2 minutes with 150
µl of PBS-NB, and then the liquid was aspirated via vacuum manifold. The plates were
wetted with 20 µl of PBS-NB buffer to prevent drying. Next, 50 µl of serum (diluted 1:50
in PBS-NB) was added to duplicate wells of the filter plate along with 50 µl of PBS-NB
containing 2.5 x103 antigen-coupled microspheres. Since the microspheres and reporter
moieties are light sensitive, all incubations were performed in the dark by sealing the
plate with foil. Subsequently, the FMIA plate was incubated at 20-22 ºC for 1 hour on a
plate shaker rotating at 600 rpm. The plate was washed 3 times with 200 µl of PBST.
Next, 50 µl of anti-swine, biotinylated IgA (heavy & light chain, diluted in PBS-NB;
Bethyl Laboratories) or IgG-FC specific polyclonal antibodies (diluted 1:2,000 dilution in
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PBS-NB; Bethyl Laboratories) were added to the filter plate and incubated at 20-22 ºC
for 1 hour. NP IgM and IgG isotype-specific antibody levels were detected using PEDVNP coated microspheres, but speciated by means of individual and separate IgM and IgGspecific secondary antibodies. Since validation was performed using serum, and because
IgA is present in very low amounts, IgA specific secondary antibodies were not used at
this step. After incubation with the secondary antibodies, 50 µl of streptavidin
phycoerythrin (2.5 µg/ml in PBS-NB, Molecular Probes) was added to each well and
incubated for 30 minutes at 20-22 ºC with shaking. The supernatant was aspirated, and
the plate was washed 3 times with PBST. Finally, the microspheres were resuspended in
125 µl of PBST per well and transferred to a clear 96-well polystyrene optical plate.
Coupled microspheres were analyzed through a dual-laser Bio-Rad Bio-Plex 200
instrument. The median fluorescent intensity (MFI) for 100 microspheres corresponding
to each individual bead analyte was recorded for each well. All reported MFI
measurements were normalized via F - F0, where F0 was the background signal
determined from the fluorescence measurement of a test sample in uncoated beads and F
was the MFI for a serological test sample using antigen-coated beads.

Establishment of serological reference standards for ELISA and FMIA development
Four serological reference serum sets were constructed as standards termed
high, medium, low and negative to serve as internal quality control standards and to
mathematically normalize individual samples for objective comparisons between testing
platforms. The high-labeled standard was designed to generate an OD above 2.0 for the
iELISA and bELISA and an MFI of approximately 25,000 for the FMIA. The high
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standard was used exclusively for the mathematical determination of the serological
response (S/P ratio) of samples used for test validation. The medium standard generated a
response of between 1.5 and 2.0 OD for the two ELISAs and approximately 10,000 MFI
for the FMIA. The low standard was designed to deliver a signal slightly above threshold
level for all 3 tests, and the negative serum generated an OD or MFI to a background
level of less than 0.2 OD for the ELISAs and 600 MFI for the FMIA.

Validation methods for the determination of diagnostic sensitivity, specificity,
repeatability and threshold cutoff level
To accurately assess the diagnostic sensitivity and specificity of the assays,
samples of known serostatus for PEDV were used. This included sera from multiple
animal populations including experimentally infected animals and serum samples
submitted to the South Dakota ADRDL. PEDV negative sample sets included samples
from selected high biosecurity herds with no history of PEDV and archived serum
samples collected prior to the emergence of PEDV in the U.S., including samples testing
positive for the related swine coronaviruses TGEV and PRCV. Known positive samples
were collected from pigs that were naturally infected at least 3 weeks prior to collection
and were previously positive by PCR. The negative-testing sample population
(uninfected animals) consisted of maximally 980 PEDV negative serum samples, while
the positive-testing (infected) population was composed of 516 serum samples. Receiver
operating characteristic (ROC) analysis was calculated for each assay to assess diagnostic
performance, which included determination of sensitivity, specificity and threshold cutoff
using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).
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The repeatability of each assay was assessed by running the same internal quality
control serum standards in multiple replicates within the same run or between runs. For
the iELISA and the bELISA, the intra-assay repeatability was calculated for 48 replicates
on 3 separate plates, then repeated over a 3-day period for inter-assay repeatability
assessment. The values for each assay were expressed as a mean, standard deviation and
percent coefficient of variation (CV%) for repeated measure.

Measurement of statistical testing agreement
Multiple comparison, inter-rater agreement (kappa measure of association) was
calculated among all four tests (bELISA, iELISA, FMIA and IFA) using IBM, SPSS
version 20 software (SPSS Inc., Chicago, IL). The sample cohort used was a wellcharacterized set of serum samples collected from “positive testing” experimentally
infected pigs over time courtesy of Dr. Richard Hesse (n=158) and from archived
experimental control uninfected PEDV “negative testing” animals. The interpretation of
kappa can be rated as follows: Kappa less than 0.0, “poor” agreement; between 0.0 and
0.20, “slight” agreement; between 0.21 and 0.40, “fair” agreement; between 0.41 and
0.60, “moderate” agreement; between 0.61 and 0.80, “substantial” agreement; and
between 0.81 and 1.0, “almost perfect” agreement [28,29].

FFN
A PEDV virus neutralization assay using a FFN format was developed for rapid
detection of neutralizing antibodies produced in response to PEDV infection. The FFN
was evaluated using serum samples or rennet treated milk and colostrum samples. Heat-
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inactivated samples were diluted in a 2-fold dilution series starting at 1:10 in MEM plus
1.5 µg/ml TPCK-treated trypsin in 96-well plates. An equal amount of cell culture
adapted PEDV stock at a concentration of 100 foci forming units/100µl was added to
each well and plates incubated for 1 hour at 37 ºC. The virus/sample mixture was then
added to washed confluent monolayers of Vero-76 cells and incubated for 2 hours at 37
ºC. Plates were washed again with MEM/TPCK-trypsin medium and incubated 20-24
hours to allow for replication of non-neutralized virus. Plates were then fixed with 80%
acetone and stained with FITC conjugated mAb SD6-29 to allow visualization of infected
cells. Endpoint neutralization titers were determined as the highest serum, milk or
colostrum dilution resulting in a 90% or greater reduction in fluorescent foci relative to
controls.

Results
Expression of recombinant PEDV-NP antigen
As shown in Figure 3.1, the purity of the recombinant protein was assessed via
SDS-PAGE and gave a band that migrated corresponding to the expected molecular mass
of 51 kDa upon staining with Coomassie brilliant blue R250. The protein yield of the
IPTG induced E. coli culture was calculated to be approximately 11 mg PEDV-NP/ liter
of 2XYT medium with a purity of greater than 95%. The identity of the protein was
further characterized by Western blot using convalescent swine serum, an anti-His mAb
and an anti-PEDV-NP mAb (Figure 3.2).

79

Diagnostic sensitivity, specificity, repeatability and threshold cutoff level
To optimize the serologic assays, various antigen and serum dilutions were used
to determine optimum concentrations. All 3 tests were optimized in a checkerboard
fashion to maximize signal-to-noise ratios. It was determined by antigen titration that the
optimal coating of Luminex™/FMIA microspheres was achieved at a concentration of
12.5 µg protein per 3.125 x 106 microspheres. Similarly, the optimum coating of both the
iELISA and bELISA plates was achieved at a concentration of 250 ng/well. In addition,
to determine the optimum serum dilution for each of the testing platforms, a wellcharacterized PEDV “high” positive serum standard was serially diluted in a log2 titration
against antigen coated microspheres (FMIA) or antigen coated ELISA wells at a fixed
concentration. Figure 3 shows concentration-dependent OD or MFI signals of various
serum standards. Overall, sample absorbance increased inversely proportional to the
serum dilution. However, based upon the highest signal-to-noise ratio, it was determined
that the optimal serum dilution for the bELISA was 1/3, while the iELISA and FMIA
each demonstrated an optimum dilution of 1/50 as indicated by arrows (Figure 3.3).
ROC analysis to determine sensitivity, specificity and threshold cut-off levels was
performed using large numbers of swine serum samples and demonstrated excellent
agreement (>0.91 kappa scores) between assays with good intra and inter assay
repeatability (Table 3.1). None of the known positive TGEV or PRCV samples tested
was shown to cross-react.
The optimal cutoff values and corresponding sensitivity and specificity of each
individual test are presented in Figure 3.4. Specifically, ROC analysis for the iELISA and
bELISA showed similar sensitivity and specificity of 97.9% and 97.6%; and 98.2% and
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98.9%, respectively. The ROC analysis for the FMIA showed estimated sensitivity and
specificity of 98.2% and 99.2%, respectively. Although the FMIA showed an identical
sensitivity as the bELISA, it demonstrated the highest degree of specificity of all three
assays at 99.2%. This observation was not surprising given that FMIA technology
inherently imparts greater sensitivity and a larger dynamic range than the ELISA
platform [30].
In addition to determining cutoff values, sensitivities and specificities, multiple
comparison tests were performed to calculate the degree of agreement among the ELISA,
FMIA and IFA tests. Specifically, the Kappa test demonstrated all diagnostic platforms
had kappa values greater than 0.91, which demonstrates that all 4 tests are in “almost
perfect” agreement with each other.

Assessment of repeatability
The iELISA and bELISA demonstrated slightly lower %CVs than the FMIA
with 3.7%, 6.8%, 10.7% intra-assay variability for bELISA, iELISA and FMIA
respectively. Inter-assay %CVs were 5.0%, 5.6% and 7.7% for the bELISA, iELISA and
FMIA respectively. Nonetheless, all the CVs were 10.7% or less, which demonstrated
that the tests were highly repeatable in a diagnostic application.

Evaluation of a kinetic PEDV antibody response
As shown in Figure 3.5, a mean antibody response to PEDV-NP could be
detected as early as 9 DPI for both the iELISA and bELISA. The FMIA detected PEDVNP antibodies slightly earlier at 6 DPI. All 3 tests detected the duration of antibody out to
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the 43 DPI time-point in this study but demonstrated a decline in detectable antibody
after 21 DPI.

Application of the FMIA to isotype PEDV-NP specific antibodies
High levels of PEDV-NP specific IgM antibodies were observed at 7 DPI
compared to IgG (Figure 3.6). However, the IgM antibodies decreased to barely
detectable levels by 20 DPI. IgG continued to increase linearly to 20 DPI. There is a
concomitant appearance of neutralizing antibodies by 14 DPI.

FFN
The FFN assay was initially evaluated using sequential serum samples from
experimentally inoculated piglets. Additional evaluation was conducted using 250 serum
samples from known PEDV naïve herds and 250 samples from herds with documented
PEDV exposure, collected at least 3 weeks after initial PCR diagnosis and whole herd
feedback. Experimentally inoculated piglets demonstrated detectable seroconversion by
14 DPI (Figure 3.6). Essentially all samples from PEDV naïve animals had serum FFN
endpoint titers of <1:20 while most samples from the PEDV positive set had endpoint
titers ranging from 1:40 to 1:1280 (data not shown). Further evaluation of the FFN
included serum, milk and colostrum samples from 27 sows from a herd that had
experienced an acute PEDV outbreak 6 to 7 weeks prior to farrowing. All animals were
exposed to live virus twice within the first week of the outbreak, followed by one dose of
Harrisvaccines Porcine Epidemic Diarrhea Vaccine, RNA (Harrisvaccines, Inc., Ames,
IA) at 1 week pre-farrow. Serum and colostrum samples were tested at the time of
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farrowing, followed by serum and milk samples at 1 week and 2 weeks later. As shown in
Figure 3.7, mean colostrum titers were approximately 4-fold higher than serum titers at
the time of farrowing. At later time-points, serum and milk titers were similar in
magnitude, although substantial animal to animal variation was apparent.

Discussion
Overall, this repertoire of assays is useful for initial identification and efficient,
high throughput quantitation of PEDV antibodies. We evaluated all three diagnostic
platforms against a well characterized IFA and compared the individual serum IgM and
IgG kinetic antibody responses in an FMIA to the appearance of neutralizing antibody as
detected by the FFN assay. Each of the antibody-capture assays was validated using a
large number of serum samples (n >1,100) based upon the assay validation methods of
Jacobson, which is supported by the Office International des Epizooties [25].
Since PEDV was first identified in the U.S. in May 2013, it has spread rapidly
to at least 33 states (www.aasv.org) and has been reported in Mexico and Canada [31].
The virus causes severe gastroenteritis, destroying villus enterocytes in pigs of all ages,
and is characterized by vomiting and diarrhea, leading to subsequent dehydration, high
mortality rates and economic losses, particularly in nursery piglets [3,32]. A variety of
serological tests have been developed against PEDV, but they vary by antigen used and
in the degree of validation. In addition, few have used North American NP based antigens
or compared the array of serologic assays described here. In the current study, four tests
(IFA, bELISA, iELISA, FMIA) showed strong correlation. Each has advantages, which
dictate how they will be used in the field. In addition, newly developed NP mAbs were
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used in the bELISA and for expediting FFN testing in the detection of neutralizing
antibodies.
In the development of the ELISAs and FMIA, the full length NA PEDV-NP gene
was amplified directly from RNA extracted from PEDV-infected ileal tissue. Multiple
sequence alignment analysis showed that the amplified NP gene shared a 100%
nucleotide homology with that of the US Colorado strain isolated in 2013 (Genbank
accession no. 13-019349). Several authors confirm that the NP carries multiple antigenic
determinants that are conserved among the Coronaviridae [33,34]. However, we
performed one-way cross-reactivity testing using serum from TGEV and PRCV, and no
antibody cross-reactivity was detected within any of our assays. In addition to being
highly conserved among various PEDV variants, the NP is the most abundant viral
protein expressed in PEDV infected cells, making it an attractive target antigen [12,13].
Using Western blotting experiments, we confirmed the finding of Hou et al. [19], in
which they observed the level of expression of NP protein to be significantly higher than
the level of the spike protein. Our study demonstrated that it is possible to achieve a
protein yield of over 10 mg per liter of culture with a purity of greater than 95%.
The recombinant NP has previously been identified as a useful antigen in other
ELISAs developed to detect antibodies in pigs located in China and Korea [19]. In a
study by Hou et al. [19], the authors showed similar sensitivities and specificities of their
iELISA compared to the iELISA described in this study. However, smaller numbers of
known positive and negative samples were evaluated than in the current study.
Since no test has 100% specificity, a bELISA was developed that is useful for
confirmatory testing due to its higher inherent specificity than the iELISA [35]. Blocking
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or competitive ELISAs have been constructed using monoclonal antibodies in PEDV
serodiagnosis, and the specific methodology can affect the overall specificity and
performance of the assay. Our method was based upon coating plates with highly purified
NA PEDV-NP, then using a combination of two separate NA, anti- PEDV-NP specific,
biotinylated, monoclonal antibodies as the blocking/competitive detection step. This
allows the capture of anti-NP antibodies at higher quantities and those with a greater
range of antigen specificities. The analytical specificity of the NP-based bELISA is also
dependent on the affinity of the mAbs used. The antibodies used in this study are directed
against conserved epitopes on the nucleocapsid protein without any evidence of crossreactivity to any other genera of Alphacoronavirus tested. A previous assessment of
antigenic cross-reactivity was performed using these same mAbs against different strains
of PEDV and TGEV [7]. In that study, the authors reported that both mAbs used in the
bELISA reacted with all PEDV strains tested, namely the homologous US isolate PC22A
and the heterologous strains S INDEL IOWA 106, S 197DEL PC177 and CV777, at
similar titers. Neither of the PEDV-NP mAbs cross-reacted with either the TGEV Miller
or Purdue strains. Not only were the bELISA mAbs tested for heterologous crossreactivity, but all three diagnostic platforms were evaluated in their ability to capture
antibody against TGEV and PRCV, and there was no cross-reactivity to either
heterologous virus.
Serology testing with IFA, iELISA, bELISA or FMIA is useful in determining
whether pigs were previously infected with PEDV, or if piglets have acquired antibodies
through colostrum (eg. passive antibody transfer). However, tests that evaluate the
functionality of the antibodies such as the FFN are needed to determine if the detected
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immune response could be helpful in providing protection to nursing piglets. Neutralizing
antibodies may be protective through actions including blocking uptake of the virus into
cells, preventing virus binding to receptors on cells, preventing uncoating of the virus
genomes in endosomes and/or causing aggregation of virus particles. For enveloped
viruses, such as PEDV, lysis of the virus may also occur when antiviral antibodies and
serum complement disrupt the viral membrane. For these reasons, an FFN-based virus
neutralization assay was developed to assess levels of PEDV neutralizing antibodies in
serum, milk or colostrum samples. The FFN provides a more rapid determination of
neutralizing antibody levels than is possible with traditional virus neutralization assays
that rely on visualization of virus-induced CPE after three or more days’ incubation to
allow for full development of PEDV CPE. The direct observation of fluorescent stained
infected cells, or lack of stained infected cells in the case of virus neutralization, allows
for simple endpoint determination. This feature is particularly valuable when dealing with
a fastidious, trypsin-dependent virus such as PEDV where CPE-based endpoints may not
be obvious or may be confused with trypsin-induced CPE in the cell monolayer.
Although neutralizing antibodies present in the serum would not be expected to provide
direct protection from a strictly enteric infection such as PEDV, our data suggest a
correlation between detectable neutralizing antibody levels in the serum and those present
in milk and colostrum of previously exposed or vaccinated sows.
Some correlation between PEDV neutralization results and ELISA results exists
as described in the literature. One study performed a comparative analysis between a
whole-virus antigen ELISA and a serum neutralization test for the serodiagnosis of
PEDV [21]. The presence of antibodies was confirmed by each test, and an overall testing
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agreement of 84.2% was demonstrated using 1,024 field serum samples. Furthermore, a
pairwise correlation was performed that showed corrected cutoff values between the
ELISA OD and SN titers having an R value of 0.837, indicating that the CPE-based
neutralization test had roughly the same reliability as the ELISA test [21].
Newer technologies such as the FMIA are useful for the detection of antibodies
against multiple antigens simultaneously for surveillance purposes. FMIA are bead based
assays for simultaneous high throughput detection of antibodies to multiple antigens. The
FMIA differs from the ELISA since it involves a fluid incubation step with “beads
suspended in solution, which allows for higher surface area exposure in 3 dimensions”
[30]. Therefore, there is a shorter diffusion path to antibody binding sites on the antigen
coated beads resulting in rapid reaction times. Instead of a method using an enzymatic
reaction such as with the ELISA, the FMIA detection is with laser technology, which
results in a shorter detection time. This PEDV antigen specific bead set can be “mixed”
with additional coated beads to other antigens, such as SIV, PCV2, PRRSV or other
pathogens, for simultaneous detection of antibodies to these antigens. In addition, an
FMIA could be developed for differentiation of wild-type infected vs vaccinated animals
(DIVA) if proteins used in the vaccine were different from those produced in a wild-type
infection.
Individual kinetic serum IgG and IgM levels were measured by FMIA in
experimentally infected animals over time. The appearance of the IgM subclass is
considered an immunological parameter of early infection and generally appears prior to
the appearance of IgG, and this was confirmed in our study. This was in contrast to the
data of Woo et al., 2004, which was unable to detect IgM antibodies using their NP-based
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indirect ELISA [36]. IgG antibodies may be more easily detected as they are
characterized by higher antigen affinity but lower avidity than IgM [37]. Further
understanding of various antibody profiles will provide important information on the
ability of vaccines to stimulate a protective immune response.

Conclusions
These well-validated NA PEDV iELISA, bELISA, FMIA and FFN assays are
useful for a range of serological investigations. They can serve as a complement to
nucleic acid detection and determine the PEDV status of asymptomatic individuals for
cost-effective tools in management strategies and monitoring virus exposure within the
herd. The FMIA will be useful for isotyping the antibody responses and in multiplexing
for determining exposure to multiple pathogens simultaneously. In addition, the FFN is
useful for determining whether the antibodies measured are providing a biological
function of blocking virus infectivity. Work is ongoing to further validate these assays on
other sample matrices such as milk and colostrum for measuring passive transfer of
antibodies and oral fluids for pen-based surveillance.
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Table 3.1. Evaluation of statistical agreement among serological testing platforms.
Multiple comparison, inter-rater agreement (kappa association) was calculated among all
four tests. Kappa values shown represent a statistical measure of test agreement and were
calculated using MedCalc version 11.1.1.0.
FMIA

bELISA

Indirect ELISA

IFA

IFA

0.932

0.945

0.941

1
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Figure 3.1. Purification of antibody capture antigen SDS-PAGE / Coomassie blue
staining of E. coli expressed and purified NA PEDV-NP antigen used to coat ELISA
microtiter plates and FMIA microspheres. Molecular weight ladder (MW) PEDV-NP (51
kDa).
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Figure 3.2. Antigen/antibody specificity. Western blot analysis showing detection of
recombinant expressed NA PEDV-NP protein and specificity of the monoclonal antibody
used in the bELISA.
L- Molecular weight ladder.
A- anti-PEDV-NP mAb 6-29.
B- anti-polyhistidine mAb.
C- anti PEDV-NP convalescent swine serum.
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Figure 3.3. Serum dilution optimization for both ELISA assays and FMIA.
Reference serum standard was titrated 2-fold in antigen coated wells at a fixed
concentration in order to gauge a maximum signal-to-noise ratio for each assay (A)
bELISA, (B) iELISA, (C) FMIA. Arrows show the optimum dilution of swine serum
from which the highest signal to noise ratio was achieved.
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Figure 3.4. Receiver operator characteristic (ROC) validation and determination of
diagnostic sensitivity and specificity of the PEDV-NP iELISA, bELISA and FMIA
assays. Diagnostic sensitivity and specificity were calculated using serum samples from a
known PED-uninfected and PED-infected population. ROC analysis was performed using
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the
dot plot on the left represents the negative testing population, and the dot plot on the right
represents the positive population. The horizontal line bisecting the dot plots represents
the cutoff value that gives the optimal diagnostic sensitivity and specificity. (A) Serum
iELISA, (B) Serum bELISA, (C) Serum FMIA.
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Figure 3.5. Kinetic time course antibody evaluation. Antibody time course kinetics
were calculated for each of the ELISAs and FMIA using serum samples from
experimentally infected pigs collected at weekly intervals. The horizontal line indicates
the diagnostic cutoff for each test. All three tests demonstrate similar kinetic curve
responses via their calculated S/P values. (A) Antibody kinetic time course via iELISA,
(B) Antibody kinetic time course via bELISA, (C) Antibody kinetic time course via
FMIA.
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Figure 3.6. FFN antibody and FMIA isotype time course evaluation. Using serum
collected over time from experimentally infected pigs, the FMIA demonstrates the kinetic
nucleoprotein-directed, isotype-specific response of IgG and IgM in serum. In addition,
the data show a concomitant appearance of neutralizing antibodies as soon as 14 DPI.
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Figure 3.7: Assessment of neutralizing antibody titers in different sample matrices
following PEDV exposure. FFN titers were detected in various sample matrices
including colostrum (n=25), milk (n=23) and serum (n=27) collected at the time of
farrowing and weekly for two weeks post-farrowing. Error bars indicate a 95% confident
interval for mean titers indicated by horizontal lines.
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Abstract
Background: A novel porcine deltacoronavirus (PDCoV), also known as porcine
coronavirus HKU15, was reported in China in 2012 and identified in the U.S. in early
2014. Since then, PDCoV has been identified in a number of U.S. states and linked with
clinical disease including acute diarrhea and vomiting in the absence of other identifiable
pathogens. Since PDCoV was just recently linked with clinical disease, few specific
antibody-based reagents were available to assist in diagnosis of PDCoV and limited
serological capabilities were available to detect an antibody response to this virus.
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Therefore, the overall objective of this project was to develop and validate selected
diagnostic reagents and assays for PDCoV antigen and antibody detection.

Results: The nucleoprotein of PDCoV was expressed as a recombinant protein and
purified for use as an antigen to immunize mice for polyclonal, hyperimmune sera and
monoclonal antibody (mAb) production. The resulting mAb were evaluated for use in
fluorescent antibody staining methods to detect PDCoV infected cells following virus
isolation attempts and for immunohistochemistry staining of intestinal tissues of infected
pigs. The same antigen was used to develop serological tests to detect the antibody
response to PDCoV in pigs following infection. Serum samples from swine herds with
recent documentation of PDCoV infection and samples from expected naïve herds were
used for initial assay optimization. The tests were optimized in a checkerboard fashion to
reduce signal to noise ratios using samples of known status. Statistical analysis was
performed to establish assay cutoff values and assess diagnostic sensitivities and
specificities. At least 629 known negative serum samples and 311 known positive
samples were evaluated for each assay. The enzyme linked immunosorbent assay
(ELISA) showed diagnostic sensitivity (DSe) of 96.1% and diagnostic specificity (DSp)
of 96.2%. The fluorescent microsphere immunoassay (FMIA) showed a DSe of 95.8%
and DSp of 98.1%. Both ELISA and FMIA detected seroconversion of challenged pigs
between 8-14 days’ post-infection (DPI). An indirect fluorescent antibody (IFA) test was
also developed using cell culture adapted PDCoV for comparative purposes.
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Conclusion: These new, specific reagents and serological assays will allow for
improved diagnosis of PDCoV. Since many aspects of PDCoV infection and transmission
are still not fully understood, the reagents and assays developed in this project should
provide valuable tools to help understand this disease and to aid in the control and
surveillance of porcine deltacoronavirus outbreaks.

Keywords: porcine deltacoronavirus (PDCoV), monoclonal antibodies, serology,
ELISA, fluorescent microsphere immunoassay (FMIA)

Background
Coronaviruses are enveloped, positive sense RNA viruses divided among several
genera, including Alphacoronavirus, Betacoronavirus, Gammacoronavirus and the
recently described genus Deltacoronavirus. A novel porcine deltacoronavirus (PDCoV)
was reported in China in 2012 and designated HKU15 [1]. Other important porcine
coronaviruses include porcine epidemic diarrhea virus (PEDV), transmissible
gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV); members of
the genus Alphacoronavirus [2]. In February 2014, the Ohio Department of Agriculture
announced the identification of PDCoV in swine feces at five farms in Ohio and
associated with enteric disease similar to PEDV in the U.S. [3]. Since then, PDCoV has
been identified in numerous U.S. states and Canada, linked with apparent clinical disease
including acute diarrhea and vomiting in the absence of other identifiable pathogens.
According to field observations in the U.S., PDCoV infections cause less severe clinical
disease than PEDV, but analysis of the field data is complicated since co-infections with
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PEDV or other pathogens are common. PDCoV is currently diagnosed by real time PCR
and clinical symptoms [1, 4].
The severity of disease in both gnotobiotic and conventional piglets has further
defined the pathogenicity and pathogenesis of the virus [5, 6, 7]. PDCoV causes diarrhea
and vomiting in all age groups and mortality in nursing pigs but the mortality rates are
less than that shown in cases of PEDV. Previously, there was little information about
deltacoronavirus infections in pigs and only one surveillance study from Hong Kong
reported its detection in pigs prior to its emergence in the U.S. The virus had not been
reported to be associated with clinical disease in China. The newly emergent strain found
on the Ohio farms, PorCoV HKU15 OH 1987, is closely related to the 2 strains from
China, but it is unknown how this virus was introduced into the US [3].
Recently, Jung et al. [7] developed in-situ hybridization and immunofluorescence
staining techniques to demonstrate the areas of PDCoV replication in tissues of infected
pigs. The OH-FD22 and OH-FD100 PDCoV strains were confirmed as causing an acute
infection through the entire intestine, but primarily the jejunum and ileum, and clinically
lead to severe diarrhea and vomiting. Clinical signs and pathological features of PDCoVinfected pigs resemble those of PEDV and TGEV infections. Effective differential
diagnosis between PDCoV, PEDV, and TGEV is important to control the diseases.
Polymerase chain reaction (PCR) assays were quickly developed for the detection
of PDCoV infections following the initial U.S. identification in 2014 but available
serological assays are limited. Thachil et al. [8] developed an indirect anti-PDCoV IgG
enzyme-linked immunosorbent assay (ELISA) based on the S1 portion of the spike
protein. Although this assay was shown to be a highly sensitive (91%) and specific test
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(95%), there is need for other ELISAs utilizing alternative antigen targets, such as the
nucleoprotein of PDCoV, to serve as primary serological surveillance or confirmatory
assays. As noted in Thachil’s research, several serum samples collected in 2010 were
found positive for PDCoV antibody by their ELISA, but all those collected in 2011 and
2012 tested negative by that assay. This finding is interesting since PDCoV was not
thought to be circulating in North America prior to late 2013 [7, 9]. Therefore,
availability of several serological assay formats targeting different viral antigens can be
valuable as confirmatory assays in the investigation of unexpected laboratory findings.
Since no specific antibody-based reagents were available to assist in diagnosis of
PDCoV, one purpose of the current study was to develop readily available reagents for
detection of PDCoV antigen in diagnostic tests, such as virus isolation,
immunohistochemistry and fluorescent antibody techniques. Serological tests for the
detection of antibody responses to PDCoV were also very limited. Therefore, another
objective of this study was to develop and optimize several serological assays including
an indirect ELISA, a fluorescent microsphere immunoassay (FMIA), and an indirect
fluorescent antibody (IFA) test.
Both specific antibody-based reagents and serological tests are essential for the
further study and control of PDCoV and the differentiation of PDCoV infection from
other related diseases such as PEDV or TGEV. The tools developed during the course of
this study can be applied to many ongoing and future studies to better understand and
control PDCoV.
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Methods
Serum Samples
Samples used for optimization and validation of the PDCoV ELISA and FMIA
assays included samples from a large PDCoV challenge study associated with National
Pork Board (NPB) research project 14-182. These samples and samples from another
group of 30 pigs which were collected near the time of initial field exposure to PDCoV
and 28 days later were used in a time course study.
For further validation and assessment of diagnostic sensitivity (DSe) and
diagnostic specificity (DSp), samples of known PDCoV serostatus were used (n=940).
The expected positive samples were submitted field serum samples (n=311) from herds
previously testing PDCoV positive by PCR at least 3 weeks prior to sample collection.
Expected negative samples included archived experimental serum collected prior to 2009
(n=108) and field samples from high-health herds with no known history of PDCoV
exposure (n=521). The total number of expected negative samples was 629.

Viruses and cells
Swine testicle (ST) cells were cultured in Eagle’s minimum essential medium
(MEM; Gibco BRL Life Technologies) supplemented by 10% fetal bovine serum (FBS),
and antibiotics (100 units/ml penicillin and 20 g/ml streptomycin). Cells were maintained
at 37 °C in a humidified 5% CO2 incubator. Cell culture adapted PDCoV was provided
by the National Veterinary Services Laboratories, designated porcine coronavirus
HKU15 strain Michigan/8977/2014 (GenBank accession KM012168). PDCoV was
propagated on ST cells utilizing 0.8 µg/ml trypsin (TPCK-treated, bovine derived
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(Sigma, St. Louis, MO)) in the inoculation and maintenance media. Virus infected cells
were harvested 24-48 hr after inoculation, when significant cytopathic effect (CPE) was
noted.

Antigen production
The antigen used for the FMIA and indirect ELISA validation was a
recombinantly expressed, full length, PDCoV nucleoprotein (NP). RNA isolated from
semi-purified cultured virus corresponding to the PDCoV-NP was amplified by reverse
transcriptase polymerase chain reaction (RT-PCR) and resulting DNA cloned into the
pET-28a protein expression vector (Novagen). Primers used for amplification of the
nucleocapsid region are described:
PDCoV-NP fwd (5’-CGCGGATCCATGGCCGCACCAGTAGTC 3’);
PDCoV-NP rev (5’-CACACTCGAGCGCGCTGCTGATTCCTGCTT- 3’).
The NP gene was prokaryotically expressed as an insoluble 41 kDa, 6x
polyhistidine-tagged, fusion protein then purified according to previously described
methods [10]. Purified protein was analyzed by sodium dodecyl sulfate- polyacrylamide
gel electrophoresis (SDS-PAGE) to determine purity and linear integrity. The expressed
PDCoV NP was recognized in Western blotting by convalescent serum and two separate
monoclonal antibodies developed in our laboratory were used to confirm the specificity
of the proteins.

Refolding of the PDCoV NP purified protein
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The purified protein was refolded by first solubilizing the recombinant protein
expressed as insoluble inclusion bodies in E. coli. Briefly, the protein was solubilized in
50mM 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS buffer, pH 11.0) containing
1.0% N-lauroylsarcosine and 1.0mM DTT. The protein was then dialyzed overnight at
4oC in 20 mM Tris-HCL pH 8.5 containing 0.1 mM DTT to encourage correct disulfide
bond formation and subsequent refolding of the protein. A second dialysis step was done
in phosphate buffered saline (PBS) to remove excess reducing agent. Testing of the refolded NP-based ELISA and FMIA began with checkerboard titrations of both the
antigen and PDCoV convalescent sera to determine optimum concentrations of each.
Depending on the calculation of signal to noise ratios, optimum concentration of NP
antigen was identified for coating of the ELISA plates and coupling FMIA beads. We
also identified optimum test serum dilutions and blocking agents.

Development and diagnostic application of rabbit antisera and monoclonal
antibodies
Rabbits and mice were immunized with selected recombinant PDCoV proteins for
production of hyperimmune antisera and monoclonal antibodies (mAbs) as previously
described [11, 12, 13]. Immunoglobulin isotyping of the resulting mAbs was performed
using a commercial lateral flow assay (Serotec, Raleigh, NC).

Indirect fluorescent antibody assay
An IFA assay was developed for reference purposes using pig serum of known
serostatus. ST cells were grown in cultures for 2 to 3 days to 80% confluence on 96-well
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plates. Odd numbered lanes were infected with PDCoV (approximately 1000 50% tissue
culture infective doses (TCID50)/ml) in MEM supplemented with 0.8 ug/ml TPCKtreated trypsin. The plates were incubated for 18 to 24 h. then fixed with 50% (vol/vol)
acetone/methanol for 20 min at -20 °C, air dried, and frozen with a desiccant at -20 °C
until they were used. Serum dilutions of 1:20 and 1:40 were applied to infected and
control wells of the IFA plates and incubated 1 hour. After washing three times with 300
µl of phosphate buffered saline (PBS), 40 µl of fluorescein isothiocyanate (FITC)-labeled
goat anti-swine immunoglobulin G (41.7 g/ml; KPL, West Chester, PA) was added to
each well. The plates were incubated at 37 °C for 1 h and washed with PBS three times.
The cells were examined for specific fluorescence with an inverted microscope and a UV
light source (Nikon Eclipse TS100). Serum samples were considered positive if PDCoV
specific fluorescence was observed at the 1:20 serum dilution.

Antibody detection indirect ELISA
The refolded PDCoV NP antigen-based indirect ELISA was performed using
methods previously described in Okda et al. [13]. Briefly, alternate wells of Immulon 1B,
96-well, microtiter plates (Thermo Labsystems, Franklin, MA) were coated for 1 hour at
37 °C with 200 ng/well of purified, refolded PDCoV-NP antigen diluted in 15 mM
sodium carbonate-35 mM sodium bicarbonate, antigen coating buffer (ACB) pH 9.6.
Next, non-bound antigen was poured off and the plates washed 3X with PBS plus 0.05%
tween-20 (PBST), then the remaining free-binding sites were blocked with 200 µl of
sample milk diluent ((SMD)-PBST plus 5% nonfat dry milk) and incubated overnight at
4 ºC. Test and control sera were diluted 1:50 in SMD, and 100 µl of the solution was
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added to each well of a washed plate. The plates were incubated for 1 hour at 22 ºC.
Next, 100 µl of biotinylated, FC-specific, goat anti-swine detection antibody (Bethyl
Laboratories, Montgomery, TX) was diluted 1:4000 in PBST and allowed to incubate at
22 ºC for 1 hour. Plates were washed 3X, then 100 µl of streptavidin-horseradish
peroxidase conjugate (Pierce, Rockford, IL, diluted 1:4000) was added and incubated for
1 hour at 22 ºC, then washed and developed using TMB (Surmodics, Eden Prairie, MN).
Colorimetric development was stopped using 2N H2SO4, then OD’s were quantified
spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek Instruments
Inc., Winooski, VT). The raw OD’s were normalized and the corrected S/P values were
calculated as follows: S/P= (OD of sample - OD of buffer) / (OD of positive control - OD
of buffer).
The optimal dilution of the recombinant protein and secondary detection antibody
was determined by a checkerboard titration that gave the highest signal to noise ratio. In
addition, a single lot of pooled convalescent serum from PDCoV infected pigs was used
to generate quality control standards that gave high, medium and low Sample to Positive
(S/P) values. The negative, low and medium samples served as internal quality standards
while the high standard served as a serum constant to mathematically calculate S/P values
of individual unknowns. For the ELISA, a high positive S/P = 0.8-1.0; medium S/P= 0.60.8; low S/P = 0.4-0.6; and negative S/P < 0.2.

Microsphere coupling and FMIA procedure
The coupling of purified, recombinant, refolded PDCoV-NP antigen to
fluorescent microspheres was performed using a two-step, carbodiimide coupling
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reaction as previously described [14]. Prior to performing large scale coupling reactions
for test validation, the optimization of the amount of antigen used was obtained by
performing a checkerboard titration of antigen-coupled microspheres against a two-fold
titration of swine serum. It was found that initiating a coupling reaction having 12.5ug of
purified protein per 3.125 x 106 microspheres was optimal in obtaining the highest signalto-noise fluorescence ratio. The performance of the FMIA test was described in detail
previously by Okda et al. [11]. In the initial optimization of the FMIA test, we performed
two-fold serial dilutions of swine serum and concluded that a dilution of 1:50 provided
the highest signal-to-noise ratio. For the generation of sample fluorescence, antigencoupled microsphere/antibody complexes were analyzed through a dual-laser Bio-Rad
Bio-Plex 200 instrument. The median fluorescent intensity (MFI) for 100 microspheres
corresponding to each individual bead analyte was recorded for each well. All reported
MFI measurements were normalized by calculating individual S/P values using the
following formula: S/P = MFI of sample - MFI of buffer control / MFI of high positive
control - MFI of buffer control. The buffer control equated to the background signal
determined from the fluorescence measurement of antigen-coated beads. Lastly, a single
lot of pooled convalescent serum from PDCoV infected pigs was used to generate quality
control standards that gave high, medium and low S/P values. The negative, low and
medium samples served as internal quality standards while the high standard served as a
serum constant to mathematically calculate S/P values of individual unknowns. For the
FMIA, a high positive S/P = 0.8-1.0; medium S/P= 0.6-0.8; low S/P = 0.4-0.6; and
negative S/P < 0.2, is consistent with the data of the ELISA standards.
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Antibody capture efficacy comparison between refolded vs linear PDCoV-NP
antigen
An antibody capture titration assay was employed to compare the efficacy of
refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in swine serum.
Wells of a 96-well microtiter plate were coated with 10-fold decreasing concentrations of
either linearly expressed or refolded PDCoV-NP antigen in ACB, pH 9.6., then allowed
to incubate for 1 hour at 37 °C. Each well was then blocked with 200 µl of SMD and
allowed to incubate overnight at 4 ºC. The following day, the plates were washed 3X with
300 µl of PBST. Well characterized positive control sera having a “high” positive OD
was diluted 1/50 in SMD, mixed, and 100 µl of the solution was added to each well. The
ELISA was continued pursuant to the stated protocol and the OD was recorded at each
titration point, then a logarithmic regression curve was generated. Relative capture
efficiencies for each antigen-coated well was determined by analyzing the OD at each
dilution point and position under the linear portion of the curve.

Assay validation
(i) Cutoff determination, DSe and DSp. To accurately assess the DSe and DSp
of the assays, the assays were validated using seronegative and seropositive samples from
different distinct animal populations. The expected positive samples used were field
serum samples submitted to the ADRDL from herds previously testing PDCoV positive
by PCR. Expected negative samples included archived experimental serum collected
prior to 2009 and field samples from high-health herds with no known history of PDCoV
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exposure. Receiver operating characteristic (ROC) analysis was performed using
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).
(ii) Measurement of repeatability. The repeatability of the FMIA and ELISA
was assessed by running the same lot of internal quality control serum standards multiple
times on the same plates and on different plates over time. The intra-assay repeatability
was calculated for 36 replicates on a single plate and then repeated over a 3-day period
for inter-assay repeatability assessment. Each assay was run in a single-plex format, and
median fluorescence intensity values were expressed as median, standard deviations, and
percent coefficients of variation (CV) for repeated measurements. Percent CV was
calculated using a method described earlier [15].

Statistical analyses and Measurement of testing agreement
Multiple comparison, inter-rater agreement (kappa measure of association) was
calculated among all three tests (ELISA, FMIA and IFA) using IBM, SPSS version 20
software (SPSS Inc., Chicago, IL). The sample cohort used included a set of archived
serum samples collected from PDCoV “positive testing” experimentally infected pigs
over time and from archived experimental control uninfected PDCoV “negative testing”
animals. The interpretation of kappa can be rated as follows: Kappa less than 0.0, “poor”
agreement; between 0.0 and 0.20, “slight” agreement; between 0.21 and 0.40, “fair”
agreement; between 0.41 and 0.60, “moderate” agreement; between 0.61 and 0.80,
“substantial” agreement; and between 0.81 and 1.0, “almost perfect” agreement [16].
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Validation of the tests was performed by ROC analysis using Medcalc statistical
software. Correlations between the tests and scatterplots for seroconversion were
performed using SPSS 20.

Results
Expression of recombinant full-length nucleoprotein
The full-length NP of PDCoV was cloned and expressed in E. coli as a
polyhistidine fusion protein. Antigen purity was then evaluated using SDS-PAGE in
which the His-tagged recombinant NP migrated through the gel according to its predicted
molecular mass of 41 kDa upon staining with Coomassie brilliant blue R250 (Figure
4.1A). The recombinant protein was expressed in the form of insoluble inclusion bodies.
It was purified by Nickel-NTA affinity column chromatography and yielded a calculated
concentration of approximately 10mg PDCoV-NP /liter of 2XYT medium and having a
purity greater than 95% as measured by the Lowry protein assay. The protein was
subsequently refolded back to its soluble, conformational structure and its specificity was
tested via Western blotting (Figure 4.1B). The figure illustrates the migration pattern and
antigen specificity of the refolded PDCoV-NP/polyhistidine fusion protein as compared
to the adjacent lane loaded with semi-purified, concentrated PDCoV. Both the rPDCoVNP and native virus are recognized with equal intensity by a PDCoV-NP-specific
monoclonal antibody (SD55-197) developed in our laboratory. Also, the recombinant
nucleocapsid protein is shown to have a higher molecular mass than the native virus
nucleocapsid due to its dual amino and carboxy terminus polyhistidine tags.
Experiments were conducted to assess the immunoreactivity of refolded vs non-
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refolded PDCoV-NP antigen used for both tests. Specifically, an antibody capture
titration ELISA was employed to compare the ability of a refolded and non-refolded
version of the antigen to capture antibodies within swine serum. The immunoreactivity of
antigen was determined by end-point titration and relative absorbance values as we
observed differences in immunoreactivity based upon the conformational state of antigen
tested. Figure 2 demonstrates in a dose-dependent fashion, that as the concentration of
each antigen coated well decreases, the refolded antigen imparts a greater degree of
antibody capture efficacy of swine antibodies than the non-refolded version. Specifically,
a 27 fold difference at the end of the linear portion of the curve was calculated,
illustrating that the refolded protein maintained a marked enhancement of
immunoreactivity resulting in a greater dynamic range of the assay.

Fluorescent microsphere immunoassay and indirect ELISA development
(i) Establishment of control standards: ELISA and FMIA test reference
standards for PDCoV were developed for each of the respective prototype assays (Figure
4.3 A & B). A control high positive standard was established by pooling several lots of
serum collected from convalescent, seropositive pigs, and used to mathematically
calculate S/P values of each assay. The medium and low positive samples served as
internal quality control standards. The negative standard was pooled from a set of known
seronegative pigs from a herd with no known prior PDCoV infection that also tested
negative by PDCoV IFA and virus neutralization.
(ii) Test optimization: A series of coupling processes were performed using a
two-fold titration of antigen to determine the optimum coupling concentration. A total of
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3.125 x106 beads, were incubated with various concentrations (100 µg, 50 µg, 25 µg, and
12.5 µg) of purified NP. Based upon the highest signal-to-noise ratio reflecting the
detection of PDCoV-specific antibodies in standard serum, 12.5 µg per reaction was the
optimal concentration for microsphere coupling. ELISA microtiter plates were coated
with an optimized concentration of 200 ng antigen per well.
Testing the re-folded, NP antigen-based ELISA and FMIA began with
checkerboard titration of both antigen and PDCoV convalescent and naïve swine serum
to determine the optimum signal-to-noise ratio of each test. We also identified optimum
test serum dilutions and blocking agents. The optimal serum dilution of each assay was
determined by diluting serum samples two-fold in their respective blocking/detergent
buffer diluent. For both the FMIA and ELISA, a serum dilution of 1:50 was shown to
produce an optimal signal-to-noise ratio (Figure 4.3 C & D). Testing field samples of
known serological status was performed to gauge initial sensitivity of the assay. Our
results showed a positive to negative sample ratio (P/N) of greater than 16-fold with
ELISA and a P/N of greater than 40-fold with FMIA. The P/N is a relative measure of
PDCoV antibody concentration between seropositive and seronegative samples. Having a
diagnostic P/N of greater than 10 is highly desirable with any serological assay.

Assessment of test repeatability
The intra-assay repeatability was calculated for 36 replicates on a single plate and
then repeated over a 3-day period for inter-assay repeatability assessment. Internal
control serum standards were used to determine the precision of each FMIA and ELISA.
The inter-assay and intra-assay repeatability of each test demonstrated a coefficient of
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variation of less than 8.6%. These results confirmed that the serological tests are highly
repeatable in diagnostic applications.

Validation methods and cutoff determination
ROC analysis of both FMIA and ELISA was performed using MedCalc software
to calculate an optimized cutoff value that maximizes the DSe and DSp of each assay.
Using known seronegative and seropositive serum samples (n=940), the expected
positive samples used were submitted as field serum samples (n=311) from herds
previously testing PDCoV positive by PCR. Expected negative samples included
archived experimental serum collected prior to 2009 (n=108) and field samples from
high-health herds with no known history of PDCoV exposure (n=521). ROC analysis was
performed and DSe and DSp were shown to be 96.1% and 96.2% respectively for the
ELISA; and 95.8% and 98.1% respectively for the FMIA (Figure 4.4). The similar cutoff
values of both assays confirm the utility of these new diagnostic tests to aid in the control
and surveillance of PDCoV outbreaks.

Evaluation of the kinetic swine antibody response in serum
Once validated, the assays were used to evaluate the kinetic antibody response
over time using serum collected from experimentally infected pigs over weekly intervals.
Serological responses detected by the PDCoV ELISA and FMIA following challenge
show seroconversion between days 8 and 14 DPI (Figure 4.5). Both assays demonstrate a
similar dynamic range using the same serum samples and “high” positive standard from
which the S/P values are calculated. However, the FMIA appears to detect a slightly
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higher level of antibody over a longer period of time at days 35 and 42 post infection.
Additional testing of seroconversion included serum samples collected from a group of
30 piglets near the time of initial field exposure to PDCoV then 28 days later. Figure 4.6
shows clear seroconversion to the naturally circulating virus within the 28 day timeframe using the same diagnostic cutoff values previously determined by ROC analysis.

Measurement of statistical testing agreement
Multiple comparison, inter-rater (kappa) agreement is a statistical measure of
testing agreement, and was calculated among all three tests (ELISA, FMIA & IFA) using
629 positive testing and 311 negative testing serum samples. Statistical comparison
calculated kappa values to be 0.940 between FMIA and IFA, 0.902 between ELISA and
IFA, and 0.914 between ELISA and FMIA (Table 4.1). Because all three diagnostic
platforms had kappa values above 0.81, it demonstrates that the tests are in “almost
perfect” agreement with each other according to the interpretation of kappa by Landis et
al. [16].

Cross Reactivity
Serological cross reactivity testing was performed between PDCoV and other
closely related swine coronaviruses. There was no cross reactivity among the 93 TGEV
positive serum samples, 20 PRCV positive serum samples, 167 PEDV field positive
serum samples and 84 PEDV experimentally positive serum samples tested via ELISA
and FMIA (Table 4.2). The data show mean OD and MFI readings from ELISA and
FMIA tests, respectively. The lack of cross reactivity between PDCoV and
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aforementioned alphacoronavirus species was also confirmed via western blotting using
seropositive, convalescent sera from individual pigs (data not shown).

Development of reagents for detection of PDCoV antigen in diagnostic tests
Both denatured and refolded versions of the NP were used to immunize rabbits
for hyperimmune serum and mice for monoclonal antibody production. Rabbit
hyperimmune sera specifically recognize the NP and can be used in indirect fluorescent
antibody staining at dilutions of 1:1000 to 1:5000. In addition, the polyclonal antisera
was used successfully in immunohistochemical staining procedures for the detection of
PDCoV antigen in intestinal tissues (Figure 4.7B). The resulting monoclonal antibodies
all recognized native viral protein in infected ST cells demonstrated by bright
cytoplasmic immunofluorescent staining (Figure 4.7A) and within intestinal enterocytes
stained immunohistochemically (Figure 4.7C).

Discussion
As a recently identified pathogen, the impact of PDCoV on the swine industry is
not yet fully understood. Field observations and recent research studies have suggested
that the virus can cause substantial morbidity and mortality in nursing piglets [5, 6, 7,
17]. Specific antibody-based reagents and serological tests are essential for the further
study and control of PDCoV, as well as the differentiation of PDCoV infection from
other related coronaviruses such as PEDV or TGEV.
Therefore, the primary objective of this study was to develop an initial generation
of antibody-based diagnostic reagents and serological assays for the further study of
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PDCoV, including NP-based indirect ELISA and FMIA tests that were developed and
validated for diagnostic applications. Specific antibody-based reagents were also not yet
available for PDCoV so monoclonal antibodies against selected PDCoV structural
proteins were developed. The tools developed during the course of this study can be
applied to many ongoing and future studies to better understand and control PDCoV.
The new monoclonal antibody reagents described here should be of substantial
value in the detection of PDCoV antigen in a variety of applications including: early
verification of virus isolation attempts and virus titrations; immunohistochemistry
staining of fixed tissues; development of neutralization assays; fluorescent antibody
staining of fresh tissues; development of field-based antigen capture assays such as lateral
flow devices; and ELISA applications (competitive ELISA and antigen capture). Through
extensive testing via ELISA (over 364 samples) and Western blot analysis, we were not
able to demonstrate any cross-reactivity with other major swine coronaviruses including
PEDV, PRCV and TGEV. However, since many described deltacoronaviruses of other
species have not yet been adapted to cell culture replication or fully characterized, we do
not yet know if these reagents may cross-react with other members of the genus.
Several new serological assays for detection of antibody responses to PDCoV
were developed during the course of this study. The ELISA and FMIA tests were based
on a recombinant nucleoprotein antigen since this protein is highly conserved among
PDCoV isolates. In addition, the NP is known to be the most abundant viral protein
within host cytoplasmic compartments [18]. The highly immunoreactive PDCoV-NP
interacts with itself to form non-covalently linked oligomers and associates with the viral
genome to serve as the architectural basis of the ribonucleoprotein complexes during

121

virus assembly [19]. These reasons provided the rationale for its utility as a target antigen
for the serodiagnosis of PDCoV in indirect ELISA and FMIA platforms.
Antibody responses to the nucleoprotein of coronaviruses are very robust and
have been reported to appear as soon as 7-9 days’ post infection. We originally
hypothesized that antibody reactivity to PDCoV may be conformationally dependent so
we designed an experiment to determine whether NP specific immunodominant epitopes
tend to be present in greater abundance on conformationally or linearly expressed
antigen. A refolded version of the NP was used as an antigen in both assays as it was
shown to impart a higher degree of immunoreactivity than its unfolded, linear
counterpart. This phenomenon was also observed by Johnson et al. [20] whereby the
authors compared reactivity differences among single point serum titrations to provide a
surrogate measure of antibody titer. They showed that the enhancement of
immunoreactivity of PRRSV-N and nsp1 was completely dependent on refolding, and the
reactivity of nsp2P was enhanced by twofold. Furthermore, we confirmed their
observations that there is a loss of immunoreactivity when the linear protein (solubilized
in 8M urea) was dialyzed in PBS prior to coating on microtiter plates or used for coupling
to FMIA microspheres. This may indicate that using an antigen in its more native
conformational state may present a higher number of immunoreactive epitopes that are
able to capture a larger percentage of PDCoV-NP antibodies. Therefore, the production
of a well purified, refolded recombinant protein maintained in a near-native conformation
was required for the production of an efficacious assay.
Both assays provide the capability of high-throughput testing with reasonable DSe
and DSp. ROC analysis was performed for both assays demonstrating DSe of greater
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than 95%. The FMIA demonstrated good DSp of 98.1% while the ELISA showed a
slightly lower DSp of 96.2%. Inter-rater (kappa) agreement, a statistical measure of test
agreement demonstrated a significant level of agreement among the IFA, ELISA and
FMIA. Furthermore, each of the antibody-capture assays was validated using a large
number of well characterized serum samples (n=940) based upon the suggested 5-stage
validation methods of Jacobson, which is supported by the office International des
Epizooties [21].
Although preliminary DSe and DSp determinations for the first generation
serological assays described here were slightly less than ideal, these new assays should
provide valuable tools for assessment of PDCoV exposure on a herd level. One
explanation for the approximately 95-96% DSe values determined to date may be related
to selection of the presumed positive field populations used for test validation. In this
case, the initial stages of validation relied on characterizing the assay using known serum
samples from experimentally infected pigs. Because this was the only sera of known
serostatus we had at our disposal, we believe that the resulting initial ROC characteristics
were of sufficient value to begin testing samples from other sources believed to not have
been exposed to PDCoV and from field sources known to have seroconverted to PDCoV
within a specific time frame. By following the methodology outlined by Jacobson [21] in
which he recommends the inclusion of these initial ROC cut-off values from
experimentally infected pigs, we demonstrated similar assay characteristics on chosen
field samples which substantiated our final cut-off value of the assay. These sample sets
were collected at approximately 3 weeks after initial diagnosis of PDCoV by PCR. It is
possible that PDCoV may not move through a herd at the very rapid rate seen with
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PEDV. Therefore, some animals in some herds may not have been infected until a week
or more after initial detection in the population, resulting in delayed seroconversion in a
percentage of the presumed positive population. Likewise, since the initial origination
and distribution of PDCoV in the U.S. is not fully understood at this time, it is possible
that a small percentage of our presumed seronegative population may have been subject
to prior exposure. Many of the samples in our presumed negative population were
archived samples collected prior to 2009. However, some originated from recent field
submissions from high health, biosecure herds with no clinical or PCR evidence of prior
PDCoV or PEDV exposure. The observed DSp values of approximately 98% for FMIA
and 96% for indirect ELISA are within the expected range for first generation assays
using these test formats. Apparent false positive reactions could also be due to an epitope
on the expressed antigen having commonality with another low prevalence infectious
agent or due to low levels of residual E. coli protein contaminants in the purified antigen
preparations.
Recently, Thachil et al. [8], developed an indirect anti-PDCoV IgG enzymelinked immunosorbent assay based on the putative S1 portion of the spike protein and
evaluated it using a total of 968 tested serum samples. Although it is a reasonably
sensitive (91%) and specific (95%) test, there is room for other ELISAs utilizing other
target antigens, such as the NP of PDCoV, to serve as primary serological surveillance or
confirmatory assays. As noted in Thachil’s research, serum samples collected in 2010
were found positive for PDCoV antibody by their ELISA, but not those collected in 2011
and 2012. This was controversial because PDCoV was not thought to be circulating in
North America in pigs before its identification in late 2013 [9]. It will be very beneficial
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to have confirmatory assays to validate this finding. Additional screening of archived
historical swine serum samples using multiple serological assays may provide further
insight into the origin and epidemiology of PDCoV in North America.

Conclusions
The monoclonal antibody reagents developed here provide important research and
diagnostic tools for the industry. They are valuable for fluorescence and
immunohistochemical staining methods associated with diagnostic and pathogenesis
studies. The serological assays allow the detection of antibodies developed in response to
PDCoV infection. The PDCoV indirect ELISA and FMIA will allow high-throughput
screening of swine serum samples. These tests should be adequately optimized and
validated for sero-surveillance on a herd level, but further improvement is needed for full
confidence on an individual animal basis. The IFA or other tests may be required for
confirmation of individual unexpected results. Work is ongoing to further validate these
assays and to adapt them to different sample matrices such as milk or oral fluid samples.
Since lactogenic immunity is likely critical for protection of nursing piglets, these assays
will be modified for detection of IgA as well.
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FMIA

Indirect ELISA IFA

IFA

0.940

0.902

1

Indirect ELISA

0.914

1

0.902

FMIA

1

0.914

0.940

Number positive serum samples

311

311

315

Number negative serum samples

629

629

625

Total

940

940

940

Table 4.1. Evaluation of statistical testing agreement among three serological testing
platforms. Multiple comparison, inter-rater agreement (kappa association) were
calculated among all three tests, IFA, indirect ELISA and FMIA. Kappa values shown
represent a statistical measure of test agreement and were calculated using MedCalc
version 11.1.1.0.

127

TGEV
0.097
0.024

ELISA Mean OD
FMIA Mean FI
Total No. serum
samples tested
93

PRCV
0.132
0.016

PEDV
0.074
0.032

20

251

Table 4.2. Serological cross reactivity testing among related swine coronaviruses.
Antigenic cross reactivity testing was performed among both ELISA and FMIA tests
using convalescent swine serum positive for TGEV, PRCV and PEDV antibodies. Mean
ELISA OD’s and FMIA fluorescent values are reported for each test. The ELISA OD
and FMIA MFI values shown are well below the established diagnostic test cutoff
threshold levels described in figure 4 for the validation of the assay (ELISA OD = 0.36;
FMIA MFI = 0.32).
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MW

A

75

PDCoV-NP

1

2

B

50

37

Figure 4.1. Purification and antigen specificity of PDCoV-NP antibody capture
antigen. (A) Coomassie blue staining of E. coli expressed and purified PDCoV-NP
antigen used to coat ELISA microtiter plates and FMIA microspheres. Molecular weight
ladder MW and PDCoV-NP (41kDa). (B) Western blot showing antigen specificity of
recombinant, refolded PDCoV-NP/polyhistidine fusion protein probed with mAb SD-55197 (Lane 1). Lane 2 was loaded with semi-purified, concentrated PDCoV strain
HKU15/Michigan/8977/2014 then probed with mAb SD-55-197.
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4.00
Refolded PDCoV-NP
2.00

Denatured PDCoV-NP

ELISA OD

1.00
0.50
0.25
0.13
0.06

PDCoV-NP Concentration [ng/well]

Figure 4.2. Antibody capture efficacy comparison between refolded vs linear
PDCoV-NP. An ELISA antibody capture titration assay was employed to compare the
ability of refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in
swine serum. Wells of a 96-well microtiter plate were coated with decreasing
concentrations of either linearly expressed or refolded PDCoV-NP antigen. Refolded
antigen demonstrated greater dynamic range of the assay and capture efficacy of swine
antibody.
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neg PDCoV serum
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15000
10000
5000

0

0

Serum dilution
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Figure 4.3. Production and reactivity of serological reference standards and internal
quality control standards for both ELISA (A) & FMIA (B). Reference serum
standards were titrated 2-fold in antigen coated wells at a fixed concentration [250
ng/well] in order to gauge a maximum signal-to-noise ratios for each assay (C) ELISA,
and (D) FMIA. Arrows indicate the optimal serum dilution that resulted in the greatest
positive to negative (P/N) ratio for the test.
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ELISA

>.36

Negative N = 629
Positive N = 311
Sens. = 96.1%, Spec. = 96.2%, Cutoff = 0.36

FMIA

>.32

Negative N = 629
Positive N = 311
Sens= 95.8%; Spec= 98.1%, Cutoff = 0.32

Figure 4.4. Receiver operator characteristic (ROC) validation and determination of
diagnostic sensitivity (DSe) and specificity (DSp) of the PDCoV-NP ELISA and
FMIA assays. DSe and DSp were calculated using serum samples from known PDCoVinfected and known PDCoV-uninfected populations. ROC analysis was performed using
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the
dot plot on the left represents the negative population, and the plot on the right represents
the positive population. The horizontal line bisecting the dot plots for each figure
represents the tentative cutoff value that gives the optimal DSe and DSp.
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Figure 4.5. Serum antibody kinetic time course evaluation. Antibody kinetic
responses were calculated for the ELISA and FMIA tests using serum collected weekly
over six weeks from experimentally infected pigs. Serological responses detected by
PDCoV ELISA and FMIA tests show seroconversion between 8 and 14 DPI.
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A

> 0.36

B

> 0.32

Figure 4.6. ELISA (A) and FMIA (B) results from a group of 30 piglets sampled
near the time of initial PDCoV field exposure then 28 days later. Both assays show
clear seroconversion to naturally circulating PDCoV. The horizontal line between both
positive and negative testing samples shows the diagnostic cutoff value for each test
previously determined by ROC analysis.
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A

B

C

D

Figure 4.7. Development of reagents used for indirect fluorescent antibody (IFA)
testing and immunohistochemical (IHC) staining of PDCoV infected cells. Indirect
fluorescent antibody staining of PDCoV infected ST cells with PDCoV antinucleoprotein monoclonal antibody SD-55-24 [(A), 100X magnification].
Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein
rabbit polyclonal hyperimmune sera [(B), 100X magnification]. Immunohistochemistry
staining of intestinal enterocytes with PDCoV anti-nucleoprotein monoclonal antibody
55-197 [(C), 100X magnification]. Uninfected control showing hematoxylin staining of
luminal, intestinal brush-border cross section [(D), 100X magnification].
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Abstract
The porcine epidemic diarrhea virus (PEDV) spike (S) glycoprotein plays a key
role in virus entry into target cells. It mediates the functions of receptor binding (S1
subunit) and fusion (S2 subunit) of virus and cellular membranes during entry. Given its
critical functions during entry the S protein is one of the main targets of host antibodies
against PEDV. Here, immunodominant neutralizing epitopes of PEDV were identified
using a panel of S-specific monoclonal antibodies (mAbs). When mice were immunized
with inactivated whole PEDV preparations, ten mAbs against the S protein were
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obtained. The reactivity and specificity of these mAbs was confirmed by
immunofluorescence, western blots and ELISAs, and their neutralizing activity was
assessed by fluorescent focus neutralization (FFN) and plaque reduction neutralization
assays (PRN). Nine of the ten mAbs successfully neutralized PEDV infectivity in vitro.
Epitope mapping by peptide ELISAs revealed that seven mAbs recognized linear
neutralizing epitopes located in the N-terminus of the S2 glycoprotein subunit (amino
acids [aa] 744-759, 747-774 and/or 756-771). Additionally, two mAbs recognized a
neutralizing epitope located in the C-terminus of S2 (aa 1371-1377), while only one
neutralizing mAb reacted against a region of the S1 glycoprotein subunit (aa 499-600).
Notably, mAbs that recognized epitopes 744-759 and 747-774 within the S2 subunit
presented the highest neutralizing activity against PEDV. These results indicate that the
S2 glycoprotein subunit contains major antigenic determinants and, perhaps, the
immunodominant neutralizing epitopes of PEDV.

Key words: Porcine epidemic diarrhea virus (PEDV), spike, neutralizing antibodies.

Introduction
Porcine epidemic diarrhea virus (PEDV) is a member of the genus
Alphacoronavirus of the family Coronaviridae. The virus replicates primarily in
enterocytes of the small intestine causing villous atrophy and malabsorptive diarrhea
which lead to electrolyte imbalance, metabolic acidosis and death [1,2]. The
characteristic clinical signs of PEDV infection are watery diarrhea, vomiting, anorexia,
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and dehydration which are followed by high mortality rates (50-100%) in suckling piglets
or weight loss due to diarrhea in older pigs [3].
The PEDV genome consists of a large (~28 Kb) single-stranded, positive sense
RNA molecule which contains seven open reading frames (ORF1ab, and ORFs2-6) [4,5].
It is organized in a central coding region that is flanked by 5’- and 3’-untranslated regions
(UTRs). The first gene ORF1ab encompasses approximately 2/3 of the viral genome and
encodes large polyproteins (pp1a and pp1b), that are cleaved by viral encoded proteases
into 16 non-structural proteins (nsp1-16) [4]. In addition, four structural proteins are
encoded by ORFs2, -4, -5 and -6, including the S glycoprotein (180–220 kDa),
membrane (M; 27– 32 kDa), envelope (E; 7 kDa), and the nucleocapsid proteins (N; 55–
58 kDa), respectively. ORF3 encodes for a non-structural accessory protein [4,6,7].
The S protein is the major envelope glycoprotein responsible for virus attachment,
receptor binding, cell membrane fusion and entry, [8,9,10]. The S protein is expressed as
a 1,383 amino acid- (aa) precursor peptide (180-200 kDa) that is cleaved by host
proteases into two major subunits: the S1 subunit (residues 20–725) that mediates virus
attachment to the cell surface receptor; and the S2 subunit (residues 726–1383) involved
in virus and host cell membrane fusion. Like other coronavirus’ S proteins, the PEDV S
is a type I membrane glycoprotein that forms homotrimeric projections (spikes) on the
virion surface and contains an N-terminal signal peptide (residues 1-19), a large
extracellular region, a single transmembrane domain (residues 1335–1358) and a short
cytoplasmic tail (residues 1359–1385) (Li et al., 2016). The S1 subunit has been shown to
have a modular architecture with four discrete domains, including an N-terminal domain
(NTD; residues 19-233) that exhibits sialic acid binding activity and a C-terminal domain
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(CTD; residues 477–629) that can interact with protein receptor(s) [11]. The S2 subunit
presents the typical structural features found in class I fusion proteins, including a
hydrophobic fusion peptide (residues 891–908), two heptad repeat regions (HR1, residues
978–1117 and HR2, residues 1274–1313), and a C-terminal transmembrane domain
(residues 1335–1358) [11]. The homotrimeric S proteins on the virion surface are
uncleaved and undergo proteolytic processing required for fusion during entry [10,12].
Given its critical functions during cell entry, it is not surprising that the PEDV S
protein is the main target of host antibody responses against the virus [13]. Indeed,
several studies have recently shown that immunization of pigs with full-length or
truncated versions of the S protein elicits antibody responses and protection against
PEDV [14,15,16]. Most importantly, various neutralizing epitopes have been identified in
the S protein, with one of them mapping to a domain homologous to the collagenase
resistant fragment (CO-26K) of TGEV S [17], thus being named “collagenase
equivalent” (COE) in PEDV (residues 499-638) [18]. Another neutralizing epitope has
been mapped to the S1D region (residues 636-789) of the S, and it spans the S1-S2
junction [9], while a third neutralizing epitope has been found in the C-terminus of the S
protein (residues 1371-1377) [8]. It is important to note that neutralizing antibodies
directed against the S protein are thought to be major effectors of protection against
PEDV.
Here we have shown that immunization of BALB/c mice with purified and
inactivated whole virus preparations of PEDV followed by somatic cell fusion resulted in
hybridoma cell lines secreting mAbs specific for the S protein that exhibited marked
neutralizing activity against PEDV in vitro. Epitope mapping of the resultant neutralizing
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mAbs led to the identification of important antigenic determinants within the S protein.
Notably, most mAbs obtained here reacted against linear epitopes within the S2 subunit,
indicating that this region contains immunodominant neutralizing epitopes of PEDV.

Results
Selection and characterization of PEDV S-specific mAbs
PEDV S-specific mAbs were generated by immunization of BALB/c mice with
sucrose purified inactivated whole virion preparations of PEDV in a water-in-oil adjuvant
emulsion. Following three intraperitoneal immunizations, mice splenocytes were fused to
NS-1 myeloma cell lines using standard fusion protocols, and primary hybridomas
secreting S-specific mAbs were selected based on the reactivity of the mAbs with full
length PEDV S expressed by a recombinant viral vector (ORFV-PEDV-S) [14] (Figure
5.1). Approximately 25 primary hybridomas secreting S-specific mAbs were obtained
and their specificity was confirmed by immunofluorescence and Western blot assays
(data not shown). The specificity of these mAbs was assessed against the prototype
PEDV strain USA/Colorado/2013 [19] and the S-INDEL strain USA/Iowa106/2013 [20]
(Figure 5.1). Additionally, their neutralizing activity was assessed by fluorescent focus
neutralization (FFN) assay, with supernatants from nine hybridomas presenting
neutralizing titers between 4 and 16 (data not shown). These hybridoma lines were
subcloned by limiting dilution and further characterized in our study. One additional
hybridoma cell line (SD33; Figure 5.1) secreting S-specific mAbs that did not neutralize
PEDV and another line previously established at the ADRDL (SD37-11) (unpublished
data) that showed neutralizing activity in our initial screening were also included in our
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study. After subcloning one clone of each primary hybridoma line was selected and
subjected to ascites production (Envigo, Inc.). A summary of the properties and
characteristics of the mAbs generated here is presented in Table 5.1.
All mAbs specifically recognized cells infected with the recombinant ORFVPEDV-S, expressing the full length PEDV S and cells infected with the PEDV strain
CO13 (Figure 5.1; Table 5.1). Notably, seven out of eight mAbs recognized cells infected
with the S-INDEL variant PEDV strain USA/IOWA/106/2013, with mAb SD125-2 not
recognizing S-INDEL infected cells (Figure 5.1; Table 5.1).
The specificity of the PEDV-S mAbs was also evaluated by western blots and
ELISAs using whole virus preparations, and recombinant S- (amino acid [aa] 630-800 or
aa 499-600) and N proteins expressed in E. coli. On Western blots, eight of nine mAbs
recognized the full-length spike protein in whole PEDV preparations (Figure 5.2a) and
the truncated S protein spanning the S1-S2 junction region (aa 630-800) (Figure 5.2a),
with mAb SD37-11 not recognizing the full-length spike and mAb SD125-2 not
recognizing the S1-S2 recombinant protein (aa 630-800) (Figure 5.2a). None of the mAbs
reacted with the recombinant N protein (Figure 5.2a). The reactivity of the mAbs with the
S protein under denaturing western blot conditions indicate that all mAbs recognize linear
epitopes of the S protein, with most of them being specific for epitopes within the S1-S2
junction (Figure 5.1b). When tested by ELISA, all mAbs reacted against PEDV strains
CO13 (Figure 5.3a) and S-INDEL Iowa106 (Figure 5.2a and 5.2b). These results
corroborate the findings of the IFA assays, confirming the specificity of the mAbs for
PEDV.
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Next, we assessed the reactivity of the mAbs against truncated versions of the S
protein (aa 499-600 and 630-800). Notably, nine mAbs reacted against the S1-S2 region
(aa 630-800), while only one mAb (SD131-3) reacted against the product corresponding
to aa 499-600, which contains the putative receptor binding domain of the S1 subunit
(Fig 2d and 2e). These results confirmed the findings of Western blots, indicating that
most mAbs developed here specifically recognize epitopes located in the S1-S2 junction
of the S protein. It is important to note that, while mAb SD125-2 reacted with PEDV
CO13 whole virus (Figure 5.2a) this mAb did not recognize the S1- nor the S1-S2
truncated proteins (Figure 5.2d and 5.2e), suggesting that this mAb may be specific to
another region of the S protein or, perhaps, it could recognize conformational epitopes.

Neutralizing activity of PEDV S-specific mAbs
The neutralizing activity of S-specific mAbs was assessed by FFN and plaque
reduction neutralization (PRN) assays. For this, all mAbs were purified from ascites fluid
and diluted to a working solution of 3 µg/mL. Two-fold serial dilutions of the mAbs'
working stocks (1:20 - 1:1280) were tested in triplicate by FFN or PRN assays. Endpoint
titers were considered the reciprocal of the highest mAb dilution capable of reducing
PEDV infectivity by 90 (FFN) or 80% (PRN) in vitro. Nine out of ten mAbs presented
neutralizing titers ranging from 1:40 to 1:640 against PEDV strain CO13 (Table 5.2,
Figure 5.3a) and from 1:40 to 1:160 against PEDV S-INDEL variant strain (Table 5.2,
Figure 5.3a). Similarly, PRN titers against PEDV strain CO13 ranged between 1:20 to
1:640 (Table 5.2, Figure 5.3b). Consistent with the results of our preliminary screening,
no neutralizing activity was observed for PEDV S-specific mAb SD33-1, whereas mAb
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SD37-11 presented neutralizing titers of 1:40 and 1:80 in the PRN and FFN assays,
respectively. A PRRSV specific mAb (SDOW17), which was used as negative control in
our assays, did not present neutralizing activity against PEDV (data not shown). These
results demonstrate the neutralizing activity of nine S-specific mAbs against PEDV in
vitro.

Neutralizing activity of S-specific mAbs correlates with their reactivity with the
truncated S1-S2 (aa 630-800) protein
The S1-S2 junction region of the S protein has been shown to contain major
neutralizing epitopes [21]. Notably, most neutralizing mAbs developed here specifically
recognized a truncated form of the S protein (aa 630-800) spanning the S1-S2 junction
region (Figure 5.2a and 5.2d). To assess whether the neutralizing activity of the mAbs
correspond to their ability to recognize this truncated protein, the correlation between
endpoint FFN, PRNT and ELISA titers was determined. As shown in Figure 5.4a,
endpoint neutralizing and S1-S2 ELISA titers were very similar for all mAbs, resulting in
a strong positive correlation between FFN and ELISA (R2 = 0.8843; Fig 4b) and PRNT
and ELISA (R2 = 0.9563; Fig 4c) test results. Importantly, neutralizing titers detected in
convalescent polyclonal swine serum also presented a high correlation with antibody
titers detected by the S1-S2 indirect ELISA (Figure 5.4a).

Epitope mapping of S-specific mAbs
To identify immunodominant neutralizing domains in the PEDV S, the epitope
specificity of the neutralizing mAbs developed here was assessed by peptide ELISAs.
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Three regions of PEDV S protein have been shown to be targets of neutralizing
antibodies, including the RBD region (aa 499-600), the S1-S2 junction region (aa 639789) and a region in the carboxi terminus of the S protein [18,21,22]. A few linear
epitopes within these regions have been shown to induce neutralizing antibodies against
PEDV, including epitopes at aa positions 747-774 and 1371-1377 [8,21,23]. Initially, all
mAbs were screened against epitope 747-774 (which encompasses epitope 756-771 and
most aa of epitope 744-759) located in N-terminus of S2 and against epitope aa 13711377 located at the C-terminus of S. Notably, six mAbs (SD120-1, SD129-5, SD131-3,
SD137-90, SD138-108, and SD142-2) recognized the epitope 747-774, while mAb
SD125-2 specifically reacted against epitope 1371-1377 (Figure 5.5a & b).
To confirm the specificity of the mAbs and further dissect neutralizing epitopes
within the S1-S2 junction region, all mAbs were screened against two smaller
neutralizing epitopes contained almost entirely within the 747-774 epitope (744-759 and
756-771). As shown in Figure 5.5c & d six mAbs recognized epitope 744-756 (SD37-11,
SD121-1, SD129-5, SD137-90, SD138-108, and SD142-2), while only two mAbs
recognized epitope 756-771 (SD120-5 and SD129-5). A summary of the epitope
specificity of individual mAbs is presented in Table 5.2. Notably, two mAbs (SD37-11
and SD121-1) specific to the S1-S2 region recognized only epitope 744-759, three mAbs
(SD137-90, SD138-108 and SD142-2) recognized both epitopes 744-759 and 747-774,
while two mAbs (SD120-1 and SD129-5) recognized epitopes 756-771, and 747-774.
These results indicate that the amino terminus of the S2 subunit contains highly antigenic,
perhaps, immunodominant neutralizing epitopes of PEDV.
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Discussion
Given its critical functions in cell entry, the coronavirus S protein is the main
target of host humoral responses. Neutralizing antibodies directed against the S protein
likely play a key role on protection against PEDV infection. A recent study demonstrated
that neutralizing activity against PEDV in colostrum and milk correlated with levels of
IgA antibodies to the S protein (S1 and S2 subunits) [13]. Notably, at least three
neutralizing B-cell epitopes have been identified in the S protein [8,18,21], with one of
the epitopes mapping to a domain in S1 that is homologous to the collagenase resistant
fragment (CO-26 K) of TGEV S [17] (aa 499-638; named “collagenase equivalent” in
PEDV, COE) [18]. A region spanning the S1-S2 junction (aa 638-789) in PEDV S
contains another neutralizing epitope [21], with a third epitope mapping to the carboxyterminus of the S protein (aa 1371-1377) [8,23]. Results here showing the specificity of
PEDV neutralizing mAbs for these domains in the S protein confirm that epitopes located
in these regions are indeed responsible for eliciting neutralizing antibodies against PEDV.
The fact that these mAbs were generated by immunization of mice with whole virus
preparations indicates that these regions are highly antigenic, further suggesting that
epitopes within these regions may represent immunodominant neutralizing epitopes of
the PEDV S protein.
While the amino-terminal region of S (S1, aa 1-725) is involved in virus
attachment to cellular receptors, the carboxy-terminal region (S2, aa 726-1383)
undergoes conformational changes after the attachment of S1 to facilitate fusion of the
virus envelope with the host cell membrane, thus allowing entry of the viral genome into
the host cell [11]. Notably, antibodies directed against both S subunits have been
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correlated with neutralization of PEDV infectivity [13]. Immunization of mice with
inactivated whole PEDV virion preparations followed by somatic cell fusion here
resulted in production of hybridoma cell lines secreting mAbs specific for the PEDV S
protein and capable of neutralizing the virus infectivity in vitro (titers ranging from 1:40
to 1:640). Interestingly, epitope mapping ELISAs revealed that eight of nine mAbs
specifically recognized neutralizing epitopes located within the S2 subunit (SD37-11,
SD120-1, SD121-1, SD125-2, SD129-5, SD137-90, SD138-108 and SD142-2), while
only one mAb (SD131-3) reacted with the S1 subunit. While UV- or formalin inactivated
PEDV virions likely do not retain the exact antigen conformation and architecture of
infective PEDV particles, our data suggest that the S2 subunit contains important-,
perhaps, immunodominant antigenic determinants of PEDV. Results from a recent study
showing higher levels of S2-specific IgG antibodies when compared to S1-specific
antibodies in serum and colostrum of sows naturally infected with PEDV, further support
this hypothesis [13]. Nevertheless, antibodies against the S1 subunit also play a critical
role on immune responses against PEDV [13], and immunization with the recombinant
S1 protein subunit have induced neutralizing antibodies and passive protection against
infection [16]. Similar experiments would have to be performed with the S2 subunit to
assess its immunogenicity and to determine the contribution of S2-specific antibodies on
protection against PEDV.
Infection with PEDV induces neutralizing antibody responses within 14 to 21
days’ post-infection, with NA titers in convalescent polyclonal serum usually ranging
between 1:20 to 1:320 [24,25]. As shown in Figure 5.2, most S-specific mAbs produced
here (exception SD33-1) were capable of completely blocking PEDV infectivity (titers of
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1:40 to 1:160), with a few of these mAbs (SD137-90, SD138-108 and SD142-2)
presenting markedly higher neutralizing activity (titers up to 1:640) (Table 5.2).
Considering the highly stringent endpoint criteria used in the in vitro neutralization
assays (90% reduction in fluorescent focus-forming units or 80% reduction in plaque
forming-units), and the fact that these are monospecific antibodies these titers represent
remarkable neutralizing activities. It is important to note, that while these three mAbs
specifically recognized two overlapping epitopes located in the amino-terminus of the S2
subunit (aa 744-759 and 747-774), they did not react against epitope 756-771, which is
also contained within the core neutralizing epitope aa 747-774 in S2. Together these
results indicate that these mAbs either recognize aa 747-759 or, perhaps, a smaller
epitope within this domain. The specificity of mAbs SD137-90, SD138-108 and SD142-2
and their high neutralizing activity, suggest that their target epitope might represent an
immunodominant neutralizing epitope of PEDV S. However, the possibility that these
results reflect a higher avidity and/or affinity of these mAbs for the inducing epitope
cannot be formally excluded.
At least two genetically distinct strains of PEDV (prototype and S-INDEL variant
strains) have been described in the US and in other parts of the world [20,24]. The SINDEL variant strains contain aa insertions, deletions and/or substitutions mainly in the
N-terminus of the S1 protein subunit (first 350 aa). Despite the genetic and antigenic
differences between prototype and S-INDEL strains, a recent study has shown that there
is significant serological and neutralizing cross-reactivity between two representative
strains obtained in the US [24]. Consistent with these findings, our results show that all
mAbs developed here recognized both prototype (CO13) and S-INDEL (Iowa106) strains
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in IFA and/or whole virus ELISAs. Most importantly, all mAbs presented neutralizing
activity against both PEDV strains. These results are consistent with the fact that the
target neutralizing epitopes of the mAbs developed here are highly conserved (100% aa
id; data not shown) between the two PEDV strains used in our study.
Recently, Song and collaborators have demonstrated a high correlation between
the levels of neutralizing antibodies in serum, colostrum and milk of naturally infected
sows with the levels of S1- and S2-specific antibodies in these samples [13]. Given that
most neutralizing mAbs developed here are specific for epitopes located within the S1-S2
junction region, we performed endpoint ELISA titrations with those mAbs using the
recombinant S1/S2 protein (aa 630-800) and assessed the correlation between ELISA and
neutralizing antibody titers. Notably, a strong positive correlation between the ELISA
titers and FFN and PRNT titers was observed for all mAbs developed here. Similarly,
neutralizing antibody titers detected on a convalescent swine serum sample used as
positive control also matched the endpoint titers detected in the S1/S2 ELISA. Screening
of additional serum samples is, however, required to determine whether this assay could
potentially be used to determine neutralizing activity in clinical samples.
In summary, by using a panel of PEDV S-specific neutralizing mAbs we have
shown that an immunodominant neutralizing epitope of PEDV S maps to the aminoterminus of the S2 subunit. While seven neutralizing mAbs generated after immunization
of mice with whole virion preparations recognized a domain in S2, only one mAb reacted
against S1. These results suggest that S2 subunit may contain important, perhaps,
immunodominant neutralizing determinants of PEDV. This study provides important
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information and tools that may lead to the development of improved prevention, control
and/or diagnostic strategies for PEDV.

Materials and Methods
Cells and viruses
Vero-76 (ATCC® CRL-1587™) and primary ovine fetal turbinate cells were
cultured at 37oC with 5% CO2 in minimum essential medium (MEM) supplemented with
10% fetal bovine serum (FBS), and 2 mM L-glutamine, and containing penicillin (100
U/mL), streptomycin (100 µg/mL) and gentamicin (50 µg/mL). PEDV strain
USA/CO/2013 (CO13; GenBank accession no: KF272920.1) was obtained from the
National Veterinary Services Laboratory (NVSL). PEDV strains BIVI-1 and BIVI-2 were
provided by Boehringer Ingelheim Vetmedica and PEDV S-INDEL-variant strain
USA/IOWA/106/2013 (GenBank Accession No: KJ645695.1) was provided by Dr.
Qiuhong Wang, The Ohio State University. All PEDV strains were propagated in Vero76 cells in the presence of 1.5 µg tosyl phenylalanyl chloromethyl ketone (TPCK) treated
trypsin (Sigma Aldrich, St. Louis, MO). A recombinant Orf virus expressing the full
length PEDV S (ORFV-PEDV-S) was recently developed in our laboratory [14] and was
used here for screening of S-specific mAbs.

Production of S-specific monoclonal antibodies
Four-week-old female BALB/c mice were randomly allocated into three groups as
follows: Group 1: PEDV CO13-immunized (n = 3), Group 2: PEDV BIVI-1-immunized
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(n = 3), and Group 3: PEDV BIVI-2 immunized (n = 3). After a week of acclimation,
mice were immunized with sucrose purified UV-(PEDV CO13) or formalin (BIVI-1 and
BIVI-2) inactivated whole PEDV virions in a water-in-oil (W/O) adjuvant emulsion
(Montanide ISA 50 V2; Seppic, France). After a series of three intraperitoneal
immunizations (2-week intervals), splenic cells were fused with myeloma NS-1 cell lines
and cultured in the presence of hypoxanthine-aminopterin-thymidine (HAT) medium for
selection of hybridoma cells following standard protocols [26]. After 10-14 days of
culture, hybridoma cell culture supernatants were screened for the presence of S-specific
mAbs by indirect immunofluorescence assays. All animal experiments have been
reviewed and approved by the SDSU Institutional Animal Care and Use Committee
(IACUC; protocol approval no. 14-087A).

Immunofluorescence assay (IFA)
The supernatant of hybridoma cell cultures was screened for the presence of Sspecific mAbs by using IFA. For this, primary ovine fetal turbinate cells infected with the
recombinant ORFV-PEDV-S, expressing the full-length PEDV S [14], were incubated
with the hybridoma cell culture supernatants for 1 h at 37oC. Unbound antibodies were
washed out three times with phosphate buffered saline (PBS) and S-specific mAbs
detected with a goat anti-Mouse IgG+IgM+IgA DyLight®594-conjugated antibody
(Bethyl Laboratories, Inc., Montgomery, TX). Positive clones were also screened in
PEDV CO13-infected cell cultures using a goat anti-Mouse IgG+IgM+IgA FITCconjugated antibody (MP Biomedicals, Santa Ana, CA) as above. Positive primary clones
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were subcloned, expanded and re-screened in ORFV-PEDV-S- and PEDV (CO13 and SINDEL) infected cells.

Neutralization assays
The neutralizing activity of S-specific mAbs was initially assessed by FFN assays
as previously described [26]. Hybridoma culture supernatants were first screened and
clones with PEDV neutralizing antibody titers greater than 4 were used for ascites
production (Envigo, Inc., Indianapolis, IN). Immunoglobulin isotyping was performed
using a lateral flow assay kit (Bio-Rad, Hercules, CA) and mAbs were purified using
NAbTM protein G spin columns (IgG; Thermo Fisher Scientific, Waltham, MA) or the
ammonium sulfate precipitation method (IgM). Following purification, all mAbs were
diluted in PBS to final concentration of 3 µg/mL. Normalized mAbs were re-screened by
FFN assays to confirm their neutralizing activity against PEDV. Neutralizing antibody
titers were expressed as the reciprocal of the highest mAb dilution capable of reducing
PEDV infectivity by 80%.
To confirm the neutralizing activity, the mAbs were also screened by plaque
reduction neutralization (PRN) assay [27]. For this, Vero cells were seeded in six-well
plates at a density of 4 × 105 cells/well and incubated at 37°C with 5% CO2 until the cells
were approximately 90% confluent. The mAbs were subjected to serial 2-fold dilutions
(starting concentration 25 μg/mL) and each dilution incubated with 50 PFU of PEDV
strain CO13 for 1h at 37oC with 5% CO2. After incubation the antibody-virus mixture
was added to the Vero cells and incubated for 1.5 h gently rocking the plates every 15
min to distribute the inoculum homogeneously throughout the well. Cells were overlaid
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with semisolid medium (2% agar, 2X MEM, and 3 µg/mL TPCK-treated trypsin) and
incubated at 37oC with 5% CO2 for 72-96 h. Next, 1 ml of 0.2% crystal violet (SigmaAldrich, St Louis, MO) in 0.01% formaldehyde and 20% acetone solution was added to
each well and the cells were fixed and stained for 15 min at RT. Viral plaques were
counted and used to determine the PRNT for each mAb. Plaque counts for each antibody
were used to calculate percent reduction in plaques as follows: % reduction = 100 × [1 −
(average number of plaques for each dilution/average number of plaques in the virus
control well). Each mAb was tested in duplicate and four control wells used on each
assay, including, a virus control (no antibody), a negative control (MEM only)
Additionally, convalescent PEDV polyclonal serum and unrelated mAbs controls (antiPRRS, and anti-PEDV N protein antibody), were used on every PRNT assay.

Western blots
The reactivity of PEDV mAbs developed here were evaluated by using denaturing
Western blots. Each antibody was tested against sucrose purified whole virus
preparations, a recombinant/truncated version of the S protein (residues 630-800; Hain et
al., 2016), and a recombinant N protein [26]. Approximately, 20 µg of each antigen were
resolved by SDS-PAGE in 4-20% acrylamide gels (Bio-Rad, Hercules, CA) and
transferred to nitrocellulose membranes. Blots were incubated with 5% non-fat-dry-milk
TBS-Tween 20 (0.1%; TBS-T) solution for 1 hr at RT and probed with the mAbs and
control antibodies overnight at 4oC. Blots were washed three times with TBS-T for 10
min at RT and incubated with a goat anti-mouse IgG-HRP- or goat anti-mouse IgMHRP-conjugated antibody for 2 hr at RT. Blots were washed three times with TBS-T for
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10 min and developed by using a chemiluminescent substrate (Clarity, ECL; Bio-Rad,
Hercules, CA).

Epitope mapping by ELISA
The specificity and epitope mapping of the neutralizing mAbs was investigated by
ELISAs. Initially, the mAbs were screened against whole virus preparations (prototype or
I-INDEL strains) or truncated versions of the S protein known to contain neutralizing
epitopes (residues 499-630 or 630-800) [18,21]. Polystyrene microtiter plates
(Immunolon 1B, Thermo Scientific, Waltham, MA) were coated with the appropriate
antigen (50 ng/well of UV inactivated sucrose purified whole virus antigen, 100 ng/well
of S630-800, or 25 ng/well of S499-630 as previously described [26]. Optimal assay
conditions, including the amount of antigen, and secondary antibody dilution were
determined by a checkerboard titration and conditions that resulted in the highest signal
to noise ratio were used. Serial 2-fold dilutions of the mAbs and appropriate controls
were diluted in PBS-T 5% non-fat dry milk, and 100 µl of diluted samples were added to
paired coated and uncoated control wells and incubated at room temperature for 1 h.
Unbound antibodies were washed with PBS-T (three times) followed by incubation with
streptavidin-HRP specific IgG and IgM conjugate (Pierce, Rockford, IL) according to
each mAb isotype. Reactions were developed with 3,3’,5’5’ – tetramethylbenzidine
substrate (TMB) (KPL Inc., Gaithersburg, MA) and OD values determined at 450 nm
using a microplate reader (BioTek Instruments Inc., Winooski, VT). OD values for each
test and control samples were normalized to the OD value of uncoated wells and results
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expressed as sample to positive (O.D). Endpoint ELISA titers were determined for each
mAb as previously described [28].
To epitope specificity of neutralizing mAbs was assessed by peptide ELISAs.
Previously described neutralizing epitopes (744-759, 747-774 and/or 756-771) located
near the S1-S2 junction or another neutralizing antibody located in the C-terminus of S2
(1371-1377) were chemically synthesized (Genscript, NJ) and used in pepscan ELISAs.
NuncTM Immbolizer® amino plates (ThermoFisher Scientific, Waltham, MA)) were
coated with individual peptides (744-759, 80 ng/well; 756-771, 133 ng/well; 747-771,
200 ng/well and 1371-1377, 400ng/well) in bicarbonate/carbonate coating buffer (15 mM
sodium carbonate, 35 mM sodium bicarbonate, pH 9.6) in alternate wells. After
incubation at 37oC for 1h, plates were incubated overnight at 4oC next, plate were washed
four times with PBS tween 20 (PBS-T, 0.05%) and blocked 2 hr at 37oC with PBS-T 2%
non-fat dry milk. Blocking reagent was removed and plates washed three times with
PBS-T (300 µl). mAb incubations and reaction development were performed as above.
OD values for each test and control samples were normalized to the OD value of
uncoated wells and results expressed as OD values.

Statistical analysis
Statistical analysis was performed using SPSS 14 software.
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Figure 5.1. Summary of the properties and characteristics of mouse
monoclonal antibodies against PEDV and specific PEDV spike by IFA: All
mAbs specifically recognized cells infected with the recombinant ORFV-PEDV-S,
expressing the full length PEDV S and cells infected with the PEDV strain CO13.
All mAbs recognized cells infected with the S-INDEL variant PEDV strain
USA/IOWA/106/2013, except mAb SD125-2 which did not recognize this strain.
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Figure 5.2A. Evaluation of the specificity of the PEDV-S mAbs by Western blots
using whole virus preparations, recombinant S- (amino acid [aa] 630-800 or aa
499-600) and N proteins expressed in E. coli. On Western blots, eight of nine mAbs
recognized the full-length spike protein in whole PEDV preparations and the truncated
S protein spanning the S1-S2 junction region (aa 630-800). mAb SD37-11 did not
recognize the full-length spike and mAb SD125-2 did not recognize the S1-S2
recombinant protein (aa 630-800). None of the mAbs reacted with the recombinant N
protein.
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Figure 5.2B. Evaluation of the specificity of the PEDV-S mAbs by ELISA using whole virus preparations, recombinant S(amino acid [aa] 630-800 or aa 499-600) and N proteins expressed in E. coli. Specificity of the mAbs tested by ELISA, all mAbs
reacted against B: PEDV strains CO13 and C: S-INDEL Iowa106. The reactivity of the mAbs against truncated versions of the S
protein D: aa 499-600 and E: aa 630-800. Nine mAbs reacted against the S1-S2 region (aa 630-800), while only one mAb (SD1313) reacted against the product corresponding to aa 499-600, which contains the putative receptor binding domain of the S1 subunit.
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working stocks (1:20 - 1:1280) were tested in triplicate by FFN or PRN assays. Endpoint titers were considered the
reciprocal of the highest mAb dilution capable of reducing PEDV infectivity by 90 (FFN) or 80% (PRN) in vitro.
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Figure 5.4. Correlation between endpoint FFN, PRNT and ELISA titers. A: endpoint neutralizing and S1-S2
ELISA titers were very similar for all mAbs, neutralizing titers detected in convalescent polyclonal swine serum
also presented a high correlation with antibody titers detected by the S1-S2 indirect ELISA. B: a strong positive
correlation between FFN and ELISA (R2 = 0.8843) and PRNT and C: ELISA (R2 = 0.9563) test results.
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A

B

C

D

Figure 5.5. Mapping the mAbs against of the direct epitope regions within the S1-S2
junction region which are capable of inducing neutralizing antibodies against the
porcine epidemic diarrhea virus using peptide ELISA. A: all mAbs were screened
against two smaller neutralizing epitopes contained almost entirely within the 747-774
epitope (744-759 and 756-771), six mAbs (SD120-1, SD129-5, SD131-3, SD137-90,
SD138-108, and SD142-2) recognized the epitope 747-774, B: mAb SD125-2 specifically
reacted against epitope 1371-1377. C: Six mAbs recognized epitope 744-756 (SD37-11,
SD121-1, SD129-5, SD137-90, SD138-108, and SD142-2), D: while only two mAbs
recognized epitope 756-771 (SD120-5 and SD129-5).
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Table 5.1. Characterization of mouse mAbs against PEDV spike protein: The
specificity of the mAbs was assessed by IFA and Western blot using purified whole
PEDV antigen, a recombinant truncated S protein (aa position 630-800) and the full
length recombinant N protein. Immunoglobulin isotyping was performed using a
commercial lateral flow assay kit.
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Table 5.2. Mapping of mAb reactivity against the epitope regions capable of
inducing neutralizing antibodies against PEDV infected Vero cells. Also the table
shows the average neutralizing titer of three different tests for each antibody.
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Chapter 6

Development of assays for serological diagnosis of the two distinct lineages of bovine
Influenza D co-circulating in the United States

Introduction
Influenza viruses are single-stranded, negative-sense, segmented RNA viruses in
the family Orthomyxoviridae. Influenza A virus and influenza B virus contain eight
genomic segments with two surface glycoproteins, hemagglutinin (HA) and
neuraminidase (NA); whereas influenza C and influenza D are closely related and have
only seven segments with one surface glycoprotein, the hemagglutinin-esterase-fusion
protein (HEF). HEF is responsible for receptor binding, receptor destroying, and
membrane fusion activities. In influenza A and B viruses, separate HA and NA proteins
perform these functions in a cooperative fashion [1,2].
Among ten different IDV genomic sequences analyzed, seven distinct genotypes
were identified, suggesting a reassortment between two clades in the U.S. These two
lineages of IDV co-circulate in cattle herds in the U.S. and frequently reassort. The
antigenic analysis of IDV revealed a good correlation between HEF phylogeny and
reactivity in the HI assay [3].
The nucleoprotein (NP) and matrix (M) proteins are highly conserved among
members of each genus of influenza viruses. Although there is high intragenic homology
between influenza viruses, NP and M1 are highly variable among the three types of
influenza viruses with only 20–30% intergenic homologies [4].
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Serological studies showed that IDV has been present in beef cattle at least since
2004. Cattle are the reservoir for IDV and young, weaned, and immunologically naive
calves are most susceptible to influenza virus infection due the decline of maternal
antibody levels after 6 months of age [5]. Serologic evidence within small ruminants in
different states in U.S., suggests IDV exposure in 13.5% and 13.3% of sheep and goat
farms, respectively, with no presence in chickens or turkeys [6].
The seroprevalence of IDV among cattle has been estimated at 62% either alone
or with other respiratory infections which can play an important role in the severity of the
IDV disease [7]. A recent study showed that IDV has been present in the Mississippi
cattle population since at least 2004, giving the weaned, comingled calves a critical role
to play in maintenance and transmission of IDV. This study also showed that 94% of
neonatal calves sampled in 2013 and 2014 possessed maternal immunity against IDV,
which decreased by six to eight months of age [8]. Calves acquire passive immunity
within the first 24 hr through maternal immunoglobulins in colostrum [9]. The half-life of
passively acquired IgG is 21.2–35.9 days and they maintain passive immunity for three to
four months [10].
Accurate and rapid serological diagnostic assays, especially enzyme-linked
immunosorbent assays (ELISAs) and virus neutralization assays are important tools in
veterinary and human medicine. The traditional diagnosis of influenza virus has been
carried out either through direct detection of the virus itself, or through detection of
antibodies specific for the virus through hemagglutinating inhibition (HI), agar gel
precipitation (AGP), and a virus neutralization test called the micro-neutralization assay
(MN) [11,12,13].
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Influenza D viral nucleic acids can be detected by RT-PCR-based methods [4] for
virus identification but the antigen detection methods have low efficacy in the large-scale
surveillance of herds because influenza viruses can clear the bloodstream within one
week of clinical signs of infection [14]. The AGP test is one method used to test for all
influenza virus-specific antibodies, however, this test has several disadvantages, like low
sensitivity and a long processing time for test results [15,16].
Although the HI test is the most commonly used test to determine the presence of
antibodies to an influenza virus in the serum, it can be expensive and requires many
standardizations. Also the HI test is labor-intensive [17]. Although the MN assay is a
more sensitive assay than the HI assay for the detection of the protective humoral
immunity against influenza viruses, it requires further consideration as a formal tool for
the routine evaluation of vaccine-induced antibody responses [18]. Therefore, our aim
was to develop an enzyme-linked immunosorbent assay (ELISA) based on two different
epitopes. Also, we designed a quick and accurate virus neutralization assay called a
fluorescent focus neutralization (FFN) assay that is based on a fluorescent signal and
polyclonal antibody specific for the virus. The ELISA and FFN methods may be useful
and effective methods for the bovine influenza D surveillance system, especially since
the two different lineages of IDV cross react by HI. New assays which are specific for
each lineage may give further critical information needed for surveillance of the virus or
evaluation of vaccine efficacy.

Methods
Cell Culture and Virus Production
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Madin Darby canine kidney (MDCK) cells (ATCC CCL-34) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (PAA Laboratories Inc., Dartmouth, MA, USA) and 1% penicillin and
streptomycin (Life Technologies, Carlsbad, CA, USA). Influenza
D/bovine/Oklahoma/660/2013 (D/660) and D/swine/ Oklahoma/1334/2011 (D/OK) were
previously isolated from bovine or swine with respiratory disease symptoms [3]. The
cells were allowed to reach only 60-70% confluence at the time of infection. The virus
was propagated by infecting MDCK cells at a 0.01 multiplicity of infection (MOI) and
incubated at 33°C with ~5% CO2 for 5 days. For virus growth/maintenance media,
DMEM with 0.1 μg/mL exogenous tosylsulfonyl phenylalanyl chloromethyl ketone
(TPCK) treated trypsin (Sigma, St. Louis, MO, USA) was used. After 5 days, the infected
cell cultures were frozen and thawed three times and the supernatant centrifuged at 500xg
for 15 min at 4o C to remove the cellular debris. Virus titer was determined using MDCK
cells according to Reed and Meunch’s method [19].

Serum sample collection
Approximately 460 bovine serum samples were acquired from the South Dakota
State Animal Disease Research and Veterinary Diagnostic Laboratory. The selection of
the samples was random for investigation and mixed between young and adult animals.
Among them, 100 samples were from farms located in the Midwest region including
South Dakota (SD), 30 from Angus bulls- Western SD, 75 Holstein cows-Eastern SD, 10
Beef cattle- SW MN, 50 export cattle-MN, 95 export cattle-PA, 99 Holstein heifers-WA,
and 5 from Jersey cows-WI.
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Hemagglutination inhibition assay
All the bovine samples were tested by HI according to the WHO standard manual
[20]. Serum samples were pretreated with receptor destroying enzyme (Denka 261
Seiken, Chuo-ku, Tokyo, Japan) according to manufacturer’s protocol. The HI assay was
performed using 1% turkey RBCs (Lampire Biological Laboratories, 264 Pipersville, PA,
USA). An antibody titer of 1:40 was used as a threshold where a titer less than 1:40 was
judged as negative while a titer equal to, or higher than 1:40 was viewed as positive.
Serial 2-fold dilutions of serum sample were tested in duplicate. The titers were
expressed as the reciprocal of the highest dilution of serum which gave complete
hemagglutination. All samples were assayed in three separate experiments and the mean
antibody titers were calculated.

Indirect immunofluorescence assay
MDCK cells were seeded in 96 well tissue culture plates (ThermoScientific,
Waltham, MA) and grown to 70% confluence over two days. Cells were washed three
times with serum free medium containing 2.5µg/ml of TPCK treated trypsin (Sigma- 116
Aldrich, St. Louis, MO, product T1426). Alternate rows of wells were infected with
150µl of the IDV/D/660 virus culture whose titer was adjusted to 200 TCID50/100µl in
infection media. Forty-eight hours after infection, cells were washed with PBS (Boston
Bioproducts, Ashland, MA) and fixed with pre-chilled 80% acetone at 4°C for 20
minutes. Fixed cells were incubated 1 hr at 37°C with test sera at serial 2-fold dilutions
starting at 1:10 to 1:1280. After washing with PBS, FITC-labeled anti-bovine IgG
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antibody (Jackson ImmunoResearch Laboratories, Inc, USA) diluted 1:250 was applied
and plates incubated at 37°C for 1 hr. Positive and negative (FBS) controls were included
in each plate. Finally, the cells were observed with a fluorescence microscope for
characteristic cytoplasmic fluorescence. All the bovine serum samples were tested by the
IFA and classified as positive or negative.

Preparation of antigens used for ELISA
Bacterial expression and purification of the IDV nucleocapsid protein (NP):
A full length IDV NP gene sequence of the influenza D virus strain
D/bovine/Ok/660/2013 (GenBank: KF425663.1) was synthesized with the addition of a
3′ 6 × -His tag by GeneArt® Gene Synthesis (GeneScribt, Piscataway, NJ, USA) and
subsequently, expressed in E. coli. The codon optimized and amplified DNA was
directionally cloned into the pET- 28a (Novagen, Madison, WI) plasmid for bacterial
expression using the Xho I and BamHF enzymes (New England Biologicals, Ipswich,
MA). Following the verification of successful cloning by restriction digestion and
sequencing, E. coli BL21 cells (Invitrogen, Carlsbad, CA) were transformed with 2.5 ul
of the plasmids. Transformed cultures were induced with 0.5mM isopropyl β-D-1- 138
thiogalactopyranoside (IPTG, Sigma-Aldrich, St. Louis, MO), for 6 hr at 37°C. The
insoluble protein fraction was denatured using 8 M urea, then purified three times using
nickel-NTA affinity column chromatography and refolded back to its native
conformational state. Individual affinity column elutions were collected, pooled and
confirmed by SDS-PAGE, then aliquoted/frozen at −80 °C. The purified protein was
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assessed by a Western blot using our anti rabbit IDV polyclonal antisera previously
produced in our laboratories.

Bacterial and mammalian expression and purification of the IDV
Hemagglutinin-estrase (HE): A recombinant plasmid, containing the synthetic
truncated sequence of the region from 400 to 1665 of the HE sequence of the influenza D
virus strain D/bovine/Ok/660/2013 (GenBank: KF425662.1) with the addition a 3′ 6 × His tag by GeneArt® Gene Synthesis (GeneScribt, Piscataway, NJ, USA) was subcloned
in the Pet28 system for bacterial expression according to [21]. The plasmid DNA of the
HE truncated sequence and mutation at amino acid site 212 was linearized by restriction
enzyme BamH1 and Xho1 digestion and then cloned into PCDNA3.1 mammalian
expression vector.

Whole Virus antigen: Sucrose purified/UV-inactivated IDV strain D/660 and
C/OK strains were used as a whole virus purified control antigens for IFA, Western and
ELISA. Trypsin treated cleavage viruses were used as a control for HE cross-reactivity.

Determination of cross reactivity between the two lineages of IDV: Rabbit
polyclonal primary antibody (IgG) against IDV D/660 and D/OK were used as controls in
our study and also used to study the cross reactivity between the two clades D/660 and
D/OK which are antigenically different. Monoclonal antibody produced in our
laboratories against D/660 were also used in our study. The cross reactivity between the
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two lineages was evaluated using Western blot methods and IFA of the mammalian
expression system of HE protein.

Western Blot: Western blotting was performed using sucrose purified viruses and
recombinant NP and HE proteins. Fifty micrograms of protein were resolved by SDSPAGE in 7% acrylamide gels and transferred to nitrocellulose membranes. After blocking
the blots with 5% non-fat-dry-milk TBS-Tween 20 (0.1%; TBS-T) solution for 2 hr at
RT, they were probed with the hyperimmune polyclonal antibodies, mAbs and the
selected bovine antibodies overnight at 4oC diluted in 5% non-fat-dry-milk TBS-Tween
20. Blots were washed three times with TBS-T for 10 min at RT and incubated with a
goat anti-bovine IgG-HRP (Jackson ImmunoResearch Laboratories, INC, USA)
conjugate secondary antibody for bovine sera, a goat anti-rabbit IgG-HRP conjugate
secondary antibody for rabbit-polysera and a goat anti-mouse IgM-HRP conjugate
secondary antibody for the mAbs for 2 hr at RT. Commercial anti-HIS antibody
(Invitrogen, Carlsbad, CA) at (1:10000) was used as primary antibody for the
confirmation of the recombinant protein expression. Fetal bovine sera was used as a
negative control. Blots were washed three times with TBS-T for 10 min and the bands
were visualized by staining with 4-chloro-1- 180 naphthol (ThermoFisher, Grand Island,
NY).

Samples for assay development and validation
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Positive bovine samples from HI, IFA and Western blot were collected for the
preparation of a strong positive bovine sera specific for IDV and used for assay
development.

Indirect ELISA development and optimization
UV inactivated sucrose purified viruses, NP and HE recombinant proteins
expressed in E. coli, were used in indirect ELISAs. Polysorb microtiter plates
(Immunolon polysorb, 96 well, Thermo Scientific, Waltham, MA) were coated with the
appropriate antigen (50 ng/well of UV inactivated sucrose purified whole virus antigen,
HE, 100 ng/well; NP, 25 ng/well [22]. Optimal assay conditions (concentration of
antigen, serum, anti-bovine biotinylated antibodies and secondary antibody dilutions)
were determined by a checkerboard titration which gave the highest signal to noise ratio.
In addition, fetal bovine serum as negative control and a single lot of pooled convalescent
of IDV serum positive by IFA, HI and Western blot was used to generate quality control
standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD = 0.5 to
1.0; and negative OD < 0.2). The appropriate antigen concentration was diluted in
bicarbonate/carbonate coating buffer (15 mM sodium carbonate, 35 mM sodium
bicarbonate, pH 9.6) in alternate wells. Plates were washed four times with PBS tween 20
(PBS-T, 0.05%) after one hour incubation at 37°C, and blocked overnight at 4°C with
PBS-T 10% 1:1 goat to swine serum. Blocking reagent was removed and plates washed
three times with PBS-T (400 µl). Serial double fold dilution of the controls were diluted
in PBS-T 10% goat sera, and 100 µl of diluted samples were added to paired coated and
uncoated control wells and incubated at room temperature for 1 hr. Unbound antibodies
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were washed with PBS-T (three times) followed by incubation with goat-anti-bovinebiotyinylated IgG (Jackson ImmunoResearch Laboratories, Inc., USA) for one hr at RT.
After washing three times with PBS-T, streptavidin-HRP specific conjugate (Pierce,
Rockford, IL) was added and incubated one hr at RT. Reactions were developed with
3,3’,5’5’ – tetramethylbenzidine substrate (TMB) (KPL Inc., Gaithersburg, MA) and OD
values determined at 450 nm using a microplate reader (BioTek Instruments Inc.,
Winooski, VT). OD values for each test and control samples were normalized to the OD
value of uncoated wells and results expressed as sample to positive (O.D).
Bovine sera from multiple animal populations and farms were used in our study
as described above. Receiver operating characteristic (ROC) analysis was calculated for
each assay to assess diagnostic performance, which included determination of sensitivity,
specificity and threshold cutoff using MedCalc version 11.1.1.0 (MedCalc software,
Mariakerke, Belgium).

Fluorescent Focus Neutralization test
An IDV virus neutralization assay using a FFN format was developed for rapid
and accurate detection of neutralizing antibodies produced in response to IDV infection.
The FFN was evaluated using serum samples. Heat-inactivated samples were diluted in a
2-fold dilution series starting at 1:10 in MEM plus 1μg/ml TPCK-treated trypsin in 96well plates. An equal amount of cell culture adapted IDV/D/660 stock at a concentration
of 100 foci forming units/100 μl was added to each well and plates incubated for 1 h at
37°C. The virus/sample mixture was then added to washed confluent monolayers of
MDCK cells and incubated for 2hr at 37°C. Plates were washed again with
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DMEM/TPCK-trypsin medium and incubated 44 hr to allow for replication of nonneutralized virus. Plates were then fixed with 80% acetone and incubated with 100 µl of
rabbit polyclonal primary antibody (IgG) against both D/660 and D/OK Bovine IDV at a
1:250 dilution to each of the wells. The plates were incubated at 37°C for an hour.
Following washing with PBS three times, 60 µl of affinity purified fluorescein labeled
goat anti-rabbit IgG secondary antibody (KPL, Gaithersburg, MD, USA) at a 1:1000
dilution was added and incubated at 37°C for 1 hr to allow visualization of infected cells.
Endpoint neutralization titers were determined as the highest serum dilution resulting in a
90% or greater reduction in fluorescent foci relative to controls.

Measurement of statistical testing agreement and correlation:
Multiple comparison, inter-rater agreement (kappa measure of association) and
Pearson’s correlation tests were calculated among all four tests (HI, iELISA, FFN and
IFA) using IBM, SPSS version 20 software (SPSS Inc., Chicago, IL).

Results
HI assay: All the randomly collected serum samples from different states were
tested by HI using D/660 after treatment by RDE. About 317 samples were positive out
of 400 cows and bulls and 100 serum samples were negative from young cattle and
calves 7-8 months old. However, the HI test using D/OK showed only 166 positive from
400 and 100 negative out of 100.

179

Immunofluorescence assay (IFA): About 166 of the 400 field samples tested by
the IFA were classified as positive and 100 out of 100 as negative. Classically, the IDV
positive control serum showed clear cytoplasmic fluorescence started from 1:40 dilution,
while negative serum did not (Figure 6.1).

Expression of recombinant IDV-NP and IDV-HE antigens by bacterial
system: The protein yield by the IPTG induced E. coli culture was approximately 25mg
PEDV-NP/liter of 2XYT medium with a purity of greater than 95%. The purity of the
recombinant protein was assessed by SDS-PAGE in which the expected band of 64 kDa
for NP and 65 for HE migrated upon staining with Coomassie brilliant blue R250 (Figure
6.2). Confirmation of the specificity of the recombinant proteins was characterized by
Western blot using convalescent IDV-positive serum, fetal bovine serum as negative
control, and anti-His mAb, and anti-rabbit-IDV polysera as shown in Figure 6.3.

Western Blot: Western blotting was done for three purposes, first to investigate
some selective serum samples against whole virus, NP and HE using anti-bovine-HRP to
confirm the seroconversion status as shown in Figure 6.4. Second, to map our produced
monoclonal antibody in our laboratories. In order to map the mAb of isotype IgM,
sucrose purified whole virus D/660 and D/OK were treated with trypsin for 1 hr at a
concentration of 10µg/ml before running the gel. Non treated viruses were also used as a
control, all plus the NP and HE proteins. Our mAb showed cross reactivity with HE
recombinant protein and no reactivity with NP. It also it cross reacted with both D/660
and D/OK when trypsin treated and did not react with the whole virus as shown in Figure
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6.5.A compared to Figure 6.5.B (Non-cleaved virus with anti-rabbit sera). Lastly, we
used Western blot as a sensitive test to study the cross reactivity between D/660 and
D/OK using our rabbit antisera against both of them alternatively. As shown in Figure
6.6a and 6.6b, both anti-rabbit sera reacted with both viruses treated with trypsin and
non-treated, demonstrating the cross reactivity between the two clades using our rabbit
antisera.

Indirect ELISA: Receiver Operator Characteristic (ROC) analysis of the indirect
ELISA with the IFA was used to characterize the sensitivity and specificity values and
cutoff. The optimal cutoff values and corresponding sensitivity and specificity of our NP
and HE based tests are presented in Figure 6.7. Specifically, ROC analysis for the NPiELISA showed 87.9 % sensitivity and 96.2% specificity with a 0.599 cutoff. While the
ROC analysis for the HE-iELISA showed estimated sensitivity and specificity of 86.9%
and 96.2 %, respectively with a cutoff of 0.481 (Figure 6.7). The Pearson’s correlation
test between all diagnostic platforms had a high correlation values between the assays,
Table 6.2 illustrates the correlation between the assays and the P value.

Cross reactivity between the two lineages of IDV: Investigation of the cross
reactivity between IDV-D/660 and IDV-D/OK were done using our rabbit antisera
specific for both IDV lineages produced in our laboratories. Using Western blot with
different epitopes from, whole virus D/660, D/OK, trypsin treated D/660, trypsin treated
D/OK, recombinant N and HE proteins showed that there is a strong cross reactivity
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between the two lineages as in Figure 6.6.a and 6.6.b. Therefore, our rabbit antisera will
provide a good tool for the diagnosis of IDV in the U.S.
Mutation by deletion at the amino acid site 212 of the HE protein and transfection
in MDCK using lipofectamin 3000 did not effect the antigenic recognition of the epitope
against mAb and rabbit antisera for both lineages. Figure 6.8.

FFN: The FFN assay was initially evaluated using well-recognized positive
convalescent serum samples by Western blot, IFA, HI and ELISA. Essentially, the 100
negative samples showed serum FFN endpoint titers of <1:20 and included calves
between 6-7 months old. While 349 samples out of the 350 positive sample set of cows
and bulls had endpoint titers from 1:80 to 1:1280. An example of positive convalescent
sera and negative FBS is shown in Figure 6.9.

Statistical correlation between HI, FFN and iELISA-HE: There was a good
correlation between the HI results after transformation to Log-2 and FFN which showed a
value of 0.581, between HE-iELISA and FFN-log2 showed 0.548, and iELISA based on
HE and HI-log was 0.522. (Table 6.2 and Figure 6.10).

Discussion
The most common serological assays to detect antibodies to influenza virus are
the HI and the MN assays. The HI assay detects antibodies that able to block the
influenza virus hemagglutinin binding to sialic acid-linked receptors on red blood cells,
while the MN test detects functional antibodies directed toward the hemagglutinin,
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therefore preventing infection of cells in tissue culture [11,23]. One of the disadvantages
of HI is that reference sera always needs to be included when performing the test [13].
For IDV, the HI test was not able to consistently cross react between the two
genetic clusters (D/OK-like and D/660-like viruses) for IDV, which have been identified
to be antigenically distinct [24]. In this study, we used our rabbit polyclonal antisera
against both D/OK and D/660 to study the cross-reactivity between them. As shown in
Figure 6.6, a strong cross reactivity exists when using the alternative rabbit polyclonal
antisera. Therefore, our FFN test, which is a neutralization test based on using rabbit
polyclonal antisera as the detection antibody, will detect antibody to both strains of IDV
in virus neutralization assays using either type of IDV as the indicator virus, providing a
good tool for the surveillance of IDV in the U.S.
Furthermore, our study found also that both D/OK-like and D/660-like IDVs were
co-circulating in the same South Dakota herds as shown in Table 6.1. The HI results
using both clades D/660 and D/OK were different in seropositive status but the FFN
results were able to cover both. There are many different formats of the MN assay all
over the world, such as the 2-day enzyme-linked immunosorbent assay (ELISA) protocol
[25], 3-day HA protocol [15], and 7-day HA protocol [12]. Time is critical for the
purposes of seroepidemiology; therefore, the accurate and shorter protocols of 2 to 3 days
are better. Our FFN test will not only be able to detect the protective antibodies against
the two antigenically different clades of IDV co-circulating in the U.S. that the HI was
not able to detect but also will save time.
The IDV/D/660 clade has a K replacing R of the D/OK clade at position 212.
Although HI results and molecular models of the two clades revealed that amino acid 212
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plays an important role in IDV antigenicity and antibody recognition [24], in our study
we investigated the cross reactivity between the two clades. In order to do this, we treated
both sucrose purified viruses with TPCK-treated trypsin to cleave the HE protein, then
we used both rabbit polyclonal antisera against both clades alternatively as shown in
Figure 6.6. Both cleaved and non-cleaved viruses reacted with both rabbit antisera. Also,
both polyclonal antisera specific to both clades reacted with the D/OK HE recombinant
protein.
Moreover, to investigate whether the amino acid 212, which is located in the apex
of the HE receptor binding domain, has a critical role in the antibody recognition or not,
we did a mutation by deletion in this region and cloned the mutant in the PcDNA3.1
mammalian expression vector. We then transfected MDCK cells with the construct. The
transfected cells stained by both rabbit polyclonal antisera specific to the two IDV clades
and cross reacted with the mutant HE. This suggests that the amino acid 212 region alone
is not only the cause of why HI titers were different between the two clades but also may
be another region like V115I and D372G in the esterase domain [24] playing the critical
role together in the antigenic differences with the recognition of the receptor.
In order to map our produced mAb, we used Western blot techniques, in which
we blotted the whole virus of both clades in both forms, cleavage by trypsin and noncleaved. Our mAb did not recognize the non-cleaved whole virus but reacted strongly
with the cleaved version. After that, we confirmed the results by blotting the mAbs with
both recombinant NP and HE bacterial expressed protein and this showed no recognition
with NP but a strong signal with HE (Figure 6.4).
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Neutralization assays are not able to detect the cross-reactive antibodies to the
stem region of influenza viruses which decreases specificity, particularly in the older ages
of animals [26]. Also, the neutralizing assay only detects the protective antibodies against
specific epitopes but not the non-neutralizing antibodies which are produced against other
epitopes like M, NP and PB1, which the immune system can produce that also reflect the
serostatus of the animal. Therefore, our second aim after producing an accurate and quick
neutralizing test (FFN) that was able to detect antibodies against the two different clades
of IDV, was to develop another serological test that can detect both neutralizing and nonneutralizing antibodies against the IDV. This provides the veterinarian and researcher
with good tools for IDV surveillance and vaccine evaluation. ELISAs are the most costeffective and rapid serological assay, especially in the absence of active infection.
Nucleoprotein, one of the major structural proteins of IDV, plays a critical role as
a genus-specific antigen which distinguishes between the influenza A, B, and D viruses.
It is responsible for the loss of cross-recognition of viral antigens among influenza
viruses [4]. Moreover, the NP is a conservative domain among the different IDV strains
so it presents a good target for the seroprevalence of IDV. Therefore, we developed
separate iELISAs based on NP and HE.
Our NP ELISA was able to detect 332 positive samples from 350 expected
positive samples and 96 negative samples from 100 as shown in Table 6.1. The
sensitivity and specificity of the iELISA-NP was very good, although it showed higher
specificity than sensitivity. This might be due to the lower number of negative samples in
our study, therefore more negative samples are needed for the next steps of optimization
of the test. Our HE-iELISA showed a good correlation with the HI and FFN results as
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shown in Table 6.2 and Figure 6.10, which confirmed the specificity of the HI and FFN
directed toward the protective antibodies against HE. The HE protein of influenza D is
responsible for recognition and binding of the receptor therefore entrance and infection of
the virus [3].
In South Dakota, the preliminary prevalence of IDV is approximately 90% in
dairy cattle and 4-7% in healthy 7 month old calves. Furthermore, when we studied the
seroprevalence from 7 month old calves to adult cattle, we found an increase from 7.7%
at 8 month old calves to 90% in adult cattle. This may reflect the increased spread of IDV
among cattle in U.S. compared to a previous study that showed 11.3% in calves and 66.5
% in adults [8]. The differences in the calf percentage may be related to the maternal
immunity transferred from the high percent of positive adult cattle to the calves that helps
in temporary protection. However, conclusions from our observations are still limited
based on the low sample size.
The main importance of the FFN over indirect ELISAs in IDV surveillance is that
indirect ELISAs require the use of species-specific enzyme-conjugated antibodies, while
FFN does not. Also FFN can detect only the neutralizing antibodies [21]. NP-ELISA
methods can detect the antibodies which target the common viral proteins [22]. NP
ELISAs should be effective for large-scale surveillance of IDV in herds. Further
development of the FFN using milk and colostrum samples from cattle from a herd that
has experienced an acute IDV outbreak serum will be valuable tools to quantify the
maternal immunity and acquired immunity transferred to calves.
In conclusion, our study and serological assays developed here will play an
important role in seroprevalence studies, surveillance and diagnosis of IDV. Also, our
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new diagnostic tests will play a critical role in vaccine evaluation. More study will be
needed to confirm the difference between D/OK and C/OK in the HI test which may be
related to the receptor binding.
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Seropositive

Farms and state

Total
Number

Hi
IDV/D/660

ELISA
NP

ELISA
HE

IFA

HI IDV/D/
OK

FFN

Angus bulls- Western SD

10

6/10

10/10

6/10

6/10

5/10

10/10

Beef cattle-SW MN

10

7/10

10/10

8/10

7/10

6/10

10/10

Diary-SD

10

10/10

10/10

10/10

10/10

4/10

10/10

Jersey cows-WI
Holstein cows - Eastern
SD- Dairy

5

5/5

5/5

5/5

4/5

2/5

5/5

50

40/50

45/50

48/50

43/50

35/45

50/50

Dairy-SD

20

15/20

18/20

17/20

16/20

9/10

20/20

Export cattle - PA

95

95/95

95/95

95/95

90/95

20/95

95/95

100

99/100

99/100

85/100

80/100

50/100

99/100

10

0/10

0/10

0/10

0/10

0/10

0/10

90

0/90

4/90

6/90

5/90

0/90

0/90

Export cattle - MN

50

40/50

40/50

40/50

30/50

35/50

49/50

Total positive

350

317/350

332/350

314/350

286/350

166/350

349/350

Total negative

100

0/100

4/100

6/100

5/100

0/100

0/100

Holstein Heifers - WA
Angus cattle – EasternSD
Holstein cows -Eastern
SD calves 7-8 month

Table 6.1. Summary of the serological survey from different bovine farms in the U.S.
HI/D/660 90%, HI/C/Ok 47%, ELISA-NP 94.8%, ELISA-HE 89.8%, IFA 81.7% and
99.7% FFN.
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A

A

B

Figure 6.1. IFA on IDV infected MDCK cells using positive and negative
bovine serum samples and anti-bovine FITC. A: Positive convalescent
bovine anti-IDV sera showing strong fluorescent staining of virus infected
cells. B: Negative serum sample show no specific fluorescent staining.
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1

2

63kDa

3

65kDa

Figure 6.2. SDS-PAGE/Coomassie blue staining of E. coli expressed
and purified NA and HE antigen showing size and purity of
expressed proteins.
Lane 1: NP shown at size of 62 kDa, Lane. 2: ladder, and Lane 3: HE at
size of 64 kDa
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1

2

3 4

5

6

7

8

9

PB2
PB1, p3
75 kDa
50 kDa

HE
NP

P42
NS2

Figure 6.3. Confirmation of the specificity of the recombinant proteins
compared to whole virus.
Lane 1: FBS with recombinant NP
Lane 2: Ladder
Lane 3: FBS with recombinant HE
Lane 4: whole virus D/660 positive with anti IDV convalescent sera
Lane 5: Ladder
Lane 6: Recombinant NP with anti-mouse his-tag
Lane 7: Recombinant NP with anti-rabbit D/660 sera
Lane 8: Ladder
Lane 9: Recombinant HE (64kDa) with anti-mouse his-tag
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FBS
1

2

Convalescence positive
3

4

5

6

7

8

PB2
PB1
HE
NP

75 kDa
55 kDa

P42
NS2

Figure 6.4. Western blot identification of selected IDV proteins using
the IDV-convalescent sera.
Lane 1: IDV/D/OK whole virus
Lane 2: IDV/D/660 whole virus
Lane 3: NP Recombinant protein
Lane 4: ladder
Lane 5: IDV/D/660 whole virus
Lane 6: IDV/D/OK whole virus
Lane 7: IDV-NP Recombinant protein
Lane 8: IDV-HE recombinant protein
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1

2

3

4

5

6

7

PB2
PB1
75 kDa
55 kDa

HE
NP

P42
NS2

Figure 6.5.A. Mapping the IDV-mAb
Lane1: IDV-Np recombinant protein

Figure 6.5.B.

Lane2: IDV/D/660

Uncleaved IDVD/660

Lane3: IDV/D/OK

with rabbit antisera

Lane4: ladder
Lane5: Trypsin treated IDV/D/660
Lane 6: Trypsin treated IDV/D/OK
Lane7: IDV-HE recombinant protein
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A

1

2

3

4

5

6

B

7

1

2

3

4

5

6 7

PB2
PB1
100kDa
75KDa
55KDa

HE
NP

P42

100kDa
75kDa

KDA
55kDa
KDA

NS2

A. Using polyclonal rabbit anti

B. Using polyclonal rabbit anti IDV/C/OK

IDV/D/660 sera which showed strong

sera which showed strong cross reaction.

cross reaction.

Figure 6.6. Cross reactivity between the two IDV different clades of D/660 and
C/OK using specific polyclonal rabbit anti-IDV sera against each virus.

Lane1: Ladder
Lane 2: IDV-NP recombinant protein
Lane 3: IDV/D/660
Lane 4: IDV/D/OK
Lane 5: Trypsin treated IDV/D/660
Lane 6: Trypsin treated IDV/D/OK
Lane7: IDV-HE Recombinant protein
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ELISA-NP
7

A
6
5
4
3
2
1
>0.5995
Sens: 87.9
Spec: 96.2

0
0

1
ifa

ELISA-HE

B

4.0
3.5
3.0
2.5
2.0
1.5
1.0
>0.481
Sens: 86.9
Spec: 96.2

0.5
0.0
0

1
ifa

Figure 6.7. Receiver operator characteristic (ROC) assessment and
determination of diagnostic sensitivity and specificity of the IDV-NP (A), and
IDV-HE (B) iELISA. ROC analysis was performed using MedCalc version 11.1.1.0
(MedCalc software, Mariakerke, Belgium). In each panel, the dot plot on the left
represents the negative testing population, and the dot plot on the right represents the
positive population. The horizontal line bisecting the dot plots represents the cutoff
value that gives the optimal diagnostic sensitivity and specificity.
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Correlation table
ELISAHE
ELISA-HE

Correlation Coefficient

0.517

Significance Level P
ELISA-NP

Correlation Coefficient
Significance Level P

FFN (Log) Correlation Coefficient
Significance Level P
Hi_Log

Correlation Coefficient
Significance Level P

IFA_log

Correlation Coefficient
Significance Level P
n

ELISANP

<0.0001
0.517

FFN (Log) HI_Log
0.548
<0.0001
0.484

<0.0001

<0.0001

IFA_log

0.522

0.556

<0.0001

<0.0001

0.435

0.512

<0.0001

<0.0001

0.548

0.484

0.581

0.705

<0.0001

<0.0001

<0.0001

<0.0001

0.522

0.435

<0.0001

<0.0001

0.556

0.512

<0.0001

<0.0001

0.581

0.732

<0.0001
0.705
<0.0001

<0.0001
0.732
<0.0001

450

Table 6.2. Pearson correlation coefficient between all the diagnostic assays.
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A

B

D

C

Figure 6.8. Cross reactivity of the mutant HE protein at site 212
amino acid. MDCK cells stained with both IDV lineages of antirabbit-sera and mAb after transfection in MDCK.
A: Cross reaction with anti-rabbit D/660.
B: Cross reaction with anti-rabbit D/OK.
C: Control Mock.
D: Cross reacted with IDV-mAb
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Serum Dilution

A-Fetal Bovine Serum

B- Control IDV positive

1/40

1/80

1/160

1/320

1/640
End
point
1/1280

1/2540

Figure 6.9. Example of positive and negative FFN results. A: fetal bovine serum as
negative in which there was no antibody to prevent the viral replication. B: IDV positive
serum that has antibodies specific to IDV and did to inhibit virus replication showing
~90% reduction in FFU at a 1/1280 dilution.
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A

7
6

Hi_Log

5
4
3
2
1
0
0

2

4
FFN (Log)

B

6

8

4.5

ELISA-HE

3.5
2.5
1.5
0.5

C

-0.5
0

1

2

4

3
4
Hi_Log

5

6

7

ELISA-HE

3
2
1
0
-1
0

2

4
FFN (Log)

6

8

Figure 6.10. Scatter correlation between. A: fetal bovine serum as negative with no
antibody to prevent viral replication. B: IDV positive serum with antibodies specific
to IDV and was able to inhibit the virus to a titer of 1/1280.

199

References for Chapter 6

1. Palese P, Shaw ML. 2007. Orthomyxoviridae: the viuses and their replication. In:
Knipe DM, Howley PM, eds., Fields Virology. Philadelphia, PA: Lippincott
Williams & Wilkins. pp. 1647-1689.
2. Treanor JJ. 2000. Influenza virus: principles and practice of infectious diseases, 6th
edition. Mandell GL, Bennett JE, Dolin R, eds. Elsevier Churchill Livingstone,
Philadelphia, PA, 6th Edition. pp. 2060–2085.
3. Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B,
Chakravarty S, Hoppe AD, Webby RJ, Simonson RR, Li F. 2013. Isolation of a
novel swine influenza virus from Oklahoma in 2011 which is distantly related to
human influenza C viruses. PLoS Pathog. 9:e1003176.
http://dx.doi.org/10.1371/journal.ppat.1003176
4. Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F.
2014. Characterization of a novel influenza virus in cattle and swine: proposal for a
new genus in the Orthomyxoviridae family. mBio 5(2):e00031-14.
5. Cox NJ, Newman G, Donis RO, Kawaoka Y. 2005. Orthomyxoviruses: influenza. In:
Topley WWC, Wilson SGS, Mahy BWJ, eds., Topley and Wilson’s Microbiology
and Microbial Infections. London: Hodder Arnold. pp. 634-698.
6. Quast M, Sreenivasan C, Sexton G, Nedland H, Singrey A, Fawcett L, Miller G, Lauer
D, Voss S, Pollock S, Cunha CW, Christopher-Hennings J, Nelson E, Li F.
Serological evidence for the presence of influenza D virus in small ruminants.
2015. Vet. Micro. 180(0):281-285. doi:10.1016/j.vetmic.2015.09.005.
7. Ng TF, Kondov NO, Deng X, Van Eenennaam A, Neibergs HL, Delwart E. 2015. A
metagenomics and case-control study to identify viruses associated with bovine
respiratory disease. J. Virol. 89:5340–5349.
8. Ferguson L, Eckard L, Epperson WB, Long L, Smith D, Huston C, Genova S, Webby
R, Wan X. 2015. Influenza D virus infection in Mississippi beef cattle. Virology
486:28–34.
9. Quigley JD, Kost CJ, Wolfe TM. 2002. Absorption of protein and IgG in calves fed a
colostrum supplement or replacer. J. Dairy Science 85:1243-1248.
10. Fulton RW, Cook BJ, Step DL, Confer AW, Saliki JT, Payton ME, Burge LJ, Welsh
RD, Blood KS. 2002. Evaluation of health status of calves and the impact on feedlot
performance: assessment of a retained ownership program for postweaning calves.
Canadian J. Vet. Res. 66:173-180.

200

11. Julkunen I, Pyhälä R, Hovi T. 1985. Enzyme immunoassay, complement fixation and
hemagglutination inhibition tests in the diagnosis of influenza A and B virus
infections. purified hemagglutinin in subtype-specific diagnosis. J. Virol. Methods
10:75–84.
12. Newton DW, Treanor JJ, Menegus MA. 2000. Clinical and laboratory diagnosis of
influenza virus infections. Am J Manag Care. 6(Suppl):S265–S275.
13. Petric M, Comanor L, Petti CA. 2006. Role of the laboratory in diagnosis of influenza
during seasonal epidemics and potential pandemics. J Infect Dis. 194(Suppl 2):S98–
S110.
14. Chomel JJ, Thouvenot D, Onno M, Kaiser C, Gourreau JM, Aymard M. 1989. Rapid
diagnosis of influenza infection of NP antigen using an immunocapture ELISA test.
J. Virol. Methods 25:81-92.
15. Meulemans G, Carlier MC, Gonze M, Petit P. 1987. Comparison of
hemagglutination-inhibition, agar gel precipitin, and enzyme-linked immunosorbent
assay for measuring antibodies against influenza viruses in chickens. Avian Dis.
31:560–563.
16. Snyder DB, Marquardt WW, Yancy FS, Savage PK. 1985. ELISA for the detection of
antibody against avian influenza virus. Avian Diseases 29:136-144.
17. Prince HE, Leber AL. 2003. Comparison of complement fixation and
hemagglutination inhibition assays for detecting antibody responses following
influenza virus vaccination. Clin. Diagn. Lab. Immunol. 10:481-482.
18. Verschoor CP, Singh P, Russell ML, Bowdish DME, Brewer A, Cyr L, Ward BJ,
Loeb M. 2015. Microneutralization assay titres correlate with protection against
seasonal influenza H1N1 and H3N2 in children. PLoS ONE 10(6): e0131531.
doi:10.1371/journal.pone.0131531
19. Reed LJ, Meuench H. 1938. A simple method of estimating fifty percent
endpoints. Am. J. Hygiene. 27:493–497.
20. World Health Organization Global Influenza Surveillance Network (GISN). 2011.
Manual for the laboratory diagnosis and virological surveillance of influenza. World
Health Organization, Geneva, Switzerland.
http://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance_influ
enza/en/.
21. Okda F, Lawson S, Liu X, Singrey A, Clement T, Hain K, Nelson J, ChristopherHennings J, Nelson EA. 2016. Development of monoclonal antibodies and
serological assays including indirect ELISA and fluorescent microsphere
immunoassays for diagnosis of porcine deltacoronavirus. BMC Vet. Res. 12:95. doi:

201

10.1186/s12917-016-0716-6.
22. Okda F, Liu X, Singrey A, Clement T, Nelson J, Christopher-Hennings J, Nelson EA,
Lawson S. 2015. Development of an indirect ELISA, blocking ELISA, fluorescent
microsphere immunoassay and fluorescent focus neutralization assay for serologic
evaluation of exposure to North American strains of Porcine Epidemic Diarrhea
Virus. BMC Vet. Res. 11:180. doi:10.1186/s12917-015-0500-z
23. Lambrecht B, Steensels M, Van Borm S, Meulemans G, van den Berg T. 2007.
Development of an M2e-specific enzyme-linked immunosorbent assay for
differentiating infected from vaccinated animals. Avian Dis. 51(Suppl):221–226.
24. Collin EA, Sheng Z, Lang Y, Ma W, Hause BM, Li F. 2015. Cocirculation of two
distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J.
Virol. 89(2):1036-1042.
25. Li OTW, Barr I, Leung CYH, Chen H, Guan Y, Peiris JSM, Poon LLM. 2007.
Reliable universal RT-PCR assays for studying influenza polymerase subunit gene
sequences from all 16 haemagglutinin subtypes. J Virol. Methods 142:218–222.
26. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G,
Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis
RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol.
Biol. 16:265–273.

202

Chapter 7
Conclusions
Timely and accurate veterinary diagnostic services and reagents arm veterinarians
and public health officials with the tools to control new emerging diseases and improve
animal and therefore, human health. Studying the molecular biology of new emerging
viruses is the key to developing diagnostic reagents, new laboratory-based diagnostic
tests, methods for new viruses’ detection and developing new products that can help in
treatment, disease prevention, management and controls.
In 2013, PEDV suddenly emerged in the United States and has been proven a
significant pathogen of swine. PEDV caused a devastating economic loss and high
mortalities in piglets. Our goal was to serve both the industrial and academic researcher
with quick and accurate diagnostic tools and reagents. The well-validated NA PEDV
iELISA, bELISA, FMIA and FFN assays in our study are useful for a range of
serological investigations. They can complement the nucleic acid detection assays and
determine the PEDV status of asymptomatic individuals cost-effectively, thus becoming
tools in management strategies and the monitoring of virus exposure within the herd. The
FMIA will be a valuable tool for isotyping the antibody responses and by multiplexing
the assay, we will be able to determine the exposure to multiple pathogens
simultaneously. Moreover, the FFN is useful in determining whether the antibodies
measured are providing a biological function of blocking virus infectivity or not. Our
spike FMIA correlated with other assays on sample matrices, such as milk and colostrum
for measuring passive transfer of antibodies and oral fluids for pen-based surveillance.
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Another porcine deltacoronavirus disease syndrome emerged in the U.S in early
2014, more diagnostic assays and reagents were needed. PDCoV also, causes enteric
disease in swine, but the impact is not as severe as PEDV. The monoclonal antibody
reagents developed in our study provide important research and diagnostic tools for the
both the researcher and the industry. They are valuable for fluorescence and
immunohistochemical staining methods utilized in diagnostic and pathogenesis studies.
The serological assays allow the detection of antibodies developed in response to PDCoV
infection. Our PDCoV indirect ELISA and NP based FMIA will allow high-throughput
screening of swine serum samples. Our assays are adequately optimized and validated for
sero-surveillance on a herd level, but further improvement is needed for full confidence
on an individual animal basis. We were able to validate these assays and to adapt them to
different sample matrices such as milk. Our PDCoV FFN test validation is ongoing and
will be an important tool to validate vaccines. Since lactogenic immunity is likely critical
for protection of nursing piglets, these assays will be modified for detection of IgA as
well. So our specific reagents and serological assays will allow for improved diagnosis of
PDCoV. Since many aspects of PDCoV infection and transmission are still not fully
understood, the reagents and assays developed in this project should provide valuable
tools to help understand this disease and to aid in the control and surveillance of PDCoV
outbreaks.
Besides providing diagnostic reagents and assays, another objective of this study
was to do epitope mapping of the S protein of PEDV, enhancing our understanding of the
virus. Iimmunization of BALB/c mice with purified and inactivated whole virus
preparations of PEDV followed by somatic cell fusion resulted in hybridoma cell lines
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secreting mAbs specific for the S protein that exhibited marked neutralizing activity
against PEDV in vitro. Epitope mapping of the resultant neutralizing mAbs led to the
identification of important antigenic determinants within the S protein. Notably, most
mAbs obtained here reacted against linear epitopes within the S2 subunit, indicating that
this region contains immunodominant neutralizing epitopes of PEDV. Our epitope
mapping results demonstrated that particular domains on the spike are associated with
enhanced neutralization, depending on their structure and mechanism of action. For
instance, 744-759 aa is considered to be the cleavage site domain of the S1-S2 to the
target cell, whereas the receptor binding domain is localized to the 499-600, showing less
neutralizing ability. The viral plaque formation was not completely inhibited by the
mAbs specific to 499-600 aa domain in the spike protein of the PEDV. We believe that
this, at least in part, is due to the addition of trypsin, which was required to activate the
receptor-ligand interaction between the Vero cells and PEDV. It is likely that the added
trypsin degraded the antibodies, which resulted in the incomplete inhibition of the PEDVmediated plaque formation. However, our results revealed that the COE region of the
PEDV spike protein might contain the major neutralizing epitope for the virus as it the
end point was 1/40 dilution of the antibody. This finding supports the previous
observation that the same region of the TGEV spike protein also contains neutralizing
epitopes. The neutralizing epitopes have been mapped and analyzed focused on the
region encoded 630-800 and the neutralizing peptides included in this domain. The 630800 aa region is the most immunodominant region in the spike. We found that the
antibodies against this epitope have neutralizing activity for PEDV-infected Vero cells.
Furthermore, the 630-800 aa region was able to react with PEDV antiserum and evoke
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the formation of neutralization antibodies in mice and spans the S1-S2 junction region of
the S protein. Our results demonstrated that the cleavage site between S1 and S2 may be
a target for subunit vaccines. It contains the epitope region 744-759 or 15 aa in the
beginning of N terminal domain of S2 and 756-771 that is presumed to be located in the
spherical head of the S protein of PEDV and represents a considerable immunodominant
region of PEDV S protein. Both epitopes play an important role after the cleavage
between S1 and S2 by trypsin in the pathogenesis of PEDV. Our mAbs specific to the
cleavage site between S1 and S2 in addition to the 1371-1377 showed much higher
neutralization in the two neutralizing tests compared to the region encoded the RBD.
There was a high correlation between the three different tests; FFN, PRNT and ELISA. In
summary, by using a panel of PEDV S-specific neutralizing mAbs we have shown that an
immunodominant neutralizing epitope of PEDV S maps to the amino-terminus of the S2
subunit. While seven neutralizing mAbs generated after immunization of mice with
whole virion preparations recognized a domain in S2, only one mAb reacted against S1.
These results suggest that S2 subunit may contain important, perhaps, immunodominant
neutralizing determinants of PEDV. This study provides important information and tools
that may lead to the development of improved prevention, control and/or diagnostic
strategies for PEDV.
Utilizing many of the same research techniques, we were able to study the
Influenza D virus, which is a newly described disease of cattle. It is wide spread in the
U.S. with two antigenically different lineages. It affects all age groups of bovine and
causes significant respiratory disease. The purpose of this study was to analyze the viral
proteins of IDV in order to produce an accurate diagnostic test in which to determine the
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seroprevalence among cattle herds. We wanted a test based on the most conservative
domain which will be able to detect the antibodies against the two different IDV clades
circulating in the U.S. Our NP based ELISA was able to detect 332 positive samples from
350 expected positive samples and 96 negative samples from 100 assumed negative
sampels. The sensitivity and specificity of the NP-iELISA was very good, although it
showed higher specificity than sensitivity due to the lower number of negative samples in
our study. Therefore, more negative samples will be needed for second generation
optimization of the test. The main benefit of the FFN over iELISAs in IDV surveillance
is that iELISAs require the use of species-specific enzyme-conjugated antibodies, while
the FFN assays do not. Also, FFNs detect only the neutralizing antibodies while NPELISA methods can detect the antibodies which target the common viral proteins. The
HE-iELISA produced in this study showed a good correlation with the HI and FFN
results, which confirmed the specificity of the HI and FFN directed toward the protective
antibodies against the HE protein of influenza D is responsible for recognition and
binding of the receptor therefore entrance and infection of the virus.
In South Dakota, the presence of IDV appears to approach 90% in dairy cattle and
4-7% in healthy calves. The maternal immunity transferred from the cows to the calves
may help in temporary protection. Our NP ELISAs should be effective for large-scale
surveillance of IDV in herds. Further development of the FFN using milk and colostrum
samples from cattle from herds that have recently experienced an acute IDV outbreak
will be valuable tools to quantify the maternal immunity and acquired immunity
transferred to calves. Our study and serological assays developed here will play an
important role in future seroprevalence studies, surveillance and diagnosis of IDV. Also,
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our new diagnostic tests will play a critical role in vaccine evaluation. More study will be
needed to confirm the difference between D/660 and D/OK in HI test which may related
to the receptor binding.
The overall purpose of this doctoral work was to develop ways to monitor and
assess recently emerging diseases affecting livestock in the U.S. and beyond. These viral
diseases; PEDV and PDCoV in swine, and IDV in cattle, are devastating not only for the
susceptible animals but also the economies of the area where these viruses have emerged.
The information gained by this work played a significant role in diagnosing the diseases
and vaccine development to help control them. It will continue to be valuable in the
surveillance of these viruses. This study also gave a focused insight into the underlying
mechanism of invasion of these viruses by studying the molecular characteristics. A deep
molecular genetic study of the virus helps produce quick and accurate diagnostic assays
which arm the livestock producers and veterinarians in controlling disease.

